COPE Advertising options


http://www.promokine.info/products/cytokines-growth-factors/ PBL Assay Science COGITO ERGO COPE ADVERTISING SPACE

COPE Homepage Bottom of page Previous entry:
Endothelial cell neutrophil-activating peptide
Next entry:
endothelial cell-selective adhesion molecule
Random entry:
Norrie disease protein homolog
Search COPE:

Please donate

If you find COPE helpful,
please show your appreciation
by donating what you can afford.

endothelial cells


Commonly used abbreviations:

BAEC [bovine aortic endothelial cells]
BEC [blood endothelial cells]
BMEC
[bone marrow endothelial cells]
CEC [Circulating endothelial cells]
CMEC [cardiac microvascular endothelial cells]
EC [Endothelial cells]
HAEC [human aorta endothelial cells]
HBMEC [human brain microvascular endothelial cells]
HDMEC [human dermal microvascular endothelial cells]
HIMEC [human intestinal microvascular endothelial cells]
HMEC [human microvascular endothelial cells]
HSEC [hepatic sinusoidal endothelial cells]
HSVEC [human saphenous vein endothelial cells]
HUVEC [human umbilical vein endothelial cells]
LEC [lymphatic endothelial cells]
MEC
[microvessel endothelial cells;
microvascular endothelial cells]
MVEC [microvascular endothelial cells]
PAEC [pulmonary artery endothelial cells]
RCEC [retinal capillary endothelial cells]
RMEC [retinal microvascular endothelial cells]
VEC [vascular endothelial cells]


Endothelial cells are oblong shaped cells that line the lumen of all blood vessels as a single squamous epithelial cell layer. They are derived from angioblasts and hemangioblasts. The term endotheliocytes may be used synonymously.
For a cell type coexpressing myogenic cell and endothelial cell markers see: myoendothelial cells. Endothelial cells have been shown also to constitute an instructive and inductive vascular niche for the self-renewal and proliferation of hematopoietic stem cells, tumor growth, and liver regeneration (see: angiocrine factors).

Endothelial cell spheroids are aggregates of endothelial cells formed when these cells are grown under suitable conditions in suspension cultures. These spheroids usually consist of a surface monolayer of differentiated cells and a center of unorganized cells that will die by apoptosis if they are not rescued by survival factors (Oudar, 2000; Korff and Augustin, 1998). Such spheroids have been used to assay the activities of angiogenesis factors and their inhibitors (spheroidal angiogenesis assay).

Weibel-Palade bodies are specialized secretory granules found in endothelial cells. These vesicles store preformed hormones, cytokines, and growth factors, as well as enzymes, receptors, and adhesion molecules, which can be released and/or expressed on the cell surface without de novo protein syntheses by regulated exocytosis in response to stimulation of cell activation of cells (Hannah et al, 2002; Michaux and Cutler DF, 2004; van Mourik et al, 2002).

In small capillaries endothelial cells may be the only cell type present, and in some cases (large vessels of invertebrates, an endothelial cell layer is missing (Risau, 1995; Dejana et al, 1995; Munoz-Chapuli et al 2005). These cells play a major role in vascular biology under normal or pathological conditions (Wiel et al, 2005), including the control of blood pressure (vasoconstriction and vasodilation) (Cosentino and Volpe, 2005), blood clotting (thrombosis, fibrinolysis) (Wiel et al, 2005; Chen and Lopez, 2005), formation of new blood vessels (angiogenesis) (Gerhardt and Betsholtz, 2005; Szekanecz and Koch, 2005), leukocyte adhesion/trafficking and inflammatory processes (Cook-Mills and Deem, 2005; Aird, 2005; Szekanecz and Koch, 2005).

Raised numbers of so-called circulating endothelial cells (abbr. CECs) in the peripheral blood are present in a wide variety of pathophysiological conditions. Their presence can be taken as a marker of endothelial damage in a variety of vascular disorders. These cells are often defined by the expression of membrane glycoprotein CD146 and can be associated with, and contribute to, inflammatory, immune, infectious, neoplastic and cardiovascular diseases (Blann et al, 2005; Dignat-George et al, 2003; Khan et al, 2005; Hunting et al, 2005). Immature circulating endothelial cells derived from the bone marrow are being referred to as endothelial progenitor cells (see: angioblasts) (Khan et al, 2005).

Endothelial cells are quite heterogeneous with respect to their functional capacities and cell morphology and play distinct roles in different vessels, tissues, and organs (Gebb and Stevens, 2004; Conway and Carmeliet, 2004).

Specialized endothelial cells present at the leading edge of vascular sprouts, integrate directional cues from their environment to define the direction in which the new sprouts grow and also generate functional vascular networks by connecting with adjacent sprouts during angiogenesis (tip cells; see: tip endothelial cells). For another specialized endothelial cell type involved in sprouting angiogenesis see also: stalk cells; for a phenotype that reduces tumor metastasis see also: phalanx cells. The tumor vasculature contains so-called suppressor endothelial cells, which appear to be skewed by tumor cells towards disrupting functions of NK-cells, T-cells, and macrophages, and thus are involved in tumor-induced immune suppression.

Endothelial cells from large vessels participate in the control of vascular tone and blood pressure. Endothelial cells in capillaries participate in the exchange of gas and metabolic products and also permit extravasation of immune cells during infection and differ in the degree of permeability. Extravasation of mature lymphocytes circulating from blood to lymph takes place in high endothelial venules found in lymphatic organs. The corresponding endothelial cells have a characteristic morphology and express a number of selectins, integrins, and other adhesion molecules participating in regulating cell traffic.


Endothelial cells have been shown to express a plethora of factors (for a role of endothelial cells as an organ system see also: angiocrine factors). Differences in gene expression between microvascular and human umbilical vein endothelial cells have been identified. Endothelial cells from arteries and veins also differ in their gene expression patterns. Nelson et al (2007) have compared expression profiles of blood vascular endothelial cells (BEC) and the developmentally related lymphatic endothelial cells (LEC). Both cell types create complementary but distinct vascular networks and also show different phenotypes and expression profiles.

Tumor endothelial cells also differ from normal endothelial cells morphologically and by their expression and distribution of specific markers (see, for example: Charalambous et al, 2005). Clasper et al (2008) have shown that the expression profiles of primary lymphatic endothelial cells differ from those isolated from the vasculature of tumor tissues. The nature of the substratum, i.e., artificial basement membrane or fibrillar type I collagen may also influence expression. In additon, factor such as shear stress have been shown to have a profound effect on gene expression (Brooks et al, 2002; Wasserman et al, 2002; Chen et al, 2001). Gerritsen et al (2003) have used high-density oligonucleotide arrays to study changes in gene expression in human umbilical vein endothelial cells treated with HGF, VEGF, or the combination of the two. They have shown that among approximately 22000 genes studied, genes significantly upregulated and downregulated by VEGF versus HGF exhibit very little overlap, indicating distinct signal transduction pathways. Distinct changes are seen also when the cells are treated with a combination of the two growth factors acting in synergy.


Endothelial cells have been shown to possess the capacity to express the proteins listed below. Please note the following general observations, which practically apply to all cell types: expression may be influenced by tissue localization, may occur only in discrete subpopulations of cells, may vary between established cell lines, primary cells, embryonic cells, mature cells, fully differentiated cells, activated cells, non-activated cells or growth conditions (confluent vs. sparse cultures), may be influenced by various disease states (including cancer environment), and may differ between species.
Note also: expression profile information lists entities only for which there is an entry in COPE or one of its subdictionaries.

The meaning of ¥ and ¥¥ is as follows: ¥ factor/protein is expressed; ¥¥ receptor (or, in some instances, binding sites) for this factor/protein is expressed. For further explanations concerning format, "hidden" information, and/or ambiguities see my remarks in the entry cell types.


¥ 4-1BB (CD137, CDw137, Ly63, lymphocyte antigen 63, ILA, induced by lymphocyte activation, TNFRSF9, TNF receptor superfamily member 9) (Boussaud et al, 1998)
¥ 14-3-3-epsilon (YWHAE, Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein-epsilon) (Barbier et al, 2011)
¥ 14-3-3-zeta (YWHAZ, Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein-zeta, 14-3-3-delta, Exo1, FAS, factor activating ExoS) (Kobayashi et al, 2009)

¥ A20 (TNFAIP3 [TNF-alpha-induced protein 3, tumor necrosis factor-alpha-induced protein 3, Zinc finger protein A20, OTUD7C, OTU domain-containing protein 7C) (Daniel et al, 2004; Evans et al, 2000; Hu et al, 1998; Sakakibara S et al, 2012)
¥ AAMP (Angio-associated migratory cell protein) (Beckner et al, 1995)
¥ ABIN-1 (A20-binding inhibitor of NF-kappa-B activation-1, TNIP1, TNFAIP3 interacting protein 1, Nef-associated factor-1, Naf1, VAN, Virion-associated nuclear shuttling protein) (Imbeault et al, 2011)
¥ ABIN-2 (A20-binding inhibitor of NF-kappa-B activation-2, TNIP2, TNFAIP3 interacting protein 2, FLIP1, LKB1 interacting protein FLIP1) (Tadros et al, 2003)
¥ ABIN-3 (A20-binding inhibitor of NF-kappa-B activation-3, LIND, Listeria induced, TNIP3, TNFAIP3 interacting protein 3) (Sakakibara S et al, 2012)
¥ AcSDKP (N-acetyl-seryl-aspartyl-lysyl-proline, acetyl-N-Ser-Asp-Lys-Pro, Seraspenide, Goralatide, thymosin-beta-4) (Huang and Wang, 2001)
¥ ACTH (adrenocorticotropic hormone, corticotropin, POMC, proopiomelanocortin) (Scholzen et al, 1999)
¥¥ ACTH (adrenocorticotropic hormone, corticotropin, POMC, proopiomelanocortin) receptors (melanocortin receptors) (Scholzen et al, 1999; Hagi-Pavli et al, 2004; Hatakeyama et al, 2000)
¥ Activin A (EDF, erythroid differentiation factor, FRP, Follicle stimulating hormone releasing protein, Restrictin-P, WEHI-MIF, WEHI mesoderm inducing factor, activin-beta-A, INHA, inhibin-alpha, Inhibin-beta-A, INHBA) (Maeshima et al, 2004; Tannetta et al, 2003; Wang et al, 2005; Takeda et al, 2007; Barbier et al, 2011)
¥¥ Activin A (EDF, erythroid differentiation factor, FRP, Follicle stimulating hormone releasing protein, Restrictin-P, WEHI-MIF, WEHI mesoderm inducing factor, activin-beta-A, INHA, inhibin-alpha, Inhibin-beta-A, INHBA ) receptors (Endo et al, 2004; Maeshima et al, 2004; Panopoulou et al, 2005)
¥ ACVRL1 (activin A receptor type 2-like 1, ACVRLK1, Activin receptor-like kinase 1, ALK1, Activin receptor-like kinase 1, TSR1, TGF-beta superfamily receptor type 1, SKR3, Serine/threonine-protein kinase receptor R3, HHT2, Hereditary Hemorrhagic Telangiectasia Type 2, ORW2, Osler-Rendu-Weber syndrome type 2) (Van Geest et al, 2010)
¥ ADAM9 (disintegrin and metalloprotease domain 9, Meltrin-gamma, MLTNG, Myeloma Cell Metalloproteinase, MCMP, MDC-9, KIAA0021) (Nelson et al, 2007; Tunica et al, 2009)
¥ ADAM10 [disintegrin and metalloprotease domain 10, MADM, mammalian disintegrin metalloprotease, CDw156c, CD156c, kuzbanian, Kuzbanian homolog, KUZS, KUZL, EC3.4.24.81] (Boulday et al, 2001; Abel et al, 2004; Tunica et al, 2009; Donners et al, 2010)
¥ ADAM12 (disintegrin and metalloprotease domain 12, Meltrin-alpha, MLTNA) (Shastry and Tyagi, 2004)

¥ ADAM15 (disintegrin and metalloprotease domain 15, Metargidin, MDC-15, metalloproteinase-like disintegrin-like cysteine-rich protein-15, CRII-7) (Tunica et al, 2009)
¥ ADAM17 (disintegrin and metalloprotease domain 17, TACE, TNF-alpha converting enzyme, TACA, TNF-alpha converting activity, TNF-alpha convertase, TNF-alpha sheddase, cSVP, cellular snake venom-like protease, CD156b) (Bzowska et al, 2004; Blanchot-Jossic et al, 2005; Gšoz et al, 2009; Enis et al, 2008; Barbier et al, 2011)
ADAM20 (disintegrin and metalloprotease domain 20) (Nelson et al, 2007)
¥ ADAM21 (disintegrin and metalloprotease domain 21, ADAM31, disintegrin and metalloprotease domain 31) (Barbier et al, 2011)
¥ ADAM28 (disintegrin and metalloprotease domain 28, MDC-L, metalloproteinase-like disintegrin-like cysteine-rich protein L, MDC-3, metalloproteinase-like disintegrin-like cysteine-rich protein-3, ADAM23, disintegrin and metalloprotease domain 23) (Nelson et al, 2007; Barbier et al, 2011)
¥ ADAMTS1 (Disintegrin and metalloproteinase with thrombospondin motif-1, METH-1, KIAA1346) (Bongrazio et al, 2000; Glienke et al, 2000; Diamantis et al, 2000; Norata et al, 2004, 2007; Richards et al, 2005; Xu et al, 2006; Yue et al, 2006; Garcia-Conesa et al, 2009; Hatipoglu et al, 2009; Su et al, 2008; Hohberg et al, 2011; Dolan JM et al, 2012)
¥ ADAMTS4 (Disintegrin and metalloproteinase with thrombospondin motif-4, Aggrecanase-1, hyalectanase) (Glienke et al, 2000; Richards et al, 2005; Kahn et al, 2000)
¥ ADAMTS9 (Disintegrin and metalloproteinase with thrombospondin motif-9) (Jungers et al, 2005; Nelson et al, 2007; Koo BH et al, 2010)
¥ ADAMTS13 (von Willebrand factor-cleaving protease, VWFCP, C9orf8, chromosome 9 open reading frame 8, thrombotic thrombocytopenic purpura) (Lopez and Dong, 2004; Turner et al, 2006; Shang et al, 2006; Cao et al, 2008; Nelson et al, 2007; Turner et al, 2009; Kling SJ et al, 2008; Zheng GJ et al, 2012; Frentzou et al, 2012; Tati R et al, 2011)
¥ ADAMTSL3 (ADAMTS-like-3, Punctin-2, KIAA1233) (Koo et al, 2007)
¥ adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) (Kaser et al, 2005)
¥¥ adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) receptors (Kawanami et al, 2004; Lin et al, 2004; Motoshima et al, 2004; Ouchi et al, 2004; Chen et al, 2003; Chen et al, 2008; Polowinczak-Przybylek and Melen-Mucha, 2009; Lee MH et al, 2008)
¥¥ adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) receptors (ADIPOR1, adiponectin receptor 1, PAQR1, progestin and adipoQ receptor family member 1, ACDCR1, TESBP1A, CGI-45, AURA43, augmented in rheumatoid arthritis 43) (Motoshima et al, 2004; Cammisotto PG and Bendayan, 2008; Cheng KK et al, 2007; Zhao HY et al, 2011; Xu Y et al, 2011)
¥¥ adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) receptors (ADIPOR2, adiponectin receptor 2, PAQR2, progestin and adipoQ receptor family member 2, ACDCR2) (Cheng KK et al, 2007)
¥ Adrenomedullin (ADM, AM) (Agorreta et al, 2004; Martinez et al, 2004; Tomoda et al, 2001; Nikitenko et al, 2000; Hofbauer et al, 2002; Hojo et al, 2001; Ogita et al, 2001; Saito et al, 2001; Sullivan et al, 2003; Dotsch et al, 2002; Ishihara et al, 1997; Barker et al, 1998; Isumi et al, 1998; Shinoki et al, 1998; Evans et al, 2002; Sullivan et al, 2003; Kis et al, 2002; Sugo et al, 1994; Khodarev et al, 2003; Nagoshi et al, 2004; Dschietzig et al, 2001; Iinuma N et al, 2010)
¥¥ Adrenomedullin (ADM, AM) receptors (Iinuma N et al, 2010)
¥ Adrenomedullin-2 (AM2, ADM2, intermedin, IMD(1-47), IMD(8-47), IMD(1-53), IMD) (Pearson et al, 2009; Chauhan et al, 2009)
¥¥ Adrenomedullin (ADM, AM) receptors (calcitonin receptor-like receptor) (Martinez et al, 2004; Fernandez-Sauze, 2004; Nikitenko et al, 2000; Hagi-Pavli et al, 2004; Sugano et al, 2001; Barker et al, 2002; Shimekake et al, 1995; Kato et al, 1995; Aiyar et al, 2002; Fernandez-Sauze, 2004; Iimuro et al, 2004; Khodarev et al, 2003)
¥¥ Adropin (ENHO, energy homeostasis associated, C9orf165, chromosome 9 open reading frame 165) receptors (Lovren et al, 2010)
¥ aFGF (acidic fibroblast growth factor, FGF acidic, FGF-1, Fibroblast growth factor-1, FGF-alpha, Fibroblast growth factor-alpha, HBGF-1, heparin binding growth factor-1, ECGF-alpha, Endothelial cell growth factor-alpha, ECGF-beta, Endothelial cell growth factor-beta) (Aparicio et al, 2005; Antoine et al, 2005)
¥¥ aFGF (acidic fibroblast growth factor, FGF acidic, FGF-1, Fibroblast growth factor-1, FGF-alpha, Fibroblast growth factor-alpha, HBGF-1, heparin binding growth factor-1, ECGF-alpha, Endothelial cell growth factor-alpha, ECGF-beta, Endothelial cell growth factor-beta) receptors (Pendurthi et al, 1997; Delbridge and Khachigian, 1997; Garfinkel et al, 1996; Hull et al, 1996; Lingen et al, 1996; Minter et al, 1996; Iwasaka et al, 1996; Carley et al, 1996; Pendurthi et al, 1997; Kozian et al, 1997; Alessandri et al, 1999; Shin JW et al, 2006)
¥ Agrin (AGRN) (Reine TM et al, 2012; Sone and Nikolics, 1995; Zhang W et al, 2006)
¥ AIF-1 (Allograft inflammatory factor-1, daintain, MRF-1, microglial response factor-1, IBA-1, ionized calcium binding adaptor molecule-1, IRT-1, interferon response transcript 1) (Tian et al, 2009)
¥ ALK5 (Activin receptor-like kinase 5) (Ota T et al, 2002; Ray BN et al, 2010; Rudini N et al, 2008)
¥ Alpha-1-acid glycoprotein 1 (orosomucoid, orosomucoid 1, orosomucoid 2, ORM, ORM1, ORM2, ORM1*F1, ORM1*F2, ORM1*S, alpha-1-AGP, alpha-1-AGP 1, alpha-1-AGP 2, AGP, AGP1, AGP2, Alpha-1-acid glycoprotein, Alpha-1-acid glycoprotein 2, AGP-A, AGP-B, AGP-B-prime) (Sšrensson et al, 1999; Irmak et al, 2005; Boncela et al, 2006)
¥¥ Alpha-1-acid glycoprotein 1 (orosomucoid, orosomucoid 1, orosomucoid 2, ORM, ORM1, ORM2, ORM1*F1, ORM1*F2, ORM1*S, alpha-1-AGP, alpha-1-AGP 1, alpha-1-AGP 2, AGP, AGP1, AGP2, Alpha-1-acid glycoprotein, Alpha-1-acid glycoprotein 2, AGP-A, AGP-B, AGP-B-prime) receptors (Sšrensson et al, 2000)
¥ Alpha-2-Macroglobulin (Alpha-2MG, Alpha-2M, A2M) (Mallgard et al, 1988; Gruemmer et al, 2005; Talamini et al, 1998; Tunica et al, 2009)
¥ Alpha-B-crystallin (crystallin-alpha B, crystallin-alpha 2, alphaBC, CRYAB, CRYA2, REN-27, NY-REN-27, hspB5, heat shock protein beta-5) (Golenhofen et al, 2002)
¥¥ alpha-MSH (melanocyte stimulating hormone-alpha, alpha-melanotropin, alpha-melanocortin, melanotropin, POMC, proopiomelanocortin) receptors (Scholzen et al, 1999; Hartmeyer et al, 1997; de Angelis et al, 1995; Takeda N et al, 2007)
¥¥ AMF (TAMF, tumor autocrine motility factor, B16-F1 melanoma autocrine motility factor, Neuroleukin, NLK, phosphohexose isomerase, phosphoglucose isomerase, Glucose-6-phosphate isomerase, PGI, AMF/PGI, GPI, GPI1, glucose-6-phosphate isomerase, glucose-6-phosphate isomerase 1, SA-36, sperm antigen 36) receptors (AMFR) (Funasaka et al, 2002; Nakasaki et al, 2008; Jansen et al, 2009)
¥ ANF (Atrial natriuretic factor, natriuretic peptide, atrionatriuretic factor, Alpha-ANP, Atrial natriuretic polypeptide, ANP, Atrial polypeptide, Atriopeptin, cardionatrin, cardionatrin I, NPPA) (Brandt et al, 1995)
¥¥ ANF (Atrial natriuretic factor, natriuretic peptide, atrionatriuretic factor, Alpha-ANP, Atrial natriuretic polypeptide, ANP, Atrial polypeptide, Atriopeptin, cardionatrin, cardionatrin I, NPPA) receptors (Saijonmaa et al, 1998; Ignjatovic et al, 2004; Yoshizumi et al, 1998; Nazario et al, 1995; Failli et al, 2000; Furst et al, 2004; Zlock et al, 1997, Irwin et al, 2005)
¥ angiogenin (Angiogenin-1, Ang, Ang-1, RNASE5, ribonuclease A family 5, pancreatic ribonuclease, Rnase5a, ribonuclease A family 5a, RNASE1, RNASE1, DIP, degranulation inhibitory protein) (Hu et al, 2000; Moenner et al, 1994; Sadagopan et al, 2009; Nalla AK et al, 2011)
¥¥ angiogenin (Angiogenin-1, Ang, Ang-1, RNASE5, ribonuclease A family 5, Rnase5a, ribonuclease A family 5a, pancreatic ribonuclease, RNASE1, RNASE1, DIP, degranulation inhibitory protein) receptors (Chamoux et al, 1991; Badet et al, 1989; Heath et al, 1989; Hu et al, 1997; Liu et al, 2001)
¥¥ Angiogenin-3 (EF-5, E2a-Pbx1 target gene in fibroblasts 5, Angrp2, Angiogenin-related protein 2, Angl, angiogenin-like, Rnase5c, ribonuclease A family 5c) receptors (Fu et al, 1999)
¥ angiomotin (p80-angiomotin, p80-Amot, p130-angiomotin, p130-Amot, CAG-2, CAG trinucleotide repeat sequence 2) (Troyanovsky et al, 2001; Levchenko et al, 2003; Zheng Y et al, 2009; GagnŽ V et al, 2009)
¥ angiomotin-like-1 (AmotL-1, JEAP, junction-enriched and -associated protein) (Zheng Y et al, 2009; GagnŽ V et al, 2009)
¥ angiomotin-like-2 (AmotL-2, MASCOT, LCCP, Leman coiled-coil protein) (Sugihara-Mizuno et al, 2007)
¥ angiopoietin receptors (TIE-1, TIE-2) (Ross et al, 2001; Fujikawa et al, 1999; Huang et al, 1999; Hayes et al, 1999; Stahl et al, 2004; Kim et al, 2004; Favre et al, 2003; Krikun et al, 2000; Yabkowitz et al, 1997; Masckauchan et al, 2006; Wang Y et al, 2011)
¥ angiopoietin-1 (Ang-1, ANGPT1, KIAA0003) (Fan et al, 2004; Yue et al, 2006)
¥¥ angiopoietin-1 (Ang-1, ANGPT1, KIAA0003) receptors (TIE-2, TEK, tunica endothelial kinase, tunica interna endothelial cell kinase, CD202, CD202B) (Glienke et al, 2000; Kim et al, 2001; Reusch et al, 2001; Mochizuki et al, 2002; Kim et al, 2002, 2004; Kwak et al, 1999; Willam et al, 2000; Hashimoto et al, 2004; Papapetropoulos et al, 2000; Daly et al, 2004; Dumont et al, 1992; Favre et al, 2003; Tadros et al, 2003; Witmer et al, 2004; Hashimoto et al, 2004; Nilsson et al, 2004; Lee et al, 2004; Tournaire et al, 2004; Niu et al, 2004; Chen-Konak et al, 2003; Krikun et al, 2005; Khodarev et al, 2003; Abdel-Malak et al, 2007; Nguyen et al, 2007)
¥ angiopoietin-2 (Ang-2, ANGPT2) (Favre et al, 2003; Witzenbichler et al, 1998; Kim et al, 2000; Otani et al, 2001; Huang et al, 2002; Abe and Sato, 2001; Kahn et al, 2000; Lin et al, 2002; Hegen et al, 2004; Oh et al, 1999; Mandriota and Pepper, 1998; Gerritsen et al, 2003; Yamakawa et al, 2003; Bongrazio et al, 2000; Krikun et al, 2000; Gruemmer et al, 2005; Calvi et al, 2004; Bell et al, 2001; Garcia-Conesa et al, 2009; Inomata et al, 2009; Nelson et al, 2007; Rychli et al, 2010; Fuxe et al, 2010)
¥¥ angiopoietin-2 (Ang-2, ANGPT2) receptors (TIE-2, TEK, tunica endothelial kinase, tunica interna endothelial cell kinase, CD202, CD202B) (Hashimoto et al, 2004; Dumont et al, 1992; Favre et al, 2003; Tadros et al, 2003; Witmer et al, 2004; Hashimoto et al, 2004; Nilsson et al, 2004; Lee et al, 2004; Tournaire et al, 2004; Niu et al, 2004; Chen-Konak et al, 2003; Krikun et al, 2005; Khodarev et al, 2003; Witzenbichler et al, 1998; Nguyen et al, 2007)
¥¥ Angiopoietin-3 (Ang-3, ANGPT3, ANGPTL1, Angiopoietin-like-1, Angioarrestin, ARP-1, angiopoietin-related protein-1) receptors (TIE-2, TEK, tunica endothelial kinase, tunica interna endothelial cell kinase, CD202, CD202B) (Lee et al, 2004; Dumont et al, 1992; Favre et al, 2003; Tadros et al, 2003; Witmer et al, 2004; Hashimoto et al, 2004; Nilsson et al, 2004; Lee et al, 2004; Tournaire et al, 2004; Niu et al, 2004; Chen-Konak et al, 2003; Krikun et al, 2005; Khodarev et al, 2003)
¥ Angiopoietin-4 (Ang-4, ANGPT4) (Gerritsen et al, 2003; Yamakawa et al, 2003; Nelson et al, 2007)
¥¥ Angiopoietin-4 (Ang-4, ANGPT4) receptors (TIE-2, TEK, tunica endothelial kinase, tunica interna endothelial cell kinase, CD202, CD202B) (Lee et al, 2004; Yamakawa et al, 2003)
¥ angiopoietin-like-4 (ANGPTL4, ARP-4, angiopoietin-related protein-4, FIAF, fasting induced adipose factor, HFARP, hepatic fibrinogen/angiopoietin-related protein, PGAR, peroxisome proliferator-activated receptor-gamma-related protein) (Barbier et al, 2011)
¥¥ angiostatin (Angiostatin K1-4, plasminogen kringles 1-4, PK1-4, PlgK1-4, AST-1, angiostatin-1, AST-2, angiostatin-2) receptors (Jiang et al, 2001; Moser et al, 1999)
¥ Angiotensin-(1-7) receptors (mas) (Tallant et al, 1997; Santos et al, 2003; Kumar et al, 1996)
¥ angiotensin-2 (Wang et al, 1997; Fischer et al, 1997; Xiao et al, 2000; Hayashi et al, 2000; Kusaka et al, 2000)
¥¥ angiotensin-2 receptors (Feener et al, 1995; Montiel et al, 2005; Nabah et al, 2004; Sugano et al, 2001; Takeda et al, 1996; Otani et al, 2001; Stoll et al, 1995; Li et al, 1999; Li et al, 2001; Schena et al, 1999; Ferri et al, 1999; Rose and Audus, 1999; Tayeh et al, 1998; Mehta et al, 2002; Fischer et al, 2001; Grafe et al, 1997; Pueyo et al, 1997; Wolf et al, 1997; Ko et al, 1997; De Paolis et al, 1999; Bird et al, 2000; Hayashi et al, 2000; Vaughan et al, 1995; Yamagishi et al, 2005; Pan P et al, 2010)
¥¥ angiotensin-4 (Angiotensin-2(3-8), Ang-2(3-8)) receptors (Mehta et al, 2002; Briand et al, 1999; Hall et al, 1995)
¥ Annexin-1 (Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation inhibiting factor, CB9, chromobindin-9, calpactin-2) (Elderfield et al, 1993; Gil et al, 2006; Herbert et al, 2007; Oh et al, 2004; Probst-Cousin et al, 2004; Qiu et al, 2007; Raynal et al, 1993)
¥ Annexin-2 (Annexin A2, ANX2, ANXA2, PAP-4, placental anticoagulant protein 4, Lipocortin-2, Endonexin-2, Calpactin-1) (Aitkenhead et al, 2002; Dreier et al, 1998; Eberhard et al, 1994; Probst-Cousin et al, 1994; 2004; Qiu et al, 2007; Tunica et al, 2009)
¥ Annexin-5 (Annexin A5, ANX5, ANXA5, 35 kDa Calelectrin, 35-gamma Calcimedin, Anchorin C2, PAP-1, placental anticoagulant protein-1, CBP-I, Calphobindin-1, CBP, calphobindin, Endonexin-2, ENX2, Lipocortin V, Lipocortin-5, VAC-alpha, vascular anticoagulant-alpha, chromobindin-4, 32 kDa calcimedin, EEP 32-2, PP4, placental protein-4, CaBP33, calcium binding protein 33 kDa, CaBP37, calcium binding protein 37 kDa) (Boustead et al, 1993; Raynal et al, 1993; Tunica et al, 2009)
¥¥ Antiflammin-2 (AF-2, Anti-inflammatory peptide-2) receptors (Moreno, 2001)
¥ Apelin (APJ receptor ligand, APJ endogenous ligand, APLN, APEL, Apelin (42-77), Apelin-36, Apelin (65-77), Apelin-13) (Kasai et al, 2004; Eyries et al, 2008; Strasser et al, 2010; Poirier O et al, 2012; Zhang W et al, 2006)
¥¥ Apelin (APJ receptor ligand, APJ endogenous ligand, APLN, APEL, Apelin (42-77), Apelin-36, Apelin (65-77), Apelin-13) receptors (APJ, APLNR, APJR, Angiotensin Receptor-like-1, AGTRL1, B78/apj, X-msr, msr/APJ, GPR15, G-protein-coupled receptor-15, BOB; HG11) (Mukhtar et al, 2002; Li X et al, 2010; Lu Y et al, 2012)
¥ APOL1 (apolipoprotein L1, FSGS4, focal segmental glomerulosclerosis-4, TLF1, trypanosome lytic factor 1) (Zhaorigetu et al, 2008)
¥¥ Apolipoprotein A1 (APOA1, Serum PGI2 stabilizing factor) receptors (ATP5B, ATP Synthase-beta, ATPMB, ATPS-beta, ATPSB, beta-F1-ATPase, cell surface ATP Synthase, ecto-ATP Synthase, ecto-ATP Synthase-beta, ecto-ATPase, ecto-ATPS-beta, ecto-ATPSB, ecto-F1-ATPase, F0F1-ATP synthase, F0F1-ATP synthase beta subunit, F1-ATPase beta subunit, F1F0-ATP synthase, F1F0-ATP synthase beta subunit, H+-ATP synthase, mitochondrial ATP Synthase-beta) (Notari et al, 2010; Shin and Kim, 2010; VeitonmŠki et al, 2004; Fu et al, 2011)
¥ Artemin (ART, ARTN, Neublastin, Enovin) (Sawada et al, 2009)
¥ ARTS-1 (aminopeptidase regulator of TNFR1 shedding 1, A-LAP, adipocyte-derived leucine aminopeptidase) (Islam et al, 2006)
¥ autotaxin (ATX, ATX-alpha, ATX-beta, ATX-gamma, autotaxin-alpha, autotaxin-beta, autotaxin-gamma, ENPP-2 (ectonucleotide pyrophosphatase/phosphodiesterase 2, NPP-alpha, NPP-2, PDNP-2, phosphodiesterase nucleotide pyrophosphatase-2; phosphodiesterase-1/nucleotide pyrophosphatase-2, PDI-alpha, PD-1-alpha, lysophospholipase D, lysoPLD, ENPP2-beta, ENPP2-gamma, NPP2-alpha, NPP2-beta, NPP2-gamma, PD-1-alpha, PDN2-alpha) (Im et al, 2010; Ptaszynska et al, 2010; Kanda H et al, 2008; Abu El-Asrar et al, 2012)
¥¥ autotaxin (ATX, ATX-alpha, ATX-beta, ATX-gamma, autotaxin-alpha, autotaxin-beta, autotaxin-gamma, ENPP-2 (ectonucleotide pyrophosphatase/phosphodiesterase 2, NPP-alpha, NPP-2, PDNP-2, phosphodiesterase nucleotide pyrophosphatase-2; phosphodiesterase-1/nucleotide pyrophosphatase-2, PDI-alpha, PD-1-alpha, lysophospholipase D, lysoPLD, ENPP2-beta, ENPP2-gamma, NPP2-alpha, NPP2-beta, NPP2-gamma, PD-1-alpha, PDN2-alpha) receptors (Ptaszynska et al, 2010)
¥ axl (ark, adhesion related kinase, tyro7, tyrosine-protein kinase 7, UFO, JTK11) (D'Arcangelo et al, 2006; Kahn et al, 2000; Tunica et al, 2009)

¥ B7-H1 (B7 homolog-1, PDCD1L1, PDCD1 Ligand 1, PDL1, programmed death-1 ligand 1, CD274) (Mazanet and Hughes, 2003; Eppihimer et al, 2002; Brown et al, 2003; Iwai et al, 2003)
¥ B7-H3 (B7 homolog-3, B7RP-2, B7-related protein 2, B7-H3b, 2IgB7-H3, 4IgB7-H3, CD276) (Petroff et al, 2005)
¥ Bactericidal/permeability-increasing protein (BPI, CAP57, cationic antimicrobial protein 57) (Abe and Sato, 2001)
¥¥ Bactericidal/permeability-increasing protein (BPI, CAP57, cationic antimicrobial protein 57) receptors (van der Schaft et al, 2000)
¥ BAG-4 (BCL2-associated athanogene-4, BAG family molecular chaperone regulator 4, SODD, silencer of death domains) (Al-Lamki et al, 2003)
¥ BAG-5 (BCL2-associated athanogene-5, BAG family molecular chaperone regulator 5, KIAA0873) (Barbier et al, 2011)
¥ BAMBI (BMP and activin membrane-bound inhibitor, NMA, Non-metastatic gene A protein) (Guillot et al, 2012; Xavier et al, 2010)
¥ basigin (BSG, CD147, EMMPRIN, extracellular matrix metalloproteinase inducer, 5A11, CE-9, Collagenase stimulatory factor, gp42, HT7, M6, neurothelin, Oka blood group antigen, OX47) (Papoutsi et al, 2000; Yang et al, 2005; Chen et al, 2009)
¥ BASP1 (brain abundant membrane attached signal protein 1; brain acid-soluble protein 1, NAP-22, Neuron-enriched acidic protein 22kDa, 22 kDa neuronal tissue-enriched acidic protein, 9B1 antigen, CAP-23, cytoskeleton-associated protein 23) (Sprenger et al, 2006)
¥ BCL2L13 (BCL2-like-13, MIL1, BCLrambo) (Nelson et al, 2007; Barbier et al, 2011)
¥ BCL3 (B-cell lymphoma/leukemia-3) (Murakami et al, 2000; Barbier et al, 2011)
¥ BDNF (Brain-derived neurotrophic factor, Abrineurin) (Chen et al, 2005; Leventhal et al, 1999; Kim et al, 2004; Nakahashi et al, 2000; Bayas et al, 2002; Kallmann et al, 2002; Wang YD et al, 2008)
¥¥ BDNF (Brain-derived neurotrophic factor, Abrineurin) receptors (Kermani et al, 2005; Kim et al, 2004; Takeda et al, 2005)
¥ Beclin (Beclin-1, BECN1, ATG6, autophagy-related-6, coiled coil myosin-like BCL2-interacting protein, vps30, vacuolar protein sorting protein 30, APG6, autophagy gene 6, vpt30, vacuolar protein targeting protein 30) (Muller et al, 2011; Ramakrishnan et al, 2007)
¥ Beta-2-Microglobulin (Beta-2-M, B2M, Ly-m11, BDGF-2, bone-derived growth factor-2, CRG-8, cytokine responsive gene-8, Thymotaxin, GIP-2, granulocyte inhibitory protein, AURA54, augmented in rheumatoid arthritis 54) (Feng et al, 2007; Nelson et al, 2007; Tunica et al, 2009)
¥¥ Betacellulin (BTC, Bcn) receptors (Kim HS et al, 2003)
¥ betaglycan (TGFBR3, TGFR3, TbetaRIII, TbetaR3, transforming growth factor-beta receptor 3; TGF-beta receptor 3; TGF-beta receptor type 3; type 3 TGF-beta receptors) (Ciarmela et al, 2003; Brown et al, 1999; Loboda et al, 2006)
¥ Beta-IG-H3 (TGF-beta-inducible gene H3, BIGH3, TGFBI, transforming growth factor-beta-induced 68 kDa protein, TGF-beta-induced 68 kDa protein, Kerato-epithelin, ODM-42-I, RGD-CAP, RGD-containing collagen-associated protein) (Grillari et al, 2000; Aitkenhead et al, 2002; Ota T et al, 2002)
¥ Beta-Netrin (Hetrin, hepar-derived netrin-like protein, Netrin-4) (Shawber CJ et al, 2007)
¥¥ Beta-Netrin (Hetrin, hepar-derived netrin-like protein, Netrin-4) receptors (Larrieu-Lahargue F et al, 2010)
¥ bFGF (basic fibroblast growth factor, FGF basic, FGF-2, Fibroblast growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF-2, heparin binding growth factor-2) (Wijelath et al, 1997; Reinders et al, 2003; Martinez et al, 2004; Zhang et al, 2001; Coombes et al, 2001; Ko et al, 1999; Sapienza et al, 1998; Wondergem et al, 2004; Gabler et al, 2004; Maier et al, 1999; Aparicio et al, 2005; Gloe et al, 2002; Gaetano et al, 2001; Hannan et al, 1988; Gonzalez et al, 1996; Vlodavsky et al, 1987; Bae et al, 2009; Zhou et al, 2005; Antoine et al, 2005; Lecht et al, 2010; Passerini AG et al, 2003; Wang W et al, 2012)
¥¥ bFGF (basic fibroblast growth factor, FGF basic, FGF-2, Fibroblast growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF-2, heparin binding growth factor-2) receptors (Alessandri et al, 1999; Belgore et al, 2003; Bird et al, 2000; Castellon et al, 2002; Chen C et al, 1998; Feil and Augustin, 1998; Fischer et al, 1997, 2001; Gabler et al, 2004; Hayashi et al, 2005; Holmes and Zachary, 2008; Hull et al, 1996; Iwasaka et al, 1996; Jimi et al, 1995; Kessler et al, 2004; Kozian et al, 1997; Kress et al, 2006; Lecht S et al, 2010; Li et al, 2000; Lingen et al, 1996; Liu et al, 2003; Motamed et al, 2003; O'Connor et al, 2000; Pendurthi et al, 1997; Pepper et al, 1995; Sahni et al, 2004; Salcedo et al, 1999; Shin et al, 2004; Shin JW et al, 2006; Spinetti et al, 2001; Wempe et al, 1997; Wu JC et al, 2008; Wunderlich et al, 2000; Yoon et al, 2000)
¥ B-fibronectin (Zijlstra et al, 1999; Castellani et al, 2002)
¥ BFL-1 (A1, BCL2-like-5, BCL2L5, BCL2A1, BCL2-related protein A1, GRS) (Evans et al, 2000; Noble et al, 1999; Hu et al, 1998; Takeda N et al, 2007)
¥ Biglycan (BGN, PG-S1, Bone/cartilage proteoglycan 1; bone small proteoglycan 1, small proteoglycan 1, Proteoglycan-1, DSPG1, dermatan sulfate proteoglycan-1, SLRR1A) (Godoy-Guzm‡n C et al, 2012; Ayada Y et al, 2001; Calabrese et al, 2011; JŠrvelŠinen HT et al, 1991; Kaji T et al, 2004; Kinsella MG et al, 1997; Nelimarkka L et al, 1997; Schaefer L et al, 2001; Yamamoto K et al, 2012; Bjšrnson A et al, 2005; Zhang W et al, 2006; Alimohamad et al, 2005)
¥ BIRC2 (baculoviral IAP repeat-containing protein-2, API1, Apoptosis inhibitor 1, MIHB, mammalian IAP homolog B, HIAP2, Human inhibitor of apoptosis protein-2, cIAP1, cellular IAP1, TNFR2-TRAF signaling complex protein 2, RNF48, RING finger protein 48, ITA, Inhibitor of T-cell apoptosis) (Barbier et al, 2011)
¥ BIRC4 (baculoviral IAP repeat-containing protein-4, API3, Apoptosis inhibitor 3, XIAP, X-linked inhibitor of apoptosis, ILP, IAP-like protein, MIHA, mammalian IAP homolog A) (Tran et al, 1999)
¥ BLyS (B-lymphocyte stimulator, BAFF, B-cell activating factor belonging to the TNF family, TALL-1, TNF and ApoL related leukocyte expressed ligand-1, THANK, TNF homolog activating apoptosis nuclear factor-kappaB c-Jun NH2-terminal kinase, TNFSF13B, TNF ligand superfamily member 13B, TNFSF20, TNF ligand superfamily member 20, CD257) (Barbier et al, 2011)
¥ BMP1 (bone morphogenetic protein-1, procollagen C-proteinase, EC3.4.24.19; mammalian tolloid, mTld, tolloid, Tld) (Anderson et al, 2000)
¥ BMP2 (bone morphogenetic protein-2, bone morphogenetic protein-2A, BMP2A, BMP2-alpha) (Gerritsen et al, 2003; Bouletreau et al, 2002; Erickson et al, 2004; Anderson et al, 2000; Zhang et al, 2008; Abid et al, 2008; Zhou et al, 2005; Nelson et al, 2007; Su X et al, 2011)
¥¥ BMP2 (bone morphogenetic protein-2, bone morphogenetic protein-2A, BMP2A, BMP2-alpha) receptors (Li et al, 2000, 2005; Langenfeld and Langenfeld, 2004; Upton et al, 2008)
¥ BMP3 (bone morphogenetic protein-2, osteogenin) (Anderson et al, 2000)
¥ BMP4 (bone morphogenetic protein-4, bone morphogenetic protein-2B, BMP2B, DVR-4, decapentaplegic-Vg-related-4, BIP, bone-inducing protein) (Poole et al, 2002; Erickson et al, 2004; Anderson et al, 2000; Helbing T et al, 2010)
¥¥ BMP4 (bone morphogenetic protein-4, bone morphogenetic protein-2B, BMP2B, DVR-4, decapentaplegic-Vg-related-4, BIP, bone-inducing protein) receptors (Reese et al, 2004; Sorescu et al, 2004; Upton et al, 2008)
¥ BMP5 (bone morphogenetic protein-5, short ear, se) (Anderson et al, 2000; Morikawa et al, 2004)
¥ BMP6 (DVR-6, decapentaplegic-Vg-related-6, Vgr-1, vegetal-specific-related-1) (Glienke et al, 2000; Anderson et al, 2000; Sommer et al, 2009)
¥¥ BMP6 (DVR-6, decapentaplegic-Vg-related-6, Vgr-1, vegetal-specific-related-1) receptors (Upton et al, 2008)
¥ BMP7 (bone morphogenetic protein-7, OP-1, osteogenic protein-1, Eptotermin alfa, Osigraft) (Anderson et al, 2000)
¥¥ BMP7 (bone morphogenetic protein-7, OP-1, osteogenic protein-1, Eptotermin alfa, Osigraft) receptors (Upton et al, 2008)
¥ BMP9 (bone morphogenetic protein-9, GDF2, growth/differentiation factor-2) (Lin L et al, 2007)
¥¥ BMP9 (bone morphogenetic protein-9, GDF2, growth/differentiation factor-2) receptors (Star GP et al, 2010; Kim JH et al, 2012)
¥ BMPER (BMP binding endothelial regulator, Bone morphogenetic protein-binding endothelial cell precursor-derived regulator, CRIM3, cysteine-rich BMP regulator-3, Crossveinless-2, Cv-2) (Heinke et al, 2008; Moser et al, 2003; Helbing T et al, 2010; Helbing T et al, 2010)
¥ BMP receptors (Reese et al, 2004; Valdimarsdottir et al, 2002; Itoh et al, 2004; Erickson et al, 2004; David et al, 2007)
¥¥ BNP (Brain natriuretic peptide, B-type natriuretic peptide, NPPB, ASIP, Aldosterone Secretion Inhibitory Factor, BNP(1-32), BNP-32, Brain natriuretic peptide-36, N-terminal proBNP, NT-proBNP, gamma-BNP) receptors (Yoshizumi et al, 1999; Nazario et al, 1995)
¥¥ Bombesin (BN, BBS, GRP, gastrin releasing peptide, gastrin releasing hormone, Mammalian Bombesin, BLP, Bombesin-like peptide) receptors (Vigne et al, 1995)
¥ bradykinin (BK, BDK, BKN, Bradykinin(1-9), BK[1-9], Alpha-2-thiol proteinase inhibitor, Fitzgerald factor, Flaujeac factor, HMWK, HMWKa, High molecular weight kininogen, HMWK-kallikrein factor, KNG, KNG1, Kininogen, Kininogen-1, LMWK, Low molecular weight kininogen, Williams factor, Williams-Fitzgerald-Flaujeac factor) (Dedio et al, 2001)
¥¥ bradykinin (BK, BDK, BKN, Bradykinin(1-9), BK[1-9], Alpha-2-thiol proteinase inhibitor, Fitzgerald factor, Flaujeac factor, HMWK, HMWKa, High molecular weight kininogen, HMWK-kallikrein factor, KNG, KNG1, Kininogen, Kininogen-1, LMWK, Low molecular weight kininogen, Williams factor, Williams-Fitzgerald-Flaujeac factor) receptors (Bentley et al, 2000; Conklin et al, 1988; Duchene et al, 2007; Gonzalez et al, 1998; Gryglewski et al, 2002; Igarashi et al, 2001; Kimura et al, 2002; Kono et al, 2002; Liesmaa et al, 2007; McIntyre et al, 1985; Miyamoto et al, 2000; Morbidelli et al, 1998; Mount et al, 2008; Petrovic et al, 2007; Prat et al, 2000; Ritchie et al, 1998; Rodriguez et al, 2006; Scharfstein et al, 2000; Seegers et al, 2004; Smith et al, 1995; Stewen et al, 2004; Sung et al, 1988, 1989; Tayeh et al, 1998; Thuringer et al, 2002; Tran et al, 2000; Valdes et al, 2008; Vaziri et al, 2005; Venema et al, 1998; Wohlfart et al, 1997, 2008; Zhang et al, 2008)
¥ BTG1 (B-cell translocation gene-1, BTG family member 1) (Nelson et al, 2007)
¥ BTG3 (B-cell translocation gene-3, BTG family member 3, ANA, Abundant in Neuroepithelium Area) (Takeda N et al, 2007)

¥ C1 inhibitor (C1INH, Serpin G1; HAE1, hereditary angioedema type 1, HAE2, hereditary angioedema type 2) (Smaier et al, 1989; Lappin et al, 1992; Gulati et al, 1993; Gulati et al, 1994; Vastag et al, 1998)
¥ C1q (complement C1q; complement component 1 q; complement factor C1q, C1QA, complement component 1 q subcomponent A chain, C1QB, complement component 1 q subcomponent B chain, and C1QC, complement component 1 q subcomponent C chain) (Cao W et al, 2003; Bulla et al, 2008)
¥ C19orf10 (chromosome 19 open reading frame 10, SF20/IL25) (Tunica et al, 2009)
¥ C19orf33 (chromosome 19 open reading frame 33, IMUP-1, immortalization-upregulated protein 1, IMUP-2, immortalization-upregulated protein 2) (Nelson et al, 2007)
¥ cadherin-11 (Nelson et al, 2007)
¥ cadherin-13 (CDH13, CDHH, T-cadherin, T-cad, truncated cadherin, H-cadherin, heart cadherin, H/T-cadherin, T/H-cadherin, Tcad2, T-cadherin-2) (Ivanov et al, 2001; Haselton and Heimark, 1997; Wyder et al, 2000; Nelson et al, 2007)
¥ Calcitonin gene-related peptide (CALC1, CALCA, Calcitonin gene-related polypeptide-alpha, alpha-CGRP, CGRP-alpha, beta-CGRP, CGRP-beta, CGRP1, Calcitonin gene-related peptide-1, CGRP2, Calcitonin gene-related peptide-2, CALCB, Calcitonin gene-related polypeptide-beta, CALC2) (Kato et al, 1995; Doi et al, 2001; Zhang et al, 2009)
¥¥ Canstatin-N (Collagen type 4, collagen-4) receptors (He et al, 2004)
¥¥ CAP-37 (Cationic antimicrobial protein-37, Neutrophil-derived Heparin binding protein, HBP, heparin binding protein, Azurocidin, AZU1, azurocidin 1, NAZC, neutrophil azurocidin) receptors (Lee et al, 2003; Pereira et al, 1996)
¥ CARD5 (caspase recruitment domain-containing protein-5, ASC, apoptosis-associated speck-like protein containing a CARD, TMS1, target of methylation-induced silencing-1, PYCARD) (Kolly et al, 2010)
¥ CARD8 (caspase recruitment domain-containing protein-8, TUCAN, tumor upregulated CARD containing antagonist of caspase nine, NDPP-1, CARDINAL, CARD-inhibitor of NF-kappa-B-activating ligands, Dacar, KIAA0955) (Grosse et al, 2012)
¥ CARD10 (caspase recruitment domain-containing protein-10, CARMA3, CARD-MAGUK protein-3, BIMP1, BCL10-interacting MAGUK protein 1) (Barbier et al, 2011)
¥ CARD11 (caspase recruitment domain-containing protein-11, CARMA1, CARD-MAGUK protein-1, BIMP3, BCL10-interacting MAGUK protein 3) (Nelson et al, 2007)
¥¥ cardiotrophin-1 (CT-1, CTF1) receptors (Jougasaki et al, 2002; Fritzenwanger et al, 2008; Ichiki et al, 2008)
¥ Cartducin (CTRP3, C1q/TNF-related protein 3, C1ATNF3, Complement C1q tumor necrosis factor-related protein 3, C1QTNF3, C1q and tumor necrosis factor related protein 3, CORS26, collagenous repeat-containing sequence of 26-kDa protein, cartonectin) (Akiyama et al, 2007)
¥¥ Cartducin (CTRP3, C1q/TNF-related protein 3, C1ATNF3, Complement C1q tumor necrosis factor-related protein 3, C1QTNF3, C1q and tumor necrosis factor related protein 3, CORS26, collagenous repeat-containing sequence of 26-kDa protein, cartonectin) receptors (Akiyama et al, 2007)
¥ cathepsin H (Nelson et al, 2007)
¥ cathepsin L (CTSL, CAL, CATL, CTSL1, cathepsin L1, MEP, major excreted protein, IL8 converting enzyme, CP-2, cycling protein-2) (Gresser et al, 2001) (Altiok et al, 2006; Liu et al, 2006; Cunnane et al, 1999; Platt et al, 2006)
¥ caveolin-1 (CAV1, caveolae protein 1, Caveolin, CAV, caveolae protein 22 kDa, Alpha-Caveolin, beta-Caveolin, VIP21, Vesicular Integral-membrane Protein of 21 kDa, VIP21/caveolin) (Kathuria et al, 2004; Sun et al, 2003; Virgintino et al, 2002; Sprenger et al, 2006; van der Meer AD et al, 2009; Barbier et al, 2011)
¥ CCL1 (CC chemokine ligand 1, chemokine (C-C motif) ligand 1, SCYA1, I-309, TCA-3, T-cell activation-3, P500, SIS-epsilon) (Haque et al, 2000)
¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) (Cheng et al, 2002; Biernacki et al, 2004; Harkness et al, 2003; Strasly et al, 2004; Forestal et al, 2003; Somasundaram et al, 2005; Pellegrino et al, 2005; Gaugler et al, 2005; Meissner et al, 2003; Campbell et al, 2004; Oynebraten et al, 2004; Sundstrom et al, 2001; Jiang et al, 2004; Cha et al, 2000; Laudes et al, 2002; Goebeler et al, 1997; Beck et al, 1999; Guo et al, 2004; Damas et al, 2004; Wang et al, 2005; Yang et al, 2004; Reyes et al, 2002; Starnes et al, 2001; Mao et al, 2002; Lee et al, 2004; Ebnet et al, 1997; Omari et al, 2004; Vanderkerken et al, 2002; Carulli et al, 2005; Rollins et al, 1990; Tribolo et al, 2008; Ahmed et al, 2009; Norata et al, 2007; Liu et al, 2009; Ichiki et al, 2008; Sun et al, 2005; Fu et al, 2009; Morikawa et al, 2004; Murugesan G et al, 2000; Chen B et al, 2009; Chui and Dorovini-Zis, 2010; Chen T et al, 2010; Barbier et al, 2011; Kawanami et al, 2011)
¥¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) receptors (Salcedo et al, 2001; Galvez et al, 2005; Verma et al, 2003)
¥ CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) (Sundstrom et al, 2001; Cheng et al, 2003; Cha et al, 2000; Sun et al, 2005; Yang et al, 2002; Tay et al, 2004; Sommer et al, 2009; Chui and Dorovini-Zis, 2010)
¥ CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) (Sundstrom et al, 2001; Shukaliak et al, 2000; Reyes et al, 2002; Sommer et al, 2009; Barbier et al, 2011)
¥¥ CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) receptors (Quandt et al, 2004)
¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) (Cheng et al, 2002; Kotani et al, 2002; Wolf et al, 1997; Oynebraten et al, 2004; Lehmann et al, 2000; Sundstrom et al, 2001; Jiang et al, 2004; Shukaliak et al, 2000; Goebeler et al, 1997; Gnant et al, 2000; Ebnet et al, 1997; Sano et al, 1998; Omari et al, 2004; Hashimoto et al, 2000; Briones et al, 2001; Farahi et al, 2007; Khodarev et al, 2003; Sun et al, 2005; Sommer et al, 2009; Takeda N et al, 2007; Laubli et al, 2009; Chen T et al, 2010; Barbier et al, 2011)
¥¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) receptors (Quandt et al, 2004)
¥ CCL7 (CC chemokine ligand 7, chemokine (C-C motif) ligand 7, SCYA7, MCP-3, monocyte chemoattractant protein-3, FIC, Fibroblast-inducible cytokine, NC28, MARC, mast cell activation-related chemokine) (Kondo et al, 2000; Polentarutti et al, 1997; Dame et al, 2007; Sun et al, 2005)
¥ CCL8 (CC chemokine ligand 8, chemokine (C-C motif) ligand 8, SCYA8, MCP-2, monocyte monocyte chemoattractant protein-2, HC14, Cytokine 14, human) (Dame et al, 2007)
¥ CCL11 (CC chemokine ligand 11, chemokine (C-C motif) ligand 11, SCYA11, Eotaxin, Eotaxin-1) (Sundstrom et al, 2001; Jiang et al, 2004; Rothenberg et al, 1995; Ying et al, 1997, 1999; Farahi et al, 2007; Barbier et al, 2011)
¥¥ CCL11 (CC chemokine ligand 11, chemokine (C-C motif) ligand 11, SCYA11, Eotaxin, Eotaxin-1) receptors (Salcedo et al, 2001; Cheng et al, 2002)
¥ CCL15 (CC chemokine ligand 15, chemokine (C-C motif) ligand 15, HCC2, hemofiltrate CC-Chemokine-2, NCC3, new CC chemokine-3, MIP-5, macrophage inflammatory protein-5, Lkn-1, leukotactin-1, MIP-1-delta, macrophage inflammatory protein-1-delta, HMRP-2B, human MIP-related protein 2B, SCYL3, SCYA15) (Sun et al, 2005)
¥ CCL16 (CC chemokine ligand 16, chemokine (C-C motif) ligand 16, SCYA16, NCC4, new CC chemokine-4, LEC, liver-expressed chemokine, LCC-1, liver CC chemokine-1, HCC4, hemofiltrate CC-Chemokine-4, LMC, Lymphocyte and Monocyte Chemoattractant, Ck-beta-12, Chemokine-beta-12, Monotactin-1) receptors (CCR1) (Strasly et al, 2004)
¥ CCL17 (CC chemokine ligand 17, chemokine (C-C motif) ligand 17, SCYA17, TARC, Thymus and Activation Regulated Chemokine, ABCD-2) (Meissner et al, 2003; Ying S et al, 2008; Sommer et al, 2009)
¥ CCL18 (CC chemokine ligand 18, chemokine (C-C motif) ligand 18, AMAC-1, alternative activated macrophage associated CC-Chemokine, PARC, pulmonary and activation-regulated chemokine, MIP-4, macrophage inflammatory protein-4, DC-CK1, dendritic cell-derived chemokine-1, Ck-beta-7, Met-chemokine-beta-7, Met-Ck-beta-7, SCYA18) (Sommer et al, 2009; Barbier et al, 2011)
¥ CCL19 (CC chemokine ligand 19, chemokine (C-C motif) ligand 19, ELC, EBI-1-Ligand Chemokine, Exodus-3, MIP-3-beta, macrophage inflammatory protein-3-beta, Ck-beta-11, Chemokine-beta-11, SCYA19) (Nelson et al, 2007)
¥ CCL20 (CC chemokine ligand 20, chemokine (C-C motif) ligand 20, SCYA20, LARC, Liver and Activation Regulated Chemokine, Exodus, Exodus-1, MIP-3-alpha, macrophage inflammatory protein-3-alpha, Ck-beta-4, Chemokine-beta-4, ST38) (Fitzhugh et al, 2000; Meissner et al, 2003; Kriehuber et al, 2001; Hamid et al, 2007; Sommer et al, 2009; Chen T et al, 2010)
¥ CCL21 (CC chemokine ligand 21, chemokine (C-C motif) ligand 21, SCYA21, 6Ckine, chemokine with 6 cysteines, Ck-beta-9, Chemokine-beta-9, Exodus-2, SLC, Secondary Lymphoid-Tissue Chemokine, TCA-4, T-cell activation-4) (Kriehuber et al, 2001; Qu et al, 2004; Poole et al, 2002; Sun et al, 2005)
¥ CCL22 (CC chemokine ligand 22, chemokine (C-C motif) ligand 22, ABCD-1, DC/B-Ck, dendritic cell/B-cell derived chemokine, MDC, Human macrophage-derived chemokine STCP-1, stimulated T-cell chemotactic protein, SCYA22) (Sommer et al, 2009)
¥ CCL23 (CC chemokine ligand 23, chemokine (C-C motif) ligand 23, MIP-3, macrophage inflammatory protein-3, MPIF-1, Myeloid progenitor inhibitory factor-1, Ck-beta-8, Chemokine-beta-8, SCYA23) (Sun et al, 2005)
¥¥ CCL23 (CC chemokine ligand 23, chemokine (C-C motif) ligand 23, MIP-3, macrophage inflammatory protein-3, MPIF-1, Myeloid progenitor inhibitory factor-1, Ck-beta-8, Chemokine-beta-8, SCYA23) receptors (Son et al, 2006; Han et al, 2009)
¥ CCL24 (CC chemokine ligand 24, chemokine (C-C motif) ligand 24, MPIF-2, Myeloid progenitor inhibitory factor-2, Ck-beta-6, Chemokine-beta-6, eotaxin-2, SCYA24) (Farahi et al, 2007; Sommer et al, 2009)
¥ CCL26 (CC chemokine ligand 26, chemokine (C-C motif) ligand 26, chemokine N1, Eotaxin-3, IMAC, MIP-4-alpha, MIP-4a, macrophage inflammatory protein-4a, macrophage inflammatory protein-4-alpha, TSC-1, thymic stroma chemokine-1, SCYA26) (Oynebraten et al, 2004; Cuvelier and Patel, 2001; Shinkai et al, 1999; Farahi et al, 2007; Inomata et al, 2009; Miyagaki T et al, 2010)
¥ CCL27 (CC chemokine ligand 27, chemokine (C-C motif) ligand 27, ALP, CTACK, cutaneous T-cell attracting chemokine, ESkine, Embryonic stem cell chemokine, ILC, interleukin-11 receptor alpha-locus chemokine, IL11Ralpha-locus chemokine, PESKY, skinkine, SCYA27) (Farahi et al, 2007; Wick et al, 2008)
¥ CCL28 (CC chemokine ligand 28, chemokine (C-C motif) ligand 28, MEC, Mucosae-associated epithelial chemokine, mammary enriched chemokine, CCK1, SCYA28) (Sun et al, 2005)
¥ CCR1 (CC-Chemokine receptor 1, RANTES receptor, MIP-1-alpha receptor, LD78 receptor, CC-CKR1, HM145, YT4, CD191, CMKBR1, chemokine-beta receptor 1) (Strasly et al, 2004; Peiper et al, 1995; Khodarev et al, 2003; Sun et al, 2005)
¥ CCR2 (CC-Chemokine receptor 2, CC-CKR2A, CCR2A, CC-CKR2B, CCR2B, MCP-1 receptor A, MCP-1 receptor B, CMKBR2, chemokine-beta receptor 2, CD192) (Strasly et al, 2004; Weber et al, 1999; Salcedo et al, 2000; Carulli et al, 2005; Dzenko et al, 2005)
¥ CCR3 (CC-Chemokine receptor 3, CC-CKR3, Eotaxin receptor, CMKBR3, chemokine-beta receptor 3, MIP-1-alpha RL2, MIP-1-alpha receptor-like-2, CD193) (Salcedo et al, 2001; Cheng et al, 2002; Edinger et al, 1997; Hillyer et al, 2003; Mukhtar et al, 2002; Khodarev et al, 2003)
¥ CCR4 (CC-Chemokine receptor 4, CC-CKR4, CKR4, CMKBR4, chemokine-beta receptor 4, K5-5, CD194) (Hillyer et al, 2003)
¥ CCR5 (CC-Chemokine receptor 5, CC-CKR5, CMKBR5, ChemR13, CD195) (Hillyer et al, 2003; Edinger et al, 1997; Mukhtar et al, 2002; Kanmogne et al, 2000; Khodarev et al, 2003)
¥ CCR6 (CC-Chemokine receptor 6, GPRCY4, STRL22, DRY6, CKR-L3, CMKBR6, chemokine-beta receptor 6, GPR29, CD196) (Gerritsen et al, 2003; Hillyer et al, 2003)
¥ CCR7 (CC-Chemokine receptor 7, EBI-1, EBV induced gene-1, blr-2, CMKBR7, Burkitt lymphoma receptor-2, CD197) (Barbier et al, 2011)
¥ CCR8 (CC-Chemokine receptor 8, TER1, CY6, ChemR1, CMKBR8, chemokine-beta receptor 8, CKR-L1 CDw198) (Haque et al, 2001)
¥ CCR9 (CC-Chemokine receptor 9, GPR9-6, GPR28, G-protein-coupled receptor-28, CDw199) (Nibbs et al, 2001; Sun et al, 2005)
¥ CCRL2 (Chemokine CC Receptor-like-2, HCR, Human chemokine receptor, CCRL2A, Chemokine CC Receptor-like-2A, CCRL2B, Chemokine CC Receptor-like-2B, CRAM-A, chemokine receptor expressed in activated monocytes A, CRAM-B, chemokine receptor expressed in activated monocytes B, CRAM, chemokine receptor expressed in activated monocytes) (Monnier J et al, 2012)
¥ CD1b (Abe and Sato, 2001; Takeda N et al, 2007)
¥ CD1e (Nelson et al, 2007)
¥ CD9 (602-29 antigen, ALB6 antigen, BA2, BTCC-1, DRAP-27, Diphtheria toxin receptor associated protein 27 kDa, GIG2, MIC3, MRP-1, Motility-related protein-1, NCA, neural cell surface antigen, p24, SH-9, TSPAN29, tetraspanin 29) (Kagawa et al, 1996; Favaloro et al, 1993)
¥ CD10 (CALLA, common acute lymphocytic leukemia antigen; common ALL antigen, endopeptidase 24.11, enkephalinase, gp100, enkephalinase A, enkephalin-dipeptidyl-carboxypeptidase, kidney enkephalinase, renal brush-border neutral proteinase, kidney brush-border neutral proteinase, J5, atriopeptidase, MME, membrane metalloendopeptidase, NEP, neutral endopeptidase, EC3.4.24.11, neprilysin, neutral endopeptidase, neutral endopeptidase 24.11) (Gonzalez et al, 1998, 1999; Graf et al, 1995; Melzig et al, 1995; Muangman et al, 2005; Fitzpatrick et al, 2009)
¥ CD13 (alanyl aminopeptidase, AAP, ANPEP, alpha-aminoacyl-peptide hydrolase (microsomal), aminopeptidase N, PEPN, APN, APM, aminopeptidase M, EC3.4.11.2, LAP1, microsomal aminopeptidase, MY7, MCS-2, gp150) (Melzig et al, 1995; Goebeler et al, 1997; Favaloro, 1991; Favaloro et al, 1993; Petrovic et al, 2007; Tunica et al, 2009; Matsuda K et al, 2010)
¥ CD14 (endotoxin receptor, Leu M3, LPS-R, Mo2, MY4, myeloid cell-specific leucine-rich glycoprotein, hdl, heedless) (Gioannini et al, 2003; Mao et al, 2002; Brito et al, 2004; Gong et al, 2002; Jersmann et al, 2001)
¥¥ CD14 (endotoxin receptor, Leu M3, LPS-R, Mo2, MY4, myeloid cell-specific leucine-rich glycoprotein, hdl, heedless) (soluble) receptors (Pugin et al, 1995)
¥ CD15 (3-FAL, 3-Fucosyl-N-Acetyllactosamine, 3-FL, 3-Fucosyl-lactosamine, 80H.5, AGF 4.48, C3D-1, DAKO-M1, ELFT, ELAM-1 ligand fucosyltransferase, FAL, Fucosyl-N-Acetyllactosamine, 3-alpha-fucosyl-N-acetyl-lactosamine, FCT3A, alpha-3-fucosyltransferase, FUC-T-IV, fucosyltransferase 4, FUT-4, fucosyltransferase 4, LeuM1, LeX, Lewis X, X-hapten, hapten X, X-determinant, LNF-3, lacto-N-fucopentaose 3, LNFP-3, Lacto-N-Fucopentose 3 ceramide, MMA, My-1, myeloid-associated surface antigen, PMN7, polymorphonuclear leukocyte antigen 7, SSEA-1, stage-specific embryonic antigen-1) (Cebulla et al, 2000; Nelson et al, 2007)
¥ CD15s (CD15, 3-FAL, 3-Fucosyl-N-Acetyllactosamine, 3-FL, 3-Fucosyl-lactosamine, 80H.5, AGF 4.48, C3D-1, DAKO-M1, ELFT, ELAM-1 ligand fucosyltransferase, FAL, Fucosyl-N-Acetyllactosamine, 3-alpha-fucosyl-N-acetyl-lactosamine, FCT3A, alpha-3-fucosyltransferase, FUC-T-IV, fucosyltransferase 4, FUT-4, fucosyltransferase 4, LeuM1, LeX, Lewis X, X-hapten, hapten X, X-determinant, LNF-3, lacto-N-fucopentaose 3, LNFP-3, Lacto-N-Fucopentose 3 ceramide, MMA, My-1, myeloid-associated surface antigen, PMN7, polymorphonuclear leukocyte antigen 7, SSEA-1, stage-specific embryonic antigen-1) (Sialyl-Lewis X) (Cebulla et al, 2000; Akahori et al, 1997; Mitsuoka et al, 1997)
¥ CD16 (hFcRIII, Fc-gamma R3, FCGR3A, FCGR3, Neutrophil antigen NA, HNA1, human neutrophil antigen 1, Leu11, VEP13, B73.1, 31D8, N901) (Pan et al, 1998; Favaloro et al, 1993)
¥ CD20 (1F5, B1, Bp35, L26, Leu16, Ly44, MS4A1, membrane-spanning 4 domains subfamily A member 1, pan-B-cell antigen) (Favaloro et al, 1993)
¥ CD23 (CD23a, CD23b, FCER2, Fc-epsilon R2, Leu20, B6, Blast-2, 18.6 antigen, Ly42, CLEC4J, C-type lectin domain family 4 member J, EBVCS, EBV cell surface antigen, EBVCS1, EBVCS2, EBVCS3, EBVCS4, EBVCS5, MHM6) (Pino et al, 2004)
¥ CD24 (CD24a, 30F1, B2A2, BA-1, HB8, VIB E3, HIS50, HSA, heat stable antigen, J11d, JIId, Ly52, M1/69, Nectadrin, LR-1, SCLC surface antigen Cluster-4, CL-4; R13-Ag, R13 antigen, X62 heat stable antigen) (Favaloro et al, 1993; Hoeth M et al, 2012)
¥ CD26 (1F7, 2B9, 5F8, ACT-3, ADABP, ADA binding protein, ADCP2, adenosine deaminase complexing protein 2, BT5/9, DPCR1, DPP4, dipeptidyl peptidase 4, HAM.4, intestinal dipeptidyl peptidase, EC3.4.14.5, OX61, TA1, TA5/9, THAM, thymocyte-activating molecule, TP103, WC10 antigen, FAP-beta, Fibroblast activation protein-beta) (Pala et al, 2003; Favaloro et al, 1993; Aimes et al, 2003; Ghersi et al, 2006; Ugur et al, 2006)
¥ CD27 ligand (CD27L, CD27LG, CD70, Ki-24, TNFSF7, TNF ligand superfamily member 7) (Ugur et al, 2006)
¥ CD28 (T90/44, Tp44, Kolt-2) (Favaloro et al, 1993)
¥ CD29 (FNRB, fibronectin receptor beta chain, ITGB1, integrin-beta-1, platelet protein GPIIa, VLA-beta, very late activation antigen-beta, VLA-beta-1, VLA-4 beta subunit) (Lehmann et al, 2000; Favaloro et al, 1993; Banu et al, 2006; Srinivas et al, 1992; Liakka KA, 1994)
¥ CD31 (EndoCAM, endothelial cellular adhesion molecule, ER-MP12, PECAM-1, platelet-endothelial cell adhesion molecule 1) (Gaugler et al, 2005; Alessandri et al, 1999; Charalambous et al, 2005; Krikun et al, 2005; Li et al, 2001; Lehmann et al, 2000; Kriehuber et al, 2001; Norata et al, 2007; Qu et al, 2004; Gnant et al, 2000; Wondergem et al, 2004; Witmer et al, 2004; Dusserre et al, 2004; Salvucci et al, 2004; Favre et al, 2003; Sauter et al, 1998; Favaloro et al, 1993; Korff et al, 2006; Pusztaszeri et al, 2006; Srinivas et al, 1992; Matsuda K et al, 2010; Middleton J et al, 2005)
¥ CD32 (hFcRII, Fc-gamma R2, FCG2, FCGR2, CD32a, CD32b, FCGR2A, Fc-gamma R2a, FCGR2B, Fc-gamma R2b, IGFR2, immunoglobulin G Fc receptor 2) (Escribano-Burgos et al, 2005; Pan et al, 1998; Groger et al, 1996; Favaloro et al, 1993; Liang et al, 2006; Chen et al, 2008; Nan et al, 2005; Zhang W et al, 2006)
¥ CD34 (hemopoietic progenitor cell antigen 1, HPCA1, gp105-120, BI.3C5, ICH3, MY10, 188.27) (Favre et al, 2003; Sauter et al, 1998; Muller et al, 2002; Ito et al, 1995; Favaloro et al, 1993; Pusztaszeri et al, 2006; Salven et al, 2003;Minto et al, 2005; Grisanti S et al, 2004; Middleton J et al, 2005)
¥ CD35 (C3 binding protein, C3b receptor, C3bR, C3b/C4b receptor, C4b receptor, complement 3b/4b receptor, CR1, complement receptor-1, Knops blood group antigen, Kn(a), Kn(b), McCoy blood group antigen, McC, Swain-Langley blood group antigen, Sl, Yk(a), York blood group antigen) (Langeggen et al, 2002; Collard et al, 1999)
¥ CD36 (collagen type 1 receptor, FAT, fatty acid translocase, glycoprotein 3b, GP4, platelet glycoprotein 4, GPIIIb, Naka blood group antigen, OKM5, PAS-4 protein, periodic acid/Schiff-positive protein 4, PASIV, periodic acid/Schiff-positive band 4, platelet collagen receptor, thrombospondin receptor, UA009, obl, oblivious) (Schneider et al, 2003; Zhang et al, 2003; Favaloro et al, 1993; Satta et al, 2008; Martens et al, 2006; Srinivas et al, 1992; Madonna et al, 2011)
¥ CD39 (apyrase, ATPDase, ATP diphosphohydrolase, EC3.6.1.5, Ecto-Apyrase, Ecto-ATPase, ENTPD1, ectonucleoside triphosphate diphosphohydrolase 1, NTPDase-1, vascular ATP diphosphohydrolase, G28-8, Bgp95) (Kapojos et al, 2004; Kaneider et al, 2002; Kas-Deelen et al, 2001; Imai et al, 2000; Koziak et al, 1999; Kacmarek et al, 1996; Favaloro et al, 1993; Kansas et al, 1991; Morikawa et al, 2004; Nelson et al, 2007)
¥ CD40 (Bp50, TNFRSF5, TNF receptor superfamily member 5) (Dechanet et al, 1997; Omari et al, 2004; Damas et al, 2004; Reyes et al, 2002; Lienenluke et al 2000; Reinders et al, 2003; Mulhaupt et al, 2003; Sundstrom et al, 2001; Tan et al, 2004; Wagner et al, 2004; Karmann et al, 1995; Kotowicz et al, 2000; Verma et al, 2003; Norata et al, 2007; Pluvinet et al, 2008)
¥ CD40 ligand (CD40L, CD40LG, TRAP, TNF-related activation protein, CD154, 5c8, gp39, Ly62, T-BAM, IMD3, TNFSF5, TNF ligand superfamily member 5) (Mach et al, 1997; Wagner et al, 2004)
¥ CD41 (Bak, Bak(a), Bak(b), GPIIb, platelet glycoprotein IIb, HPA-3, human platelet antigen-3, ITGAB, integrin-alpha-2b, Lek(a)) (Favaloro et al, 1993)
¥ CD42a (CD42, GPIX, GP9, platelet glycoprotein 9) (Favaloro et al, 1993)
¥ CD44 (CDw44, CD44H, CD44A, CD44s, CD44st, CD44std, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, class 3 ECMR, gp85, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Price et al, 1996; Schneider et al, 2003; Serobyan et al, 2005; Forster-Horvath et al, 2004; Krettek et al, 2004; McKallip et al, 2003; Nandi et al, 2000; Favaloro et al, 1993; Kubota et al, 1990; Murray et al, 1995; Swerlick et al, 1991; Barbier et al, 2011)
¥ CD44v3 (CD44, CD44v, CD44H, CD44A, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Forster-Horv‡th C et al, 2004)
¥ CD44v6 (CD44, CD44v, CD44H, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1) (Tremmel et al, 2009)
¥ CD44v10 (CD44, CD44v, CD44H, CD44A, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Singleton PA and Bourguignon LY et al, 2004)
¥ CD46 (gp45-70, HuLy-m5, MCP, membrane cofactor protein, measles virus receptor, MIC10, TLX, TRA-2-10, trophoblast-leukocyte common antigen, trophoblast-lymphocyte cross-reactive antigen) (Li et al, 2004; Favaloro et al, 1993; Guc et al, 1993)
¥ CD47 (1D8, B6H12, BRIC 126, IAP, integrin-associated protein, integrin-associated signal transducer, MER6, OA3, ovarian carcinoma antigen 3, OVTL3) (Favaloro et al, 1993; Nelson et al, 2007)
¥ CD49 (Favaloro et al, 1993)
¥ CD49a (ITGA1, integrin-alpha-1, VLA-1, very late activation antigen 1, VLA-alpha 1, very late activation antigen alpha-1) (Lehmann et al, 2000; Norgall et al, 2007; Collo and Pepper, 1999)
¥ CD49b (Br alloantigen, DX5, ECMR-2, extracellular matrix receptor-2, GPIa, HPA-5, human platelet antigen-5, ITGA2, integrin-alpha-2, platelet glycoprotein Ia/IIa, VLA-2, very late activation antigen 2, VLAA2, VLA2 receptor alpha 2 subunit, VLA-alpha 2, very late activation antigen alpha-2, Zav alloantigen) (Kahn et al, 2000)
¥ CD49c (CSAT antigen band 2 protein, FRP-2, fusion regulatory protein-2, GAP-B3, galactoprotein B3, ITGA3, integrin-alpha-3, MSK18, VLA-3, very late activation antigen 3, ECMR-1, Extracellular matrix receptor-1, class 1 ECMR, VLA-alpha 3, very late activation antigen alpha-3, VLAA3, VLA-3 receptor alpha 3 subunit)) (Liakka KA, 1994)
¥ CD49d (ITGA4, integrin-alpha-4, VLA-4, very late activation antigen 4, VLAA4, VLA4 receptor alpha 4 subunit, VLA-alpha 4, very late activation antigen alpha-4) (Liakka KA, 1994)
¥ CD49e (fibronectin receptor alpha chain, FNRA, ITGA5, integrin-alpha-5, ECMR-6, Extracellular matrix receptor-6, class 6 ECMR, GPIc, platelet glycoprotein Ic, VLA-alpha 5, very late activation antigen alpha-5, VLA-5, very late activation antigen 5, VLA-5-alpha) (Lehmann et al, 2000; Collo and Pepper, 1999; Liakka KA, 1994)
¥ CD49f (ITGA6, integrin-alpha-6, platelet gpI, VLA-6, very late activation antigen 6, VLA-6 alpha chain, VLA-alpha 6, very late activation antigen alpha-6, GPIc*, platelet glycoprotein Ic*) (Liakka KA, 1994)
¥ CD50 (ICAM-3, intercellular adhesion molecule 3, ICAM-R, ICAM receptor) (van Buul et al, 2004; Favaloro et al, 1993; Dommann et al, 1997)
¥ CD51 (ITGAV, integrin-alpha-V, L230, MSK8 vitronectin receptor VNRA, vitronectin receptor alpha subunit) (Favaloro et al, 1993; Salven et al, 2003; Liakka KA, 1994)
¥ CD54 (7F7, BB2, human rhinovirus receptor, ICAM-1, intercellular adhesion molecule 1, IFN-gamma regulated human melanoma-associated antigen, Ly47, MALA-2, Me14-D12, P3.58) (Albrecht et al, 2004; Alessandri et al, 1999; An et al, 2009; Ancuta et al, 2004; Biernacki et al, 2004; Brossay et al, 2005; Campbell et al, 2004; Cha et al, 2000; Chang YH et al, 2005; Cheng et al, 2003; Cirillo et al, 2008; Crawford et al, 1992; Ebnet et al, 1997; Favaloro et al, 1993; Forestal et al, 2003; Galdiero et al, 1997; Gnant et al, 2000; Grafe et al, 1997; Hagi-Pavli et al, 2004; Ichiki et al, 2008; Innocenti et al, 2002; Jaruga et al, 2004; Izawa D et al, 1999; Kaplanski et al, 1998; Kawakami et al, 2002, 2004; Kim et al, 2001; Kubota et al, 1990; Lee WJ et al, 2009; Leung, 1999; Murakami et al, 2000; Murray et al, 1995; Nakagawa et al, 1995; Nelson et al, 2007; Norata et al, 2007; Otto et al, 2000; Pastore et al, 1999; Quinlan et al, 1999; Sano et al, 1998; Sommer et al, 2009; Steinhoff et al, 1993; Sundstrom et al, 2001; Swerlick et al, 1991; Takeda N et al, 2007; Tribolo et al, 2008; Ulrich et al, 2006; Verdegaal et al, 1996; Wondergem et al, 2004; Yang et al, 2007; Yang H et al, 2005; Barbier et al, 2011)
¥ CD55 (CD55a, CD55b, complement decay-accelerating factor, decay-accelerating factor, DAF, DAF-GPI, DAF-TM, GPI-DAF, TM-DAF, DAF1, decay-accelerating factor 1, DAF2, decay-accelerating factor 2, Cromer blood group antigen) (Li et al, 2004; Ahmad et al, 2003; Guc et al, 1993; Morikawa et al, 2004; Kubota et al, 1990; Lidington EA et al, 2000)
¥ CD58 (LFA-3, lymphocyte function-associated antigen-3, T11TS, T11 target structure) (Autschbach et al, 1991; Brossay et al, 2005; Crawford et al, 1992; Hansen et al, 2001; Kubota et al, 1990; Murray et al, 1995; Nakayama et al, 2001; Nelson et al, 2007; Omari and Dorovini-Zis, 1999; Savage et al, 1991; Steinhoff et al, 1993; Swerlick et al, 1991; Van Rhijn I et al, 2000)
¥ CD59 (CD59a, protectin, MIC11, MIN2, MIN3, MSK21, HRF20, homologous restriction factor-20 kDa, MACIF, membrane attack complex inhibitory factor, MAC-IP, MAC-inhibitory protein, H19, MIRL, membrane inhibitor of reactive lysis, P18, 1F5, 16.3A5, BRIC 229, YTH 53.1) (Li et al, 2004; Grubbs et al, 2003; Sprenger et al, 2006; Brossay et al, 2005; Murray et al, 1995; Tunica et al, 2009)
¥ CD61 (CD61A, F4, F11, GPIIb/IIIa, HPA-1, human platelet antigen-1, HPA-4, human platelet antigen-4, ITGB3, integrin-beta-3, Pen alloantigen, Pen(a), Pen(b), PL(A1), platelet fibrinogen receptor beta subunit, platelet glycoprotein IIIa, GP3A, Yuk alloantigen, Yuk(a), Yuk(b), Zw alloantigen, Zw(a), Zw(b)) (Sundstrom et al, 2001; Salven et al, 2003; D'Arcangelo et al, 2006; Wang YD et al, 2008)
¥ CD62E (ELAM, ELAM-1, endothelium leukocyte adhesion molecule 1, ESEL, E-selectin, selectin-E, SELE, GMP-140, GRMP, granulocyte membrane protein, LECAM-2, leukocyte adhesion molecule 2, platelet alpha-granule membrane protein) (Introna et al, 1993; Cheng et al, 2002; Forestal et al, 2003; Sundstrom et al, 2001; Zhang et al, 2001; Alessandri et al, 1999; Kim et al, 2001; Campbell et al, 2004; Hagi-Pavli et al, 2004; Grafe et al, 1997; Gnant et al, 2000; Kapper et al, 2002; Ebnet et al, 1997; Innocenti et al, 2002; Albrecht et al, 2004; Gruemmer et al, 2005; Yu et al, 2004; Sato et al, 1995; Cockerill et al, 1995; Galdiero et al, 1997; Lee et al, 2004; Makondo et al, 2004; Murakami et al, 2000; Brizzi et al, 1993; Gamble et al, 1993; Verdegaal et al, 1996; Wagnerova et al, 2002; Harrington et al, 2006; Ancuta et al, 2004; Satta et al, 2008; Norata et al, 2007; An et al, 2009; Steinhoff et al, 1993; Nelson et al, 2007, Lee WJ et al, 2009)
¥ CD62P (GMP-140, granule membrane protein 140 kDa, GRMP, LECAM-3, leukocyte-endothelial adhesion molecule 3, PADGEM, platelet activation dependent granule-external membrane protein, PSEL, P-selectin, S12 antigen, selectin-P, SELP) (Foreman et al, 1994; Tayeh et al, 1998; Sundstrom et al, 2001; Yao et al, 1996; Lehmann et al, 2000; Hailer et al, 2000; Kotowicz et al, 2000; Inomata et al, 2009; Fu et al, 2009; Norata et al, 2007; Nelson et al, 2007; Ibiza S et al, 2009; Manduteanu et al, 2010)
¥ CD63 (81H, AD1, GP55, granulophysin, HOP-26, LIMP, lysosomal integral membrane protein, LIMP-1, lysosomal integral membrane protein-1, ME491, melanoma associated antigen ME491, MLA1, melanoma-associated antigen 1, NGA, neuroglandular antigen, NKI-C3, OMA81H, ocular melanoma-associated antigen 81H, PLTGP40, platelet glycoprotein gp40, TSPAN30, tetraspanin 30) (Kobayashi et al, 2000)
¥ CD66 (CD66a, BGP, biliary glycoprotein, BGP-1, biliary glycoprotein 1, CEACAM-1, CEA-related cell adhesion molecule 1, CCAM, cell-cell adhesion molecule, CEACAMPS, NCA-160, nonspecific crossreacting antigen 160) (Kaiser et al, 2004; Salvucci et al, 2004; Kilic N et al, 2007)
¥ CD66e (CEA, carcinoembryonic antigen, CEACAM-5, CEA-related cell adhesion molecule 5, Meconium antigen 100) (Chen et al, 2000)
¥¥ CD66f (B1G1, FL-NCA-1/2, fetal liver nonspecific crossreactive antigen 1/2, PBG1, pregnancy-specific b1 glycoprotein, pregnancy-specific beta-1 glycoprotein C/D, PSBG1, PSG1, pregnancy-specific beta-1 glycoprotein 1, PSG, pregnancy-specific glycoprotein, PSG95, pregnancy-specific glycoprotein 95, PSGGA, pregnancy-specific glycoprotein gene A, SP-1, Schwangerschaftsprotein 1) receptors (Lisboa et al, 2011; Ha et al, 2010)
¥ CD73 (5'-ribonucleotide phosphohydrolase, EC3.1.3.5, L-VAP-2, Lymphocyte-vascular adhesion protein-2, NT5E, E5NT, E-5'Nu, NTE, ecto-5'-nucleotidase, 5'-nucleotidase, SH-3, SH-4) (Kalsi et al, 2002; Ledoux et al, 2002; Kas-Deelen et al, 2001; Airas et al, 1997; Li et al, 2008)
¥ CD74 (HLA-DR-gamma, HLADG, HLA class 2 histocompatibility antigen gamma chain, HLA-DR associated invariant chain, Ia-gamma, LN2, MHC class 2 invariant chain) (Barbier et al, 2011)
¥ CD77 (A4GALT, alpha-1,4-galactosylstransferase, BLA, Burkitt lymphoma antigen, Gal-beta-1-4Glc-beta-1-Cer alpha-1,4-galactosyltransferase, CD77 synthase, CTH, ceramide trihexoside, EC2.4.1.228, Gb3, GB3 synthase, Globotriaosyl ceramide Gb3, Globotriaosylceramide/CD77 synthase, Lactosylceramide 4-alpha-galactosyltransferase, P1 antigen, P1 synthase, P(k) antigen synthase, P(k) glycolipid) (Srinivas et al, 1992)
¥ CD79b (CD79-beta, B29, Ig-beta) (Nelson et al, 2007)
¥ CD80 (B7, B7-1, BB1, B-lymphoblast antigen-1, Ly53) (Tan et al, 2004; Kojima et al, 2001; Girvin et al, 2002)
¥ CD82 (4F9, C33, GR15, IA4, KAI1, KANGAI-1, R2, Inducible membrane protein R2, SAR2, surface antigen R2, ST6, suppressor of tumorigenicity-6, TSPAN27, tetraspanin 27) (Kahn et al, 2000; Nagao and Oka, 2011)
¥ CD83 (BL11, HB15) (Barbier et al, 2011)
¥ CD85d (LILRB2, leukocyte immunoglobulin-like receptor subfamily B member 2, ILT4, immunoglobulin-like transcript 4, LIR2, leukocyte immunoglobulin-like receptor 2, MIR10, monocyte/macrophage immunoglobulin-like receptor 10) (Cortesini et al, 2004; Cortesini and Suciu-Foca, 2006; Gleissner et al, 2007)
¥ CD85k (LILRB4, leukocyte immunoglobulin-like receptor subfamily B member 4, ILT3, immunoglobulin-like transcript 3, LIR5, leukocyte immunoglobulin-like receptor 5, HM18, Monocyte inhibitory receptor HM18, gp49B, gp49B1, gp49B2) (Cortesini et al, 2004; Cortesini and Suciu-Foca, 2006; Gleissner et al, 2007; Kim-Schulze et al, 2006)
¥ CD86 (B70, B72, B7-2, BU-63, CD28 ligand-2, CD28LG2, CLS1, FUN-1, GR65, LAB7-2, Ly58, MB7) (Brossay et al, 2005; Kojima et al, 2001; Maher et al, 1996; Lozanoska-Ochser et al, 2008)
¥ CD87 (MO3, PLAUR, plasminogen activator urokinase receptor, UPA-R, urokinase plasminogen activator receptor, URKR, urokinase receptor) (Sahni et al, 2004)
¥ CD88 (C5aR, C5a receptor, C5R1, complement component 5 receptor 1) (Abe and Sato, 2001; Albrecht et al, 2004; Foreman et al, 1994; Haviland et al, 1995; Hunt et al, 2005; Ikeda et al, 1997; Langeggen et al, 2001; Laudes et al, 2002; Monsinjon et al, 2003; Oksjoki et al, 2007; Schieferdecker et al, 1997; Schieferdecker et al, 2001; Schlaf et al, 1999, 2003, 2004; Schraufstatter et al, 2002; Wetsel et al, 1994; Manthey et al, 2011)
¥ CD89 (FCAR, Fc fragment of IgA receptor, IgA receptor, immunoglobulin A Fc receptor, Fc-alpha R, Fc-alpha RI) (Takeda N et al, 2007)
¥ CD90 (5E10, OX7, Thy1 [thymus cell antigen 1, Thy1.1, Thy1.2) (Wetzel et al, 2004; Saalbach et al, 2002; Ishizu et al, 1997; Mason et al, 1996)
¥ CD91 (A2MR, Alpha-2-Macroglobulin receptor, APOER, apolipoprotein E receptor, APR [apolipoprotein receptor, CED1, LRP, Low density lipoprotein receptor-related protein, LRP1, lipoprotein receptor-related protein, TGFBR5, TGF-beta receptor 5; transforming growth factor-beta receptor 5; TGF-beta receptor type 5; type 5 TGF-beta receptor, IGFBP3R, IGFBP3 receptor; Insulin-like growth factor binding protein-3 receptor) (Yan et al, 2009; Barbier et al, 2011)
¥ CD92 (CTL1, CHTL1, choline transporter-like protein 1, GR9, SLC44A1 [solute carrier family 44 member 1) (Tomi et al, 2007; Wille et al, 2001)
¥ CD93 (AA4, C1q receptor, C1qR1, C1qRp, collectin receptor, GR11, Ly68, MXRA4) (Dean et al, 2000, 2001; Nepomuceno and Tenner, 1998; Nepomuceno et al, 1999; Petrenko et al, 1999; Tunica et al, 2009)
¥ CD96 (TACTILE, TH-111 antigen) (Kaname et al, 2007)
¥ CD98 (CD98LC, 4F2lc, 4F2, 4F2hc, FRP-1, fusion regulatory protein-1, LAT1, system-L amino acid transporter 1, L-type amino acid transporter 1, Ly10, Ly-m10, MDU1, MPE16, membrane protein E16, RL-388, SLC3A2, solute carrier family 3 member 2, SLC7A5, solute carrier family 7 member 5) (Takeda N et al, 2007; Ugur et al, 2006)
¥ CD99 (12E7, MIC2, MIC2X, MIC2Y, E2 antigen, CD99R, O13, hec2, HBA-71) (Schenkel et al, 2002)
¥ CD99L2 (CD99 antigen-like 2, MIC2L1, MIC2-like protein 1) (Bixel et al, 2007)
¥ CD104 (A6 Antigen, ITGB4, integrin-beta-4, TSP-180, tumor-specific protein 180) (Morikawa et al, 2004; Nelson et al, 2007)
¥ CD105 (endoglin, ENG, Edg, L-endoglin, S-endoglin, E9 protein, MJ7/18 antigen, HHT1, hereditary hemorrhagic telangiectasia type 1, ORW, Osler-Rendu-Weber syndrome, ORW1, SH-2) (Blanco FJ et al, 2008; Cimpean AM et al, 2009; Clasper S et al, 2008; Grisanti S et al, 2004; Hawinkels LJ et al, 2010; Izawa D et al, 1999; Kwon JY et al, 2010; Li et al, 2001; Matsuda K et al, 2010; Middleton J et al, 2005; Ota T et al, 2002; Ray BN et al, 2010; Rudini N et al, 2008; Salven et al, 2003; She et al, 2004; Sullivan et al, 2003; Tian F et al, 2010; Tskitishvili E et al, 2010; Wang S and Hirschberg R, 2009; Wang YD et al, 2008; Wong et al, 2000; Yoshitomi et al, 2008; Zhang EG et al, 2002; Zhu et al, 2003; Barbier et al, 2011)
¥ CD106 (alpha-4-beta-1 ligand, INCAM-110, inducible cellular adhesion molecule 110 kDa, VCAM-1, vascular cellular adhesion molecule 1) (Alessandri et al, 1999; Hagi-Pavli et al, 2004; Jaruga et al, 2004; Kim et al, 2001; Zhang et al, 2001; Grafe et al, 1997; Tamasawa et al, 2001; Quinlan et al, 1999; Forestal et al, 2003; Sundstrom et al, 2001; Gnant et al, 2000; Kapper et al, 2002; Innocenti et al, 2002; Albrecht et al, 2004; Kaplanski et al, 1998; Wondergem et al, 2004; Gruemmer et al, 2005; Kawanami et al, 2004; Ebnet et al, 1997; Galdiero et al, 1997; Lee et al, 2004; Murakami et al, 2000; Kotowicz et al, 2000; Ulrich et al, 2006; Verdegaal et al, 1996; Verma et al, 2003; Cirillo et al, 2008; Tribolo et al, 2008; Abid et al, 2008; Ancuta et al, 2004; Chang YH et al, 2005; Norata et al, 2007; Steinhoff et al, 1993; Ibiza S et al, 2009; Lee WJ et al, 2009; Barbier et al, 2011)
¥ CD107a (LAMP-1, lysosome-associated membrane glycoprotein-1, LAMPA, lysosome-associated membrane glycoprotein A, LGP120, lysosomal glycoprotein 120) (Tunica et al, 2009)
¥ CD106 (alpha-4-beta-1 ligand, INCAM-110, inducible cellular adhesion molecule 110 kDa, VCAM-1, vascular cellular adhesion molecule 1) soluble (sVCAM-1) (Hummel et al, 2001; Wang YD et al, 2008)
¥ CD112 (HveB, Herpesvirus entry mediator B, Herpes simplex virus entry protein B, nectin-2, Nectin-2-alpha, Nectin-2-delta, PRR2, poliovirus receptor-related-2, PVRL2, Poliovirus receptor-like-2, PRR2-alpha, PRR2-delta) (Lopez et al, 1998)
¥ CD134 (OX40, TNFRSF4, TNF receptor superfamily member 4, TXGP1L, tax-transcriptionally activated glycoprotein 1 ligand, ACT-35, activation antigen-35) (Kahn et al, 2000)
¥ CD141 (thrombomodulin, TM, THBD, THRM, Alpha-Thrombomodulin, Beta-Thrombomodulin, fetomodulin, FM) (An et al, 2009; Archipoff G et al, 1991; Boehme et al, 1996; Conway and Rosenberg,1988; Edgar et al, 2006; Fang et al, 2009; Goralczyk et al, 2009; Gu et al, 2000; Hamik et al, 2007; Helenius et al, 2008; Hirokawa and Aoki, 1991; Iakhiaev et al, 2007; Kim HK et al, 2008; Lin et al, 2009; Martens et al, 2006; Minto et al, 2005; Morikawa et al, 2004; Murugesan G et al, 2000; Nachman et al, 1986; Nan et al, 2005; Ohji et al, 1995; Raife et al, 1996; Sato et al, 1998; Seguin et al, 2008; Takada et al, 1994; Takeda N et al, 2007; Uygur et al, 2009; Wang HJ et al, 2012)
¥ CD143 (ACE, angiotensin converting enzyme, angiotensin-1 converting enzyme, dipeptidyl carboxypeptidase, dipeptidyl carboxypeptidase 1, EC3.4.15.1, kininase 2, peptidase P, peptidyl dipeptidase A) (Del Vecchio et al, 1981; Ohishi et al, 1997; Melzig et al, 1995; Saijonmaa et al, 1998, 2000, 2001, 2004; Li et al, 2003; Zhang et al, 2001; Baudin et al, 1997; Villard et al, 1998; Balyasnikova et al, 1998; Koumbadinga GA et al, 2010)
¥ CD144 (7B4, cadherin-5, CDH5, VEC, vascular-endothelial cadherin, VE-cadherin, vascular-endothelial cadherin) (Alessandri et al, 1999; Charalambous et al, 2005; Kriehuber et al, 2001; Favre et al, 2003; Miao et al, 2005; Iurlaro et al, 2004; Martin et al, 2001; Takeichi et al, 2008; Zhu et al, 2008; Fainaru et al, 2008; Salven et al, 2003; Rudini N et al, 2008; Tunica et al, 2009; Matsuda K et al, 2010)
¥ CD146 (A32, BT14, L101, gp130 antigen, MCAM, Melanoma cell adhesion molecule, MelCAM, melanoma adhesion molecule, MUC18, P1H12, S-endo 1, Gicerin, 1-gicerin, s-gicerin) (Schneider et al, 2003; Middleton J et al, 2005; Li et al, 2003; Anfosso et al, 2001; Bardin et al, 1998; Schrage et al, 2008; Neidhart et al, 1999; Kahn et al, 2000; Nelson et al, 2007; Tunica et al, 2009)
¥ CD148 (143-41 antigen, DEP-1, high cell density-enhanced PTP-1, Density enhanced phosphatase-1, EC3.1.3.48, HPTP-eta, human protein tyrosine phosphatase-eta, protein tyrosine phosphatase-eta, p260, PTPRJ, Protein tyrosine phosphatase receptor type J, SCC1, susceptibility to colon cancer 1, protein tyrosine phosphatase-eta) (Takahashi et al, 2006)
¥ CD151 (PETA-3, platelet-endothelial cell tetraspan antigen 3, SFA-1, SF-HT activated gene 1, TSPAN24, tetraspanin 24, RAPH, Raph blood group) (Sincock et al, 1999)
¥ CD155 (Necl-5, Nectin-like molecule-5, PVR, poliovirus receptor, Tage-4, tumor associated glycoprotein E4, TuAg1) (Nelson et al, 2007; Zhang W et al, 2006)
¥ CD160 (BY55, NK1, NK28) (Fons et al, 2006; Yanez-Mo et al, 2008; Chabot et al, 2011)
¥ CD166 (2117 antigen, ALCAM, Activated leukocyte cell adhesion molecule, BEN, CD6L-100, DM-GRASP, F84.1 antigen, HCA, Hematopoietic cell antigen, JC7, KG-CAM, MEMD, melanoma metastasizing clone D, metastasizing melanoma protein D, MuSC, Neurolin, SC-1) (Ikeda and Quertermous, 2004)
¥ CD168 (HMMR, hyaluran-mediated motility receptor, IHABP, intracellular hyaluronic acid binding protein, RHAMM, receptor for hyaluronic acid-mediated motility, Receptor for HA-Mediated Motility) (Nelson et al, 2007; Lokeshwar and Selzer, 2000; Lowndes et al, 2009; Matou-Nasri et al, 2009)
¥ CD171 (8D9, CAML1, cellular adhesion molecule L1, G4, HSAS, HSAS1, L1, L1CAM, L1 cell adhesion molecule, MASA, MIC5, NCAM L1, neural cell adhesion molecule like-1, NgCAM, neuron-glia cell adhesion molecule, NILE, nerve growth factor-inducible large external, NGF-inducible large external, S10, SPG1, spastic paraplegia 1) (Maddaluno et al, 2007)
¥ CD200 (OX2, MOX2, MRC OX2, OX104, My033) (Cherwinski et al, 2005; Wright et al, 2001; Clasper S et al, 2008)
¥ CD201 (APC receptor, Activated protein C receptor, CCCA, cell cycle centrosome associated protein, CCD41, EPC-R, endothelial protein C receptor, PROCR, protein C receptor) (Laszik et al, 1997; Nan et al, 2005; Tunica et al, 2009; Riewald et al, 2002; Fukudome and Esmon, 1994; Ye et al, 1999)
¥ CD204 (Macrophage acetylated LDL receptor, MSR1, macrophage scavenger receptor, Scvr, Scavenger receptor class A, SR-A) (Loboda A et al, 2006; Tian et al, 2008; Shi Y and Tokunaga O, 2004; de Rijke YB and van Berkel TJ, 1994; Geng YJ and Hansson GK, 1995; Hughes DA et al, 1995)
¥ CD225 (fragilis2, IFI17, interferon-induced protein 17, IFITM1, interferon-induced transmembrane protein 1, 9-27, Interferon-inducible protein 9-27, Leu13) (Jaffe et al, 1989)
¥ CD226 (DNAM-1, DNAX accessory molecule 1, PTA1, platelet and T-cell activation antigen 1, TLiSA1, T lineage-specific activation antigen 1) (Chen et al, 2003)
¥ CD226 (DNAM-1, DNAX accessory molecule 1, PTA1, platelet and T-cell activation antigen 1, TLiSA1, T lineage-specific activation antigen 1) ligand (Kojima et al, 2003)
¥ CD243 (ABCB1, ATP-binding cassette subfamily B member 1, CLCS, Colchicine sensitivity, gp170, MDR-1, multidrug resistance to cancer 1, Mod-2, P-glycoprotein-1, PGY1) (Liu et al, 2009)
¥ CD246 (ALK1, ALK, anaplastic lymphoma kinase, anaplastic lymphoma kinase 1) (Ota T et al, 2002; Rudini N et al, 2008; Tian F et al, 2010; Wang S and Hirschberg R, 2009)
¥ CD248 (CD164L1, endosialin, TEM1, Tumor endothelial marker 1) (MacFadyen et al, 2005; Dolznig et al, 2005)
¥ CD252 (CD134 ligand, CD134L, gp34, OX40 ligand, OX40L, TNFSF4, TNF ligand superfamily member 4, TXGP1, tax-transcriptionally activated glycoprotein 1) (Kotani et al, 2002)
¥ CD275 (B7-H2, B7RP-1, B7-related protein 1, GL50, H4, ICOSL, inducible T-cell co-stimulator ligand, ICOS ligand, KIAA0653, LICOS, ligand for ICOS) (Tan et al, 2004; Khayyamian et al, 2002; Nelson et al, 2007)
¥ CD280 (CLEC13E, C-type lectin domain family 13 member E, ENDO180, KIAA0709, MRC2, mannose receptor C type 2, p180, uPARAP, Urokinase receptor-associated protein) (Sheikh et al, 2000; Wagenaar-Miller et al, 2007)
¥ CD300LG (CD300 molecule-like family member G, CLM9, CMRF35-like molecule-9, CMRF35-like molecule-9, NEPMUCIN, TREM4, triggering receptor expressed on myeloid cells 4, MAIR-IX, myeloid-associated immunoglobulin-like receptor IX) (Takatsu et al, 2006; Umemoto et al, 2006)
¥ CD337 (1C7, B144, LST1, leukocyte-specific transcript 1, Ly117, NCR3, natural cytotoxicity receptor 3, NKp30, Natural killer cell p30-related protein) (Nelson et al, 2007)
¥¥ ceruloplasmin (Cp, ferroxidase, Fe(II) - oxygen oxidoreductase, iron (II) - oxygen oxidoreductase, EC1.16.3.1, Ran-2 antigen, rat neural antigen-2, PACAP(1-38) binding factor, pituitary adenylate cyclase-activating polypeptide1-38-binding factor) receptors (Bianchini et al, 1999)
¥ Chemerin (RARRES2, retinoic acid receptor responder 2, tazarotene-induced gene-2, TIG2) (Vermi et al, 2005: Albanesi et al, 2009)
¥¥ Chemerin (RARRES2, retinoic acid receptor responder 2, tazarotene-induced gene-2, TIG2) receptors (ChemerinR, ChemR23, chemokine receptor 23, CMKLR1, chemokine-like receptor 1, Dez) (Nelson et al, 2007; Monnier J et al, 2012)
¥¥ cholecystokinin (CCK, pancreozymin) receptors (Ping J et al, 2009)
¥ Chondromodulin-1 (ChM-1, Chondromodulin, SCGP, small cartilage-derived glycoprotein, LECT1, leukocyte cell-derived chemotaxin-1) (Stagos et al, 2009; Zhou et al, 2009)
¥¥ chordin (CHRD, Chd) receptors (Reese et al, 2004)
¥ CIDE-B (Cell death-inducing DFF45-like effector B) (Zhang W et al, 2006)
¥ Claudin-8 (CLDN8) (Ohtsuki et al, 2008)
¥ CLEC14A (C-type lectin domain family 14 member A; C-type lectin 14A, CEG1, C14ORF27, chromosome 14 open reading frame 27, EGFR5, Epidermal growth factor receptor 5) (Mura et al, 2012; Rho et al, 2011)
¥ Clusterin (CLU, dimeric acidic glycoprotein, DAG protein, testosterone repressed prostate message-2, TRPM-2, sulfated glycoprotein-2, SGP-2, complement-associated protein SP-40,40, SP-40,40, complement lysis inhibitor, CLI, Apolipoprotein J) (Nelson et al, 2007)
¥¥ Clusterin (CLU, dimeric acidic glycoprotein, DAG protein, testosterone repressed prostate message-2, TRPM-2, sulfated glycoprotein-2, SGP-2, complement-associated protein SP-40,40, SP-40,40, complement lysis inhibitor, CLI, Apolipoprotein J) receptors (Sivamurthy et al, 2001; Guc et al, 1993)
¥¥ CNTF (Ciliary neuronotrophic factor, ciliary neurotrophic factor, MANS, membrane-associated neurotransmitter stimulating factor) receptors (CNTFR, ciliary neurotrophic factor receptor, CNTFR-alpha, Ciliary neurotrophic factor receptor-alpha; CNTF receptor-alpha, IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Nakazato et al, 1997)
¥ collagen type 4 (COL4A1, collagen-4-alpha-1, collagen-4, Arresten, Canstatin, Tumstatin) (Akaogi et al, 1996; Bakillah et al, 1996; Watanabe and Dvorak, 1997; Sauter et al, 1998; Lenz et al, 1998; Neubauer et al, 1999; Papadimitriou et al, 2001; Schaefer et al, 1996; Shanker et al, 2001; Webersinke G et al, 1992)
¥ collagen type 18 (collagen-18, COL18A1, collagen-18-alpha-1, HIAF-1, human inhibitor angiogenesis factor-1, endostatin precursor) (Knittel et al, 1994; Nasu et al, 2003; Wu et al, 2001; Musso et al, 2001)
¥ Collectin-12 (COLEC12, CL-P1, collectin placenta 1, SRCL, scavenger receptor with C-type lectin, SCARA4, Scavenger receptor class A member 4) (Ohtani et al, 2001; Jang et al, 2009; Graham et al, 2011; Koyama et al, 2011; Selman L et al, 2008)
¥ common beta (beta c, betac, Beta common, common cytokine receptor-beta, cytokine receptor common subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, IL3RB, IL3 receptor subunit beta, IL5RB, IL5 receptor subunit beta, GM-CSF receptor subunit beta, CD131) (Defilippi et al, 2005)
¥ complement factor C3 (ECI, Eosinophil cytotoxicity inhibitor, C3-beta-c, complement factor C3b, ETF-3, embryotrophic factor-3, HSE-MSF, hepatic sinusoidal endothelial cell-derived migration stimulating factor) (Hoie et al, 2004; Kawakami et al, 1997; Sheerin et al, 1997)
¥ complement factor H (factor H, CFH, H factor, HF, H factor-1, HF1, beta 1 H globulin, C3b inactivator accelerator, A-C3bINA, AMBP-1, AM34 antigen, Adrenomedullin binding protein-1, AM binding protein-1) (Ripoche et al, 1988; Brooimans et al, 1989; Dauchel et al, 1990; Vastag et al, 1998; Maresh et al, 2005; Nagy et al, 1996; Coulpier et al, 1995; Schwaeble et al, 1991; Guc et al, 1993; Julen et al, 1992; Griffiths et al, 2009)
¥ complement receptor-4 (CD11c, CD18) (Langeggen et al, 2002)
¥¥ Corticotropin releasing hormone (CRH, CRF, Corticotropin releasing factor, Corticoliberin) receptors (Fleisher-Berkovich and Danon, 1995; McEvoy et al, 2001; Saruta et al, 2005)
¥¥ cortistatin (Cort, CST, CST-14, Cortistatin-14, CST-17, Cortistatin-17) receptors (Yan et al, 2005)
¥ CRELD2 (cysteine-rich with EGF-like domains 2) (Albig et al, 2007)
¥ CRIM1 (cysteine-rich BMP regulator-1, cysteine-rich motor neuron protein 1) (Glienke et al, 2002)
¥¥ Cripto (Cripto-1, Cripto growth factor, CRGF, CR-1, TDGF-1, teratocarcinoma-derived growth factor-1) receptors (Bianco et al, 2005)
¥ CRP (C-reactive protein, PTX1, pentraxin-1, PCBP, phosphorylcholine-binding protein) (Kang et al, 2005; Venugopal et al, 2005; Singh et al, 2007)
¥¥ CRP (C-reactive protein, PTX1, pentraxin-1, PCBP, phosphorylcholine-binding protein) receptors (Nagoshi et al, 2004; Chen et al, 2008; Rodriguez et al, 2008; Devaraj et al, 2003; 2005, 2006; Nan et al, 2005; Venugopal et al, 2002; Liang et al, 2006; Zhang et al, 2006; Montero et al, 2006; Wang et al, 2005; Turu et al, 2008; Cirillo et al, 2005; Kawakami et al, 2006; Yang et al, 2005)
¥ CTGF (Connective tissue growth factor, Hcs24, hypertrophic chondrocyte-specific gene product 24, Fisp-12, fibroblast inducible secreted protein-12, IGFBP8, Insulin-like growth factor binding protein-8, IGFBPrP2, Insulin-like growth factor binding protein related protein-2, Ecogenin, endochondral ossification genetic factor, CCN2) (Li et al, 2000; Poole et al, 2002; Wunderlich et al, 2000; Muehlich et al, 2004; Rachfal et al, 2004; Kanyama et al, 2003; Zhou et al, 2005; Kahn et al, 2000; Morikawa et al, 2004; Samarin et al, 2010; Tunica et al, 2009; Barbier et al, 2011)
¥¥ CTGF (Connective tissue growth factor, Hcs24, hypertrophic chondrocyte-specific gene product 24, Fisp-12, fibroblast inducible secreted protein-12, IGFBP8, Insulin-like growth factor binding protein-8, IGFBPrP2, Insulin-like growth factor binding protein related protein-2, Ecogenin, endochondral ossification genetic factor, CCN2) receptors (Kaji et al, 2004; Shimo et al, 1999)
¥ CTRP1 (C1q/TNF-related protein 1, C1QTNF1, Complement C1q tumor necrosis factor-related protein 1, GIP, G protein-coupled receptor-interacting protein, ZSIG37) (Barbier et al, 2011; Lasser et al, 2006)
¥ CTRP6 (C1q/TNF-related protein 6, C1QTNF6, Complement C1q tumor necrosis factor-related protein 6, C1q and tumor necrosis factor related protein 6, ZACRP6) (Takeuchi et al, 2011)
¥ C-type natriuretic peptide (CNP, ANP-C, NPPC, natriuretic peptide precursor type C, CNP-22, CNP-53, NPPC) (Nazario et al, 1995; Zhang et al, 1999; Kubo et al, 2001; Sugiyama et al, 1995; Okahara et al, 1995; Yamada and Yokota, 1996; Komatsu et al, 1996; Suga et al, 1998; Evans et al, 2002; Pan et al, 2002; Ohta et al 1996; Jerczynska and Pawlowska, 2009)
¥¥ C-type natriuretic peptide (CNP, ANP-C, NPPC, natriuretic peptide precursor type C, CNP-22, CNP-53, NPPC) receptors (Yoshizumi et al, 1999)
¥ CX3CL1 (fractalkine, FKN, FK, CX3C membrane-anchored chemokine, C3Xkine, neurotactin, NTT, NTN, ABCD-3, SCYD1) (Ahn et al, 2004; Ancuta et al, 2004; Beck et al, 1999; Brueckmann et al, 2006; Dame et al, 2007; Feng et al, 2007; Garcia et al, 2000; Goda et al, 2000; Hamid et al, 2007; Harrison et al, 1999; Hatakeyama et al, 2004; Hosokawa et al, 2005; Hosokawa et al, 2005; Imaizumi et al, 2004; Ishida et al, 2008; Matsumiya et al, 2001; Moatti et al, 2004; Moon et al, 2006; Murakami et al, 2000; Popovic et al, 2008; Sans et al, 2007; Schulz et al, 2007; Sommer et al, 2009; Sun et al, 2005; Sung et al, 2005; Nelson et al, 2007; Yamashita et al, 2003; You et al, 2007; Zanchi et al, 2008; Manduteanu et al, 2009; Manduteanu et al, 2010; Chen T et al, 2010)
¥¥ CX3CL1 (fractalkine, FKN, FK, CX3C membrane-anchored chemokine, C3Xkine, neurotactin, NTT, NTN, ABCD-3, SCYD1) receptors (CX3CR1, V28, CMKBRL1, chemokine beta receptor-like-1, GPR13, G-protein-coupled receptor-13) (Yang et al, 2007; Lee et al, 2006; Ryu et al, 2008; SchŠfer et al, 2007; You et al, 2007)
¥ CXCL1 (CXC chemokine ligand 1, chemokine (C-X-C motif) ligand 1, SCYB1, CINC-1, Cytokine induced neutrophil chemoattractant-1, fsp, fibroblast secretory protein, GRO1, GRO-alpha, KC, MGSA, melanoma growth stimulatory activity, MGSA-alpha, melanoma growth stimulatory activity-alpha, NAP-3, neutrophil-activating protein-3, N51) (Introna et al, 1993; Ebnet et al, 1997; Beck et al, 1999; Kapper et al, 2002; Innocenti et al, 2002; Matsumiya et al, 2002; Izawa D et al, 1999; Lei et al, 2001; Gerritsen et al, 2003; Engl et al, 2004; Li et al, 2004; Otto et al, 2000; Liu et al, 2000; Laudes et al, 2002; Goebeler et al, 1997; Scholzen et al, 1999; Ohkubo et al, 1998; Armstrong et al, 2004; Oynebraten et al, 2004; Naidu et al, 2003; Warner et al, 2008; Sommer et al, 2009; Sun et al, 2005; Hamid et al, 2007; Tonai et al, 2001; Chang YH et al, 2005; Kahn et al, 2000; Takeda N et al, 2007; Tunica et al, 2009; Barbier et al, 2011; Fujie et al, 2010)
¥ CXCL2 (CXC chemokine ligand 2, chemokine (C-X-C motif) ligand 2, CINC-2-alpha, Cytokine induced neutrophil chemoattractant-2-alpha, GRO2, growth-related oncogene-2, GRO-beta, growth regulated oncogene-beta, MIP-2-alpha, macrophage inflammatory protein-2-alpha, MGSA-beta, melanoma growth stimulatory activity-beta, SCYB2) (Li et al, 2000; Gruemmer et al, 2005; Introna et al, 1993; Dame et al, 2007; Hamid et al, 2007; Sun et al, 2005; Zhou et al, 2005)
¥ CXCL3 (CXC chemokine ligand 3, chemokine (C-X-C motif) ligand 3, CINC-2-beta, Cytokine induced neutrophil chemoattractant-2-beta, DCIP-1, DC inflammatory protein-1, GRO3, GRO-gamma, growth regulated oncogene-gamma, growth-related oncogene-3, MGSA-gamma, melanoma growth stimulatory activity-gamma, MIP-2-beta, macrophage inflammatory protein-2-beta) (Engl et al, 2004; Hamid et al, 2007; Barbier et al, 2011)
¥ CXCL4 (CXC chemokine ligand 4, chemokine (C-X-C motif) ligand 4, PF4, platelet factor-4, Endothelial cell growth inhibitor, Heparin neutralizing protein, Megakaryocyte-stimulatory-factor, Oncostatin A, SCYB4) (Engl et al, 2004)
¥¥ CXCL4 (CXC chemokine ligand 4, chemokine (C-X-C motif) ligand 4, PF4, platelet factor-4, Endothelial cell growth inhibitor, Heparin neutralizing protein, Megakaryocyte-stimulatory-factor, Oncostatin A, SCYB4) receptors (Cornelius et al, 1995; Ito et al, 1995; Deo et al, 2004; Klein-Soyer et al, 1997)
¥ CXCL5 (CXC chemokine ligand 5, chemokine (C-X-C motif) ligand 5, ENA-78, Epithelial neutrophil-activating protein 78, epithelial cell-derived neutrophil attractant-78, LIX, LPS induced CXC chemokine, AMCF-2, Alveolar macrophage chemotactic factor-2, SCYB5) (Jaruga et al, 2004; Engl et al, 2004; Beck et al, 1999; Kapper et al, 2002; Imaizumi et al, 2003; Duchene et al, 2007; Hamid et al, 2007; Sun et al, 2005; Zhou et al, 2005; Fujie et al, 2010; Dolan JM et al, 2012)
¥ CXCL6 (CXC chemokine ligand 6, chemokine (C-X-C motif) ligand 6, GCP-2, granulocyte chemotactic peptide-2, CKA-3, chemokine alpha 3, SCYB6) (Engl et al, 2004; Beck et al, 1999; Gijsbers et al, 2004; Duchene et al, 2007; Sommer et al, 2009; Sun et al, 2005; Yeom HJ et al, 2009)
¥ CXCL7 (CXC chemokine ligand 7, chemokine (C-X-C motif) ligand 7, CTAP-3, Connective tissue activating protein-3, LA-PF4, low affinity platelet factor-4, LDGF, Leukocyte-derived growth factor, MDGF, macrophage-derived growth factor, NAP-2, Neutrophil-activating protein-2, PPBP, pro-platelet basic protein, PBP, platelet basic protein, SCYB7) (Beck et al, 1999; Sommer et al, 2009)
¥ CXCL9 (CXC chemokine ligand 9, chemokine (C-X-C motif) ligand 9, mig, monokine induced by gamma-Interferon, Humig, Mumig, CRG-10, cytokine responsive gene-10, M119, SCYB9) (Ebnet et al, 1997; Sheikh et al, 2001, 2005; Jaruga et al, 2004; Ghersa et al, 2002; Marx et al, 2000; Salvucci et al, 2004; Sommer et al, 2009; Dame et al, 2007; Sun et al, 2005; Feng et al, 2007; Chen WY et al, 2006)
¥ CXCL10 (CXC chemokine ligand 10, chemokine (C-X-C motif) ligand 10, IP-10, INP-10, inflammatory protein 10, Interferon-inducible protein-10, IFN-inducible protein 10, immune protein-10; 10 kDa interferon-inducible protein, gamma-IP-10, CRG-2, cytokine responsive gene-2, C7, Ifi10, interferon-inducible-10, mob-1, SCYB10) (Biernacki et al, 2004; Oynebraten et al, 2004; Jaruga et al, 2004; Narumi et al, 2000; Sundstrom et al, 2001; Marx et al, 2000; Goebeler et al, 1997; Briones et al, 2001; Sheikh et al, 2001, 2005; Ebnet et al, 1997; Salvucci et al, 2004; Takeichi et al, 2008; Dame et al, 2007; Feng et al, 2007; Chen et al, 2006; Tay et al, 2004; Ying S et al, 2008; Barbier et al, 2011)
¥ CXCL11 (CXC chemokine ligand 11, chemokine (C-X-C motif) ligand 11, H174, beta-R1, I-TAC, Interferon-inducible T-cell alpha chemoattractant, IP-9, interferon-gamma-inducible protein-9, SCYB11, SCYB9B) (Jaruga et al, 2004; Pellegrino et al, 2005; Marx et al, 2000; Mazanet et al, 2000; Sheikh et al, 2001, 2005; Dame et al, 2007; Chen WY et al, 2006; Takeda N et al, 2007; Nelson et al, 2007; Monnier J et al, 2012)
¥ CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced in hepatomas, SDF-1-alpha, CXCL12-alpha, SDF-1-beta, CXCL12-beta, SDF, SDF-1, Stromal cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic lymphoma cell stimulating factor-alpha, Thymic lymphoma cell stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA repressed gene-1, SCYB12) (Phillips and Ager, 2002; Yun and Yo, 2003; Pellegrino et al, 2005; Heidemann et al, 2004; Salvucci et al, 2004; Sommer et al, 2009; Sun et al, 2005; Sung et al, 2009; Liu KK and Dorovini-Zis, 2009)
¥¥ CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced in hepatomas, SDF-1-alpha, CXCL12-alpha, SDF-1-beta, CXCL12-beta, SDF, SDF-1, Stromal cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic lymphoma cell stimulating factor-alpha, Thymic lymphoma cell stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA repressed gene-1, SCYB12) receptors (CXCR4) (Salcedo et al, 2001)
¥ CXCL13 (CXC chemokine ligand 13, chemokine (C-X-C motif) ligand 13, BLC, B-lymphocyte chemoattractant, BCA-1, B-cell attracting chemokine 1, blr-1L, blr-1 ligand, Angie-2, SCYB13) (Amft et al, 2001; Takemura et al, 2001)
¥¥ CXCL13 (CXC chemokine ligand 13, chemokine (C-X-C motif) ligand 13, BLC, B-lymphocyte chemoattractant, BCA-1, B-cell attracting chemokine 1, blr-1L, blr-1 ligand, Angie-2, SCYB13) receptors (Spinetti et al, 2001)
¥ CXCL16 (CXC chemokine ligand 16, chemokine (C-X-C motif) ligand 16, SR-PSOX, scavenger receptor that binds phosphatidylserine and oxidized lipoprotein, SCYB16) (Abel et al, 2004; Heydtmann et al, 2005; Postea et al, 2008;Chen T et al, 2010; Barbier et al, 2011)
¥ CXCL17 (CXC chemokine ligand 17, chemokine (C-X-C motif) ligand 17, DMC, dendritic cell and monocyte chemokine-like protein, VCC-1, VEGF co-regulated chemokine 1) (Weinstein et al, 2006)
¥ CXCR3 (CXCR3A, CXC-Chemokine receptor 3, IP-10 receptor, Mig receptor, CKR-L2, GPR9, CD183) (mig, IP-10 receptors) (Hillyer et al, 2003; Ghersa et al, 2002; Romagnani et al, 2001; Salcedo et al, 2000; Garcia-Lopez et al, 2001)
¥ CXCR4 (CXC-Chemokine receptor 4, LESTR, leukocyte-derived 7-transmembrane domain receptor, HUMSTR, NPYRL, neuropeptide Y receptor-like, NPY3R, neuropeptide Y receptor Y3, HM89, Fusin, LCR-1, FB22, LAP3, Lipopolysaccharide-associated protein 3, SDF-1 receptor, CD184, AURA86, augmented in rheumatoid arthritis 86) (Hillyer et al, 2003; Edinger et al, 1997; Heidemann et al, 2004; Mukhtar et al, 2002; Lee et al, 2002; Yun and Yo, 2003; Salcedo et al, 2000; Mirshahi et al, 2000; Kahn et al, 2000; Kanmogne et al, 2000; Molino et al, 2000; Murdoch et al, 1999; Feil and Augustin, 1998; Gupta et al, 1998; Schutyser et al, 2007; Melchionna et al, 2005; Sun et al, 2005; Abdel-Malak et al, 2007; Takagi et al, 2009; Takeda N et al, 2007; Liu KK and Dorovini-Zis, 2009; Ota T et al, 2002; Strasser et al, 2010; Hoeth M et al, 2012)
¥ CXCR6 (CXC-Chemokine receptor 6, TYMSTR, T-lymphocyte-expressed seven-transmembrane domain receptor, Bonzo, STRL33, CD186) (Edinger et al, 1997; Hillyer et al, 2003; Salcedo et al, 1999)
¥ CXCR7 (CXC-Chemokine receptor 3, RDC1, CMKOR1, chemokine orphan receptor 1, GPR159, G-protein-coupled receptor-159) (Schutyser et al, 2007; Poole et al, 2002; Neusser et al, 2010; Monnier et al, 2011; Monnier J et al, 2012)
¥ cyclophilin A (CYPA, CYPH, Cyclosporin A binding protein, PPIA, peptidyl-prolyl cis-trans isomerase A, peptidylprolyl isomerase A, PPIase A, Rotamase A, sp18, secreted protein 18 kDa) (Kim H et al, 2004)
¥¥ cyclophilin A (CYPA, CYPH, Cyclosporin A binding protein, PPIA, peptidyl-prolyl cis-trans isomerase A, peptidylprolyl isomerase A, PPIase A, Rotamase A, sp18, secreted protein 18 kDa) receptors (Jin ZG et al, 2004; Yang et al, 2005; Kim SH et al, 2004)
¥ Cystatin C (CST3, Cystatin-3, Gamma-TRACE, post-gamma globulin) (Morata et al, 2003; Tunica et al, 2009)

¥ D6 (CCBP2, chemokine binding protein-2, CMKBR9, chemokine-beta receptor 9) (Bonecchi R et al, 2004; Nibbs RJ et a, 2001)
¥ DBP-Maf (vitamin D-binding protein-macrophage activating factor, GC, group-specific component, GC-globulin, VDBG, vitamin D-binding alpha-globulin, VDBG, DBP, vitamin D-binding protein) (Takeda N et al, 2007)
¥ DcR-3 (Decoy receptor-3, M68, TR6, TNF receptor-like-6, TNF receptor superfamily member 6b, TNFRSF6b) (Yu et al, 1999; Yoo S et al, 2012)
¥ DC-SIGN (dendritic cell-specific ICAM3-grabbing nonintegrin, DC-SIGN-1, dendritic cell-specific ICAM3-grabbing nonintegrin-1, CD209, CD209a, CIRE, C-type lectin immune receptor, CLEC4L, C-type lectin domain family 4 member L, gp120 binding protein, HIV gp120 binding protein, SIGNR1, SIGN related gene 1) (Mukhtar et al, 2002; Martens et al, 2006)
¥ DDR2 (discoidin domain receptor 2, MIG20a, cell migration-inducing protein 20, NTRKR3, neurotrophic tyrosine kinase receptor-related 3, Smallie, slie, TKT, tyrosine kinase related to TRK, tyro10, tyrosine-protein kinase 10, CD167b) (Goldsmith et al, 2010; Barbier et al, 2011)
¥ Decorin (DCN, PG40, proteoglycan 40 kDa, proteoglycan-2, PG2, decoron, Dermatan sulphate-containing proteoglycan 2, DS-PG2, PG-S2, proteoglycan S2, SLRR1B) (Bjšrnson A et al, 2005; Alimohamad et al, 2005)
¥ Dectin-1 (DC-associated C-type lectin 1, Dendritic cell-associated C-type lectin 1, dectin-1A, dectin-1B, CLEC7A, C-type lectin domain family 7 member A, CLECSF12, C-type lectin domain superfamily member 12, BGR, beta-glucan receptor, BGRA, Beta-glucan receptor A, BGRB, Beta-glucan receptor B) (Zhang PP et al, 2011)
¥ defensin-beta-1 (beta-Defensin-1, HBD-1, DEFB1, DEFB101) (Duits et al, 2000)
¥ defensin-beta-2 (beta-Defensin-2, DEFB4, HBD-2, SAP-1, skin antimicrobial peptide 1) (Kawsar et al, 2010)
¥ dermokine (Dmkn, sk30, sk30/sk89, sk89, sk89/sk30, Epidermis-specific secreted protein sk89) (Naso et al, 2007)
¥ dll4 (delta-like-4, delta-like ligand-4, Drosophila delta homolog 4, delta-4) (Harrington LS et al, 2008; Liu et al, 2003; Hainaud et al, 2006; Strasser et al, 2010; Claxton and Fruttiger, 2004)
¥ Dickkopf-1 (dkk-1, dickkopf-related protein 1, Sk) (Ueland et al, 2009)
¥ dickkopf-2 (dickkopf-related protein 2, dkk-2) (Hoeth M et al, 2012)
¥ dickkopf-3 (dickkopf-related protein 3, dkk-3, REIC, reduced expression in cancer) (Zitt et al, 2008; Tunica et al, 2009)
¥ delta-1 (dll1, delta-like-1, delta-like ligand-1, Drosophila delta homolog 1, CRLM-2, cytokine receptor-like molecule-2) (Takeda N et al, 2007; Sšrensen I et al, 2009)
¥ DRAK1 (DAP kinase-related apoptosis-inducing protein kinase-1, STK17A, serine/threonine protein kinase 17A) (Nelson et al, 2007)
¥ DR6 (death receptor-6, TNFRSF21, TNF receptor superfamily member 21, CD358) (Nelson et al, 2007)
¥ Duffy Antigen Receptor for Chemokines (CD234, DFA-ECKR, Duffy antigen-erythrocyte chemokine receptor, ECKR, erythrocyte chemokine receptor, DARC, Dfy, Duffy glycoprotein D, FY, Fy3, Fy6, Fya, Fya, Fyb, Fyb, glycoprotein D, glycoprotein Fy Duffy blood group antigen, gpFy) (Tournamille, 2000; Wick et al, 2008; Hadley et al, 1994; Middleton J et al, 2005; Izawa D et al, 1999)
¥ DUSP1 (dual-specificity phosphatase 1, CL100, PTPN10, protein-tyrosine phosphatase nonreceptor-type 10, nonreceptor-type protein-tyrosine phosphatase 10, 3CH134, par-1, prostate apoptosis response protein 1, hVH1, human VH1, erp, externally regulated phosphatase, MKP-1, MAP kinase phosphatase-1, AURA23, augmented in rheumatoid arthritis 23) (Sato et al, 1998; Chandrasekharan et al, 2004)

¥ EBI-3 (EBV induced gene-3, IL27B; IL27-beta, interleukin-27-beta) (Heidemann et al, 2007; Larousserie et al, 2004)
¥ E-cadherin (epithelial cadherin, Arc-1, cadherin-1, CDH1, CAM 120/80, ECAD, L-CAM, liver cell adhesion molecule, Uvomorulin, rrl antigen, CD324) (Zhu et al, 2008; Barbier et al, 2011)
¥ ECE-1 (Endothelin-converting enzyme 1, ECE, Endothelin-converting enzyme) (Ihling et al, 2001)
¥ ECGF receptors (Belloni et al, 1992)
¥ ECM1 (ECM1a, extracellular matrix protein 1, secretory component p85) (Albig et al, 2007)
¥ ECSM2 (Endothelial cell-specific molecule 2, ECSCR, endothelial cell-specific chemotaxis regulator, apoptosis regulator through modulating IAP expression) (Armstrong LJ et al, 2008; Ma F et al, 2009)
¥ EDIL3 (EGF-like repeats and discoidin I-like domains 3, Del-1, Developmental endothelial locus-1, Developmentally-regulated endothelial cell locus 1 protein) (Hidai et al, 1998, 2007)
¥¥ EGF (epidermal growth factor, EGF-URO, HMGF, human milk growth factor, PGF, prostatic growth factor, beta-Urogastrone, URO, URG, Urogastrone, tooth-lid factor) receptors (EGFR, EGF receptor 1, epidermal growth factor receptor 1, erb, erbB1, HER1, SA-7, species antigen 7) (Belloni et al, 1992; Bird et al, 2000; Lingen et al, 1996; Iwasaka et al, 1996; Kozian et al, 1997; Schraufstatter et al, 2003; Ushiro et al, 1996; Kallmann et al, 2002; Mergler et al, 2005; Hirata et al, 2004; Wunderlich et al, 2000; Schraufstatter et al, 2002; Moccia et al, 2003; Haug et al, 2001; Ohyama et al, 2001; Nelson et al, 2007; Sommer et al, 2009; Kim HS et al, 2003)
¥ Egr-1 (Early growth response gene-1, ETR103, d2, zif268, NGFI-A, nerve growth factor-inducible A, Krox-24, GOS-30, G0/G1 switch gene 30, TIS8, TPA-inducible sequence-8, tetradecanoyl phorbol acetate-inducible sequence-8, ZENK, zfp6, Zinc finger protein 6) (Gerritsen et al, 2003; Wang X et al, 2006; Abe and Sato, 2001; Lv et al, 2009; Patel N and Kalra VK, 2010; Zhang W et al, 2006)
¥ egr-2 (Early growth response gene-2, krox-20) (Abe and Sato, 2001)
¥ egr-3 (Early growth response gene-3, PILOT) (Liu et al, 2003; Abe and Sato, 2001)
¥ EG-VEGF (Endocrine gland-derived vascular endothelial growth factor, prokineticin-1, PROK1, PK1, PRK1, mambakine, black mamba toxin-related protein, MIT1, mamba intestinal protein 1, Bv8, Bombina variagata peptide 8) (Battersby S et al, 2004; Denison FC et al, 2008; Le Couter et al, 2003; Masuda et al, 2002; Guilini C et al, 2010)
¥¥ EG-VEGF (Endocrine gland-derived vascular endothelial growth factor, prokineticin-1, PROK1, PK1, PRK1, mambakine, black mamba toxin-related protein, MIT1, mamba intestinal protein 1, Bv8, Bombina variagata peptide 8) receptors (PROKR1, ZAQ, PK-R1, GPR73, GPR73a, GPR73b, G-protein-coupled receptor-73, G-protein-coupled receptor-73a, G-protein-coupled receptor-73b, PROKR2, I5E, PK-R2, GPR73L1, G-protein-coupled receptor-73-like 1 ) (Battersby S et al, 2004; Denison FC et al, 2008; LeCouter and Ferrara, 2003; Lin et al, 2002; Masuda et al, 2002; Hoffmann P et al, 2007; Jiang X et al, 2009; LeCouter J et al, 2001, 2003; Lin R et al, 2002; Masuda Y et al, 2002; Kisliouk T et al, 2003, Podlovni H et al, 2006)
¥¥ elastokine receptors (67-kDa elastin-binding protein, EBP, 67 kDa EBP, EBP67), GLB1, Bgl-e, beta-galactosidase-1, GM1 gangliosidase, GM1 ganglioside beta-galactosidase, EC3.2.1.23, Acid beta-galactosidase) (de Reeder EG et al, 1990; Fahem A et al, 2008; Robinet A et al, 2007; Barbier et al, 2011)
¥ EMAP-2 (Endothelial-monocyte activating polypeptide-2, p43, AIMP1, ARS-interacting multi-functional protein 1, SCYE1) (Clarijs R et al, 2003)
¥¥ EMAP-2 (Endothelial-monocyte activating polypeptide-2, p43, AIMP1, ARS-interacting multi-functional protein 1, SCYE1) receptors (Schwarz et al, 1999)
¥ EMP-1 (epithelial membrane protein-1, B4B, TMP, tumor-associated membrane protein, CL-20) (Bangsow et al, 2008)
¥ engrailed (Takeda N et al, 2007)
¥ Endocan (ESM-1, endothelial cell-specific molecule 1) (Lassalle et al, 1996; Aitkenhead et al 2002; Abid et al, 2008)
¥ Endostatin (collagen type 18, endostatin 18, endostatin XVIII) (Wu et al, 2001)
¥¥ Endostatin (collagen type 18, endostatin 18, endostatin XVIII) receptors (Li et al, 2005; Jiang et al, 2001)
¥ endothelin-1 (ET-1(1-21), ET-1, EDN1) (Saijonmaa et al, 1998; Ferri et al, 1999; Satoh et al, 1999; Zhang et al, 2001; Oriji, 1999; Morikawa et al, 2004; Nishikawa et al, 1998; Maes et al, 2004; Kusaka et al, 2000; Brandt et al, 1995; Saito et al, 2001; Sullivan et al, 2003; Barker et al, 2002; Charalambous et al, 2005; Bodin et al, 1995; Milner et al, 2004; Quehenberger et al, 2001; Ros et al, 1997; Molet et al, 2000; Evans et al, 2002; Sullivan et al, 2003; Saito et al, 1995; Frank et al, 2006; Stachon et al, 2004; Verma et al, 2003; Garcia-Conesa et al, 2009; Cai et al, 1999; Yang et al, 2005; Dschietzig et al, 2001; Spinella F et al, 2009; Star GP et al, 2010)
¥¥ endothelin-1 (ET-1(1-21), ET-1, EDN1) receptors (Charalambous et al, 2005; Schena et al, 1999; Kuhlmann et al, 2005; Saito et al, 1995; Frank et al, 2006; Daher et al, 2008; Spinella F et al, 2009)
¥ endothelin-2 (ET-2, EDN2) (Li et al, 2000; Zhou et al, 2005)
¥ endothelin-3 (ET-3, EDN3) (Cai et al, 1999; Spinella F et al, 2009)
¥ EOLA1 (endothelial-overexpressed lipopolysaccharide-associated factor-1) (Liang and Yang, 2004)
¥ EphA1 (Eph receptor A1, EPH, Esk, embryonic stem cell kinase) (Ivanov and Romanovsky, 2006; Yamashita et al, 2008; Sakamoto et al, 2011)
¥ EphA2 (Eph receptor A2, ECK, epithelial cell kinase) (Brantley-Sieders et al, 2004; Ivanov and Romanovsky, 2006; Cheng et al, 2002; Ojima et al, 2006; Tang FY et al, 2007; Barbier et al, 2011; Sakamoto et al, 2011)
¥ EphA3 (Eph receptor A3, HEK4, human embryo kinase-4, MEK4, mouse embryonic kinase-4, EPH-like tyrosine kinase, ETK1, eph-like tyrosine kinase 1, tyro4, tyrosine-protein kinase 4, Rek4) (Ivanov and Romanovsky, 2006; Nelson et al, 2007; Sakamoto et al, 2011)
¥ EphA4 (Eph receptor A4, Sek, Sek1, HEK8, human embryo kinase-8, tyro1, tyrosine-protein kinase 1) (Goldshmit et al, 2006; Ivanov and Romanovsky, 2006; Nelson et al, 2007; Sakamoto et al, 2011)
¥ ephA5 (Eph receptor A5, BSK, brain-specific kinase, HEK7, human embryo kinase-7, Rek7) (Sakamoto et al, 2011)
¥ EphA6 (Eph receptor A6, EHK2, EPH homology kinase-2) (Shaut et al, 2007; Sakamoto et al, 2011)
¥ EphA7 (Eph receptor A7, HEK11, human embryo kinase-11, MDK-1, Mouse Developmental Kinase-1) (Shaut et al, 2007; Sakamoto et al, 2011; Hoeth M et al, 2012)
¥ ephA8 (Eph receptor A8, HEK3, human embryo kinase-3, EEK, EPH and ELK-related kinase) (Sakamoto et al, 2011)
¥ EphB1 (Eph receptor B1, HEK6, human embryo kinase-6, ELK, Eph-like kinase, NET, neuronally expressed EPH-related tyrosine kinase, Cek6, chicken embryonic kinase 6, Xek, Xenopus Elk-like kinase) (Kojima et al, 2007; Sakamoto et al, 2011)
¥ EphB2 (Eph receptor B2, ERK, ELK-related tyrosine kinase, HEK5, human embryo kinase-5, Tyro5, tyrosine-protein kinase 5, Sek3, Rek5, DRT, developmentally regulated EPH-related tyrosine kinase, Nuk, Cek5, chicken embryonic kinase 5) (Iso et al, 2006; Diehl et al, 2005; Kim et al, 2002; Sakamoto et al, 2011)
¥ EphB3 (Eph receptor B3, HEK2, human embryo kinase-2, Tyro6, MDK5, Mouse Developmental Kinase-5, Sek4, Cek10, chicken embryonic kinase 10) (Kim et al, 2002; Sakamoto et al, 2011)
¥ EphB4 (Eph receptor B4, HTK, hepatoma transmembrane kinase, Myk1, Tyro11, tyrosine-protein kinase 11, MDK2, Mouse Developmental Kinase-2) (Gerety et al, 1999; Yuan et al, 2004; Hamada et al, 2003; Favre et al, 2003; Sakamoto et al, 2011)
¥ EphB6 (Eph receptor B6, HEP, human kinase-defective eph-family receptor protein, MEP, murine eph-family protein) (Sakamoto et al, 2011)
¥ ephrin A1 (EFNA1, B61, EPLG1, EPH-related receptor tyrosine kinase ligand-1, Epl1, TNFAIP4, tumor necrosis factor-alpha-induced protein 4, TNF-alpha-induced protein 4, LERK1, Ligand of eph-related kinase-1) (Cheng and Chen, 2001; Takahashi and Ikeda, 1995; Ota T et al, 2002; Favre et al, 2003)
¥ Ephrin A2 (EFNA2, ELF-1, Eph ligand family-1, EPLG6, EPH-related receptor tyrosine kinase ligand-6, Cek7 ligand, LERK6, Ligand of eph-related kinase-6) (Sakamoto et al, 2011)
¥ Ephrin A3 (EFNA3, LERK3, Ligand of eph-related kinase-3, ELF-2, Eph ligand family-2, EPLG3, EPH-related receptor tyrosine kinase ligand-3) (Takeda N et al, 2007; Sakamoto et al, 2011)
¥ Ephrin A4 (EFNA4, LERK4, Ligand of eph-related kinase-4, EPLG4, EPH-related receptor tyrosine kinase ligand-4) (Sakamoto et al, 2011)
¥ Ephrin A5 (EFNA5, AL-1, RAGS, repulsive axon guidance signal, LERK7, Ligand of eph-related kinase-7, EPLG7, EPH-related receptor tyrosine kinase ligand-7) (Sakamoto et al, 2011)
¥ ephrin B1 (EFNB1, ELK-L, ELK ligand, 25H11 antigen, EPLG2, EPH-related receptor tyrosine kinase ligand-2, LERK2, Ligand of eph-related kinase-2) (Favre et al, 2003; Huynh-Do et al, 2002; Kim et al, 2002; Sakamoto et al, 2011; Genet et al, 2012)
¥ ephrin B2 (EFNB2, HTK ligand, HTKL, EPLG5, EPH-related receptor tyrosine kinase ligand-5, LERK5, Ligand of eph-related kinase-5, NLERK1) (Ivanov and Romanovsky, 2006; Korff et al, 2006; Negrete et al, 2005; Hayashi et al, 2005; Goettsch et al, 2005; Diehl et al, 2005; Hamada et al, 2003; Korff et al, 2008; Hainaud et al, 2006; Favre et al, 2003; Braun J et al, 2011; Sakamoto et al, 2011; Kim JH et al, 2012; Hoeth M et al, 2012)
¥ ephrins (Holzman et al, 1990)
¥ erbB2 (p185erbB2, NGL, neuro/glioblastoma-derived, neu, HER2, human EGF receptor-2, EGF receptor 2, epidermal growth factor receptor 2, CD340) (Kim HS et al, 2003)
¥ erythropoietin (Epo, Ep, ECSA, erythroid colony stimulating activity, ESF, erythropoiesis stimulating factor) receptors (Zhong et al, 2004; Beleslin-Cokic et al, 2004; Fuste et al, 2002; DiFalco et al, 2002; Banerjee et al, 2000; Liefeldt et al, 1998; Yamaji et al, 1996; Anagnostou et al, 1994; Chong et al, 2007)
¥ ESAM (endothelial cell-selective adhesion molecule, ESAM-1, endothelial cell-selective adhesion molecule-1) (Hirata K et al, 2009; Hara T et al, 2009)
¥ E-selectin ligand-1 (ESL-1, CFR, cysteine-rich FGF receptor, CFR-1, cysteine-rich FGF receptor-1, MG-160, Selel, GLG1, Golgi complex-localized glycoprotein-1, GLG2) (Khodarev et al, 2003)

¥¥ factor VIIa (coagulation factor VIIa, FVIIa, F7a, coagulation factor VII, F7, SPCA, serum prothrombin conversion accelerator, proconvertin, convertin) receptors (Sethi et al, 2005; Brown et al, 2002)
¥ Factor XII (coagulation factor XII, FXII, F12) (Takeda N et al, 2007)
¥¥ Factor XII (coagulation factor XII, FXII, F12) receptors (Gordon et al, 1996; Schousboe I, 2003)
¥¥ factor Xa (FX, F10, coagulation factor X) receptors (Busch et al, 2005; Shimizu et al, 2004; Camerer et al, 2002; Bono et al, 2000; Senden et al, 1998; Jiang R et al, 2011)
¥ FAP-alpha (fibroblast activation protein, Fibroblast activation protein-alpha, FAP, FAPA, seprase, Seprase-s, seprase-l) (Aimes et al, 2003; Ghersi et al, 2006; Okada et al, 2003; Zhang W et al, 2006)
¥ FAS ligand (FASL, FASLG, APT1LG1, apoptosis antigen ligand 1, CD95 ligand, CD95L, APO-1 ligand, APTL, Apoptosis antigen ligand, TNF ligand superfamily member 6, TNFSF6, CD178) (Schneider et al, 2003)
¥ Favine (fat/vessel-derived secretory protein, CCDC3, Coiled-coil domain-containing protein 3) (Kobayashi et al, 2010)
¥ ferritin (H-Ferritin, FTH1, FTH, L-Ferritin, FTL, CD-GF, carcinoma-derived growth factor) (Oberle et al, 1998)
¥ ferroportin (FPN, FPN1, ferroportin-1, SLC40A1, solute carrier family 40 (iron-regulated transporter) member 1, SLC11A3, Solute carrier family 11 member 3, IREG1, iron-regulated transporter-1, MTP1, metal transporting protein 1, weissherbst, flatiron, ffe) (Khan et al, 2005; Nanami et al, 2005; Yang et al, 2002; Wu et al, 2004)
¥ Fetuin-A (FETUA, Fetuin, pp63, phosphorylated N-glycoprotein, 59 kDa bone sialoprotein, alpha-2-HS-glycoprotein, AHSG, alpha-2-Heremans-Schmid glycoprotein, Countertrypin, Haemonectin) (Mallgard et al, 1988)
¥ FGF-4 (fibroblast growth factor-4, K-FGF, Kaposi fibroblast growth factor, KS-FGF, Kaposi sarcoma FGF, KS protein, KS3, Kaposi sarcoma oncogene, eFGF, embryonic fibroblast growth factor, hst, hst-1, HBGF-4, heparin binding growth factor-4, HSTF-1, heparin binding secretory transforming factor-1) (Terada M et al, 1989; Dell'Era et al, 2001; Barbier et al, 2011)
¥¥ FGF-4 (fibroblast growth factor-4, K-FGF, Kaposi fibroblast growth factor, KS-FGF, Kaposi sarcoma FGF, KS protein, KS3, Kaposi sarcoma oncogene, eFGF, embryonic fibroblast growth factor, hst, hst-1, HBGF-4, heparin binding growth factor-4, HSTF-1, heparin binding secretory transforming factor-1) receptors (Dell'Era et al, 2001)
¥ FGF-5 (Fibroblast growth factor-5, HBGF-5, heparin binding growth factor-5, SMAG-82, smooth muscle cell activation-induced gene-82) (Keithan et al, 1997; Antoine et al, 2005)
¥¥ FGF-6 (Fibroblast growth factor-6, HBGF-6, heparin binding growth factor-6, hst-2, hst-1-related) receptors (Asada et al, 1999)
¥ FGF-8 (Fibroblast growth factor-8, AIGF, androgen induced growth factor) (Antoine M et al, 2005)
¥¥ FGF-9 (Fibroblast growth factor-9, HBGF-9, heparin binding growth factor-9, GAF, glia activating factor) receptors (Hendrix et al, 2006)
¥ FGF-12 (Fibroblast growth factor-12, FHF-1, fibroblast growth factor homologous factor-1) (Khodarev et al, 2003)
¥ FGF-16 (Fibroblast growth factor-16) (Gerritsen et al, 2003; Antoine et al, 2006; Yue et al, 2006; Kahn et al, 2000; Antoine et al, 2005; Nelson et al, 2007)
¥¥ FGF-16 (Fibroblast growth factor-16) receptors (Antoine et al, 2006)
¥ FGF-18 (Fibroblast growth factor-18) (Antoine et al, 2005, 2006; Hamid et al, 2007)
¥¥ FGF-18 (Fibroblast growth factor-18) receptors (Antoine et al, 2006; Kawano M et al, 2005; Nelson et al, 2007)
¥ FGF-20 (Fibroblast growth factor-20) (Zhang W et al, 2006)
¥ FGF-22 (Fibroblast growth factor-22) (Nelson et al, 2007)
¥ FGFR1 (fibroblast growth factor receptor-1, BFGFR, basic fibroblast growth factor receptor, FGFBR, FGFB receptor, flt-2, fms-like tyrosine kinase-2, flg, fms-like gene, N-sam, Cek1, chicken embryonic kinase 1, KAL2, Kallmann syndrome 2, CD331) (Antoine M et al, 2005; Bastaki et al, 1997; Chen C et al, 1998; Gonzalez et al, 1996; Hao Q et al, 2009; Holmes and Zachary, 2008; Kress et al, 2006; Larsson et al, 1999; Magnusson et al, 2005; Sahni et al, 2004; Tsou and Isik, 2001; Wang X et al, 2006; Wu JC et al, 2008; Wu JH et al, 2005; Zhang C et al, 2009)
¥ FGFR2 (fibroblast growth factor receptor-2, TK-14, bek, bacterially expressed kinase, Cek3, chicken embryonic kinase 3, K-sam, KATO-III cell-derived stomach cancer amplified gene, KGF receptor, KGFR, CD332) (Antoine M et al, 2005; Bastaki et al, 1997; Khodarev et al, 2003; Tsou and Isik, 2001; Nelson et al, 2007)
¥ FGFR3 (fibroblast growth factor receptor-3, Cek2, chicken embryonic kinase 2, flg-2, fms-like gene-2, JTK4, CD333) (Antoine M et al, 2005; Claus and Grothe, 2001; Shin JW et al, 2006; Lee S et al, 2009; Pan et al, 2009)
¥ FGFR5 (fibroblast growth factor receptor-5, FHFR, FGF homologous factor receptor, FGFRL1, Fibroblast growth factor receptor-like-1, FGF receptor-like protein 1) (Antoine M et al, 2005)
¥ fibronectin (FN, fibronectin-1, FN1, LETS, large external transformation-sensitive protein, Fibroblast surface antigen, SF antigen, SFA, CIg, CI globulin, cold-insoluble globulin, CSP, galactoprotein A, MSF, migration stimulating factor, Z protein) (Wang et al, 2005; Kondo S et al, 2007; Webersinke G et al, 1992)
¥ fibroleukin (T49, pT49, FGL2, fibrinogen-like-2, HEP64) (Ding et al, 1998; Clark et al, 1998; Liu et al, 2003; Ghanekar et al, 2004; Ning et al, 2005)
¥ Fibromodulin (FMOD, collagen binding 59 kDa protein, SLRR2E) (Alimohamad et al, 2005; Schšnherr et al, 2004; Mormone et al, 2012)
¥ Fibulin-1 (FBLN1, BM-90, basement membrane protein 90) (Tunica et al, 2009)
¥ Fibulin-5 (FBLN5, DANCE, developmental arteries and neural crest EGF-like, EVEC, embryonic vascular EGF-like repeat-containing protein) (Gruemmer et al, 2005; Albig and Schiemann, 2004)
¥ FIZZ-1 (found in inflammatory zone-1, HIMF, Hypoxia-induced mitogenic factor, Resistin-like molecule-alpha, RELM-alpha, Retnla, resistin-like alpha, XCP2, ten-cysteine protein 2) (Li D et al, 2005; Wagner et al, 2004)
¥¥ FIZZ-1 (found in inflammatory zone-1, HIMF, Hypoxia-induced mitogenic factor, Resistin-like molecule-alpha, RELM-alpha, Retnla, resistin-like alpha, XCP2, ten-cysteine protein 2) receptors (Tong Q et al, 2006; Yamaji-Kegan K et al, 2006; Pesce J et al, 2006)
¥¥ FIZZ-2 (found in inflammatory zone-2, RELM-beta, resistin-like molecule-beta, RETNLB, resistin like beta, XCP3, ten-cysteine protein 3) receptors (Angelini et al, 2009)
¥ FLRG (follistatin-related gene, follistatin-like-3, FSTL3) (Hayette et al, 1998)
¥ flt-3 (fms-like tyrosine kinase-3, flk-2, Fetal liver kinase-2, STK-1, stem cell tyrosine kinase-1, Ly72, CD135) (Zhong et al, 2004)
¥ follistatin (FST, Follicle stimulating hormone suppressing protein, FSP, Activin-binding protein) (Michel et al, 1996)
¥¥ follistatin (FST, Follicle stimulating hormone suppressing protein, FSP, Activin-binding protein) receptors (Maeshima et al, 2004)
¥ follistatin-like-1 (FSTL1, FSL1, TSC-36, TGF-beta-stimulated clone-36, follistatin-related protein, FRP, Follistatin-related protein-1, follistatin-like, occ1, Flik, XFRP, Xenopus laevis follistatin-related protein) (Tunica et al, 2009)
¥¥ follistatin-like-1 (FSTL1, FSL1, TSC-36, TGF-beta-stimulated clone-36, follistatin-related protein, FRP, Follistatin-related protein-1, follistatin-like, occ1, Flik, XFRP, Xenopus laevis follistatin-related protein) receptors (Ouchi et al, 2008)
¥¥ FPR1 (formyl peptide receptor-1, fMLP receptor, FRP, N-formyl peptide receptor, formyl peptide receptor) (Becker et al, 1998; Langeggen et al, 2001; Barbier et al, 2011)
¥¥ FPRL1 (formyl peptide receptor-like-1, FPRH1, formyl peptide receptor homolog-1, FPR2, formyl peptide receptor-2, lipoxin A4 receptor, ALXR, LXA4R, HM63) (O'Hara et al, 2004; Rotrosen et al, 1987; Lee HY et al, 2009; Mou H et al, 2012)
¥¥ FPRL2 (formyl peptide receptor-like-2, FPR-like-2, FPRH2, formyl peptide receptor homolog-2, FPR3, formyl peptide receptor-3) (Lee SY et al, 2008)
¥ frizzled-1 (frizzled family receptor 1, FzD1, Fz1) (Mao et al, 2000)
¥ frizzled-2 (frizzled family receptor 2, FzD2, FzE2, Fz2) (Mao et al, 2000)
¥ frizzled-3 (frizzled family receptor 3, FzD3, Fz3) (Goodwin et al, 2006)
¥ Frizzled-4 (frizzled family receptor 4, FzD4, Fz4, CD344, EVR1, exudative vitreoretinopathy 1) (Favre et al, 2003; Masckauchan et al, 2005; Dufourcq et al, 2008; Klein et al, 2008, 2009; Goodwin et al, 2006)
¥¥ Frizzled-4 (frizzled family receptor 4, FzD4, Fz4, CD344, EVR1, exudative vitreoretinopathy 1) receptors (Klein et al, 2009)
¥ frizzled-5 (frizzled family receptor 5, FzD5, Fz5, C2orf31, chromosome 2 open reading frame 31; HFZ5) (Masckauchan et al, 2005)
¥ frizzled-6 (frizzled family receptor 6, FzD6, Fz6, HFZ6) (Masckauchan et al, 2005; Goodwin et al, 2006)
¥ frizzled-7 (frizzled family receptor 7, FzD7, Fz7, FzE3) (Dufourcq et al, 2008)
¥¥ F-spondin (SPON1, spondin-1, VSGP, Vascular smooth muscle cell growth-promoting factor) receptors (Terai et al, 2001)

¥ Galectin-1 (Gal-1, LGALS1, galactose-specific soluble lectin 1, L-14-I, Lactose-binding lectin 1, S-lac lectin-1, Galaptin, 14 kDa beta-galactoside-binding lectin, 14 kDa lectin, HLBP14, 14 kDa laminin binding protein) (Perillo et al, 1995; Qiu et al, 2008; Thijssen et al, 2006, 2008; He and Baum, 2006; Clausse et al, 1999; Lotan et al, 1994; Baum et al, 1995; Tunica et al, 2009; Than et al, 2008; Stancic et al, 2011)
¥ Galectin-3 (Gal-3, LGALS3, galactose-specific soluble lectin 3, Mac-2, macrophage galactose-specific lectin-2, L-29, CBP-35, carbohydrate binding protein-35, IgE binding factor epsilon, Epsilon BP) (Fukushi et al, 2004; Gil et al, 2006; Thijssen et al, 2008; Lotan et al, 1994; Tunica et al, 2009; Stancic et al, 2011)
¥¥ Galectin-3 (Gal-3, LGALS3, galactose-specific soluble lectin 3, Mac-2, macrophage galactose-specific lectin-2, L-29, CBP-35, carbohydrate binding protein-35, IgE binding factor epsilon, Epsilon BP) receptors (Shekhar et al, 2004; Greenwald et al, 2009)
¥ Galectin-4 (Gal-4, LGALS4, galactose-specific soluble lectin 4, lectin galactoside-binding soluble 4, L-36, L-36LBP, Lactose-binding lectin 4, NY-CO-27 antigen) (Nelson et al, 2007)
¥ Galectin-8 (Gal-8, LGALS8, galactose-specific soluble lectin 8, PCTA1, Prostate carcinoma tumor antigen 1, Po66-CBP, Po66 carbohydrate-binding protein) (Thijssen et al, 2008; Delgado et al, 2011; Stancic et al, 2011)
¥ Galectin-9 (LGALS9, galactose-specific soluble lectin 9, Ecalectin, UAT, urate transporter, Tim-3L, Tim-3 ligand) (Thijssen et al, 2008; Imaizumi et al, 2002, 2007; Ishikawa et al, 2004; Stancic et al, 2011; Alam et al, 2011)
¥ gas-1 (Growth arrest-specific gene-1) (Barbier et al, 2011)
¥ gas-3 (Growth arrest-specific gene-3, peripheral myelin protein-22, PMP22, PAS2) (Bongrazio et al, 2000)
¥ gas-6 (Growth arrest-specific gene-6, Growth-potentiating factor, GPF, AXLLG, axl receptor tyrosine kinase ligand, AXSF, axl stimulatory factor) (Healy et al, 2001; Avanzi et al, 1998; Chan MC et al, 2000)
¥¥ gastrin (gastrin-17, Gastrin component 3, little Gastrin, Cholecystokinin B) receptors (Ibiza S et al, 2009)
¥ G-CSF (Granulocyte colony stimulating factor, CSF-3, colony stimulating factor-3, CSF-beta, colony stimulating factor-beta, G-CSA, granulocytic neutrophil colony stimulating activity, Pluripoietin-beta) (Dechanet et al, 1997; Korpelainen et al, 1995; Jonsson and Palmblad, 2001; Numasaki et al, 2004; Sato et al, 1995; Lenhoff and Olofsson, 1996; Ko et al, 1999; Yue et al, 2006; Hamid et al, 2007; Numasaki et al, 2004)
¥¥ G-CSF (Granulocyte colony stimulating factor, CSF-3, colony stimulating factor-3, CSF-beta, colony stimulating factor-beta, G-CSA, granulocytic neutrophil colony stimulating activity, Pluripoietin-beta) receptors (CD114, CSF3R, AURA28, augmented in rheumatoid arthritis 28) (Fuste et al, 2004; Schneider et al, 2003; Zhong et al, 2004)
¥¥ GDF5 (growth/differentiation factor-5, BMP14, Bone morphogenetic protein-14, CDMP-1, Cartilage-derived morphogenetic protein-1, LAP4, Lipopolysaccharide-associated protein 4, LPS-associated protein 4) receptors (Yamashita et al, 1997; Upton et al, 2008)
¥¥ GDNF (Glial cell line-derived neurotrophic factor, B49-derived neurotrophic factor, Astrocyte-derived trophic factor, ATF, ATF-1, Astrocyte-derived trophic factor-1, ATF-2, Astrocyte-derived trophic factor-2) receptors (ret) (Igarashi et al, 1999, 2001)
¥ ghrelin (GHRL, GRLN, MTLRP, motilin-related peptide, GHSR ligand, growth hormone secretagogue receptor ligand, GGDT, ghrelin gene-derived transcript) (Nelson et al, 2007; Ahluwalia A et al, 2009; Kleinz MJ et al, 2006; Li A et al, 2007)
¥¥ ghrelin (GHRL, GRLN, MTLRP, motilin-related peptide, GHSR ligand, growth hormone secretagogue receptor ligand, GGDT, ghrelin gene-derived transcript) receptors (GHSR, growth hormone secretagogue receptor, Growth hormone secretagogue receptor type 1, GHSR-1a, growth hormone secretagogue receptor 1a, GHSR-1b, growth hormone secretagogue receptor 1b, GRLNR, GH-releasing peptide receptor) (Li et al, 2004; Baiguera et al, 2004; Baldanzi et al, 2002; Hedayati et al, 2009; Hu et al, 2009; Ahluwalia A et al, 2009; Xu X et al, 2008; Xu Z et al, 2004; Chow KB et al, 2009; Iantorno M et al, 2007; Zhang M et al, 2007; Li A et al, 2007)
¥ gliomedin (GLDN, CRGL2, cancer-related gene liver 2) (Nelson et al, 2007)
¥¥ glucagon-like peptide-1 (GLP-1, 7-37, glucagon-like peptide 1 (7-37), GLP-1 (1-37), insulinotropin) receptors (Nelson et al, 2007; Ishibashi et al, 2010)
¥¥ glycodelin (PP14, placental protein 14, GdA, Glycodelin-A, GdS, Glycodelin-S, PAEP, progestagen-associated endometrial protein, pregnancy-associated endometrial alpha-2-globulin, progestagen-dependent endometrial protein) receptors (Song et al, 2001; Park JK et al, 2006)
¥ Glypican (glypican-1, glypican proteoglycan 1, GPC1, M12) (Bjšrnson A et al, 2005)
¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) (Li et al, 2000, 2004; Jurczyluk et al, 2003; Lehmann et al, 2000; Numasaki et al, 2004; Sato et al, 1995; Cockerill et al, 1995; Munoz et al, 1996; Lenhoff and Olofsson, 1996; Lacasse et al, 1997; Galdiero et al, 1997; Chen et al, 2003; Imaizumi et al, 2003; Kosaki et al, 1998; Ko et al, 1999; Ochiai et al, 1999; Jonsson and Palmblad, 2001; Burg et al, 2002; Nilsen et al, 1998; Sommer et al, 2009; Hamid et al, 2007; Zhou et al, 2005; Numasaki et al, 2004)
¥¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) receptors (CSF2RA, CSF-2 receptor-A, Colony stimulating factor-2 receptor A, Colony stimulating factor-2 receptor-alpha, CSF2R, CSF-2 receptor, Colony stimulating factor-2 receptor, CSF2RY, GMCSFR, GM-CSF receptor, CDw116, CD116; common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Soldi et al, 1997; Zhong et al, 2004; Krubasik et al, 2008; Nelson et al, 2007)
¥ GMF-gamma (Glial maturation factor-gamma, GMFG) (Ideka et al, 2006)
¥¥ gp130 (IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Ruprecht et al, 2001; Wang et al, 1992; Matsumiya et al, 2001; Jougasaki et al, 2002; Mahboubi et al 2003; Kahn et al, 2000; Rychli et al, 2010)
¥ GPR30 (G-protein-coupled receptor-30; CMKRL2; chemokine receptor-like 2; CEPR; constitutively/commonly expressed peptide-like receptor; LyGPR; lymphocyte-derived G-protein-coupled receptor; FEG1; flow induced endothelial G-protein-coupled receptor gene-1, GPER, G-protein-coupled estrogen receptor, GPER1, G-protein-coupled estrogen receptor1, DRY12, GPCR-Br) (Broughton et al, 2010; Holm et al, 2011; Isensee et al, 2009; Lindsey et al, 2011; Takada Y et al, 1997)
¥ Granzyme B (GZMB, Granzyme 2, serine protease B, SE-2, serine esterase-2, CSP-B, cytotoxic serine protease B, CCP1, cytotoxic cell protease-1, Asp-ase, CGL1, cathepsin G-like-1, CTLA-1, cytotoxic T-lymphocyte-associated serine esterase-1, fragmentin-2, RNKP1, rat natural killer protease-1) (Nelson et al, 2007)
¥ GRB10 (growth factor receptor-bound protein-10, Grb-IR, Meg-1, maternally expressed gene-1, KIAA0207) (Gerritsen et al, 2003)
¥ GRB14 (growth factor receptor-bound protein-14) (Gerritsen et al, 2003)
¥¥ growth hormone (GH, Somatotropic hormone, Somatotropin, GH1, growth hormone 1, GHN, growth hormone normal) receptors (Banziger-Tobler et al, 2008)

¥ HAI-1 (HAI, HGF activator inhibitor type 1, HGFA inhibitor-1, Hepatocyte growth factor activator inhibitor, HAI-1A, HGF activator inhibitor type 1A, HAI-1B, HGF activator inhibitor type 1B, SPINT1, serine peptidase inhibitor Kunitz type 1) (Akiyama et al, 2007)
¥ haptoglobin (Hp) (Zhang W et al, 2006)
¥ HB-EGF (Heparin binding EGF-like factor, Heparin binding EGF-like growth factor, Hegfl, par-2, prostate apoptosis response protein 2, DTR, Diphtheria toxin receptor) (Abe and Sato, 2001; Gerritsen et al, 2003; Kayanoki et al, 1999; Coombes et al, 2001; Arkonac et al, 1998; Sato et al, 1998; Asakawa et al, 1996; Iivanainen et al, 2003; Barbier et al, 2011)
¥¥ HB-EGF (Heparin binding EGF-like factor, Heparin binding EGF-like growth factor, Hegfl, par-2, prostate apoptosis response protein 2, DTR, Diphtheria toxin receptor) receptors (Ushiro et al, 1996; Chen C et al, 1998)
¥ HDGF (hepatoma-derived growth factor, HuHGF, HMG1L2, high mobility group protein 1-like-2; TDRM1 protein) (Clewrmont et al, 2008)
¥ Hedgehog-interacting protein (HIP, HHIP) (Olsen et al, 2004)
¥ Hepsin (HPN, transmembrane serine protease-1, TMPRSS1) (Aimes et al, 2003)
¥ heregulin-beta-1 (Gerritsen et al, 2003)
¥ HER3 (human EGF receptor-3, EGF receptor 3, epidermal growth factor receptor 3, erbB3, p180erbB3) (Kim HS et al, 2003)
¥ HER4 (human EGF receptor-4, EGF receptor 4, epidermal growth factor receptor 4, erbB4, tyro2, tyrosine-protein kinase 2) (Kim HS et al, 2003)
¥ hevin (SC1, synaptic cleft-1, SPARC-like-1, SPARCL1, MAST9, QR1, RAGS1 antigen, radial glial stop signal molecule 1, ECM2, extracellular matrix protein 2) (Edgar et al, 2006)
¥ HGF (hepatocyte growth factor, HGF/SF, Hepatocyte growth factor-scatter factor, F-TCF, fibroblast tumor cytotoxic factor, HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic factor, Lung fibroblast-derived mitogen) (Morisako et al, 2001; Harrington LS et al, 2008; Sommer et al, 2009)
¥¥ HGF (hepatocyte growth factor, HGF/SF, Hepatocyte growth factor-scatter factor, F-TCF, fibroblast tumor cytotoxic factor, HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic factor, Lung fibroblast-derived mitogen) receptors (met, HGFR, HGF receptor, hepatocyte growth factor receptor, scatter factor receptor) (Gerritsen et al, 2003; Zeng et al, 2004; Ishizawa et al, 2004; Duan et al, 2004; Wang et al, 2004; Makondo et al, 2004; Nakagami et al, 2004; Oh et al, 2002; Ma et al, 2002; Haug et al, 2001; Martin et al, 2001; Wang and Keiser, 2000; Hayashi et al, 2005; Conrotto et al, 2005; Akiyama et al, 2006; Abid et al, 2008)
¥ HGF-like protein (Hepatocyte growth factor-like protein, HLP, HGFL, HGFLP, Macrophage stimulating 1, MST1, macrophage stimulating 1, MSP, macrophage stimulating protein) (Li et al, 2000)
¥ HLA-G (Human leukocyte antigen G, HLA-6.0, HLA60, Qa) (Blaschitz et al, 1997; Wiendl et al, 2005; Sheshgiri et al, 2009)
¥¥ HMG-1 (high mobility group protein-1, HMGB1, high mobility group box-1, amphoterin, DEF, Differentiation enhancing factor, Neurite growth-promoting protein, SBP-1, Sulfoglucuronyl carbohydrate binding protein-1) receptors (Lv et al, 2009)
¥ hsp60 (heat shock protein 60, HSPD1, heat shock 60 kDa protein 1, GroEL, chaperonin 60, cpn60) (Qiu et al, 2008)
¥ hsp65 receptors (Verdegaal et al, 1996)
¥ hsp70 (heat shock protein 70) (Zhan et al, 2009; Barbier et al, 2011)
¥ hsp90 (heat shock protein 90, HSPCA, HSPC1, Lipopolysaccharide-associated protein 2, LAP2, hsp90-alpha, hsp90-beta) (Joseph et al, 2002)
¥ Humanin (HN, Rattin) (Bachar et al, 2010)
¥ HVEM (Herpesvirus entry mediator, HveA, Herpes simplex virus entry protein A, HveAt, TR2, TNF receptor-like-2, ATAR, another TRAF-associated receptor, TNFRSF14, TNF receptor superfamily member 14, LIGHTR, LIGHT receptor, CD270) (Hung et al, 2002; Dahl et al, 2008; Sandberg et al, 2009; Chang YH et al, 2005; Otterdal et al, 2006)

¥ ICAM-2 (intercellular adhesion molecule 2, Ly60, CD102) (Thompson et al, 2002; Shahgasempour et al, 1998; Steinhoff et al, 1993; Tunica et al, 2009)
¥ ICOS (inducible T-cell co-stimulator, H4, AILIM, Activation-inducible lymphocyte immunomediatory molecule, Crp1, CD28-related protein-1, CD278) (Lozanoska-Ochser et al, 2008)
¥ ID1 (Inhibitor of differentiation-1, Inhibitor of DNA binding-1, IDB1) (Pammer et al, 2004; Sakurai et al, 2004; Morikawa et al, 2004; Lacal et al, 2009; Ota T et al, 2002; Kim JH et al, 2012)
¥ ID2 (Inhibitor of differentiation-2, Inhibitor of DNA binding-2, IDB2) (Aitkenhead et al, 2002; Hamid et al, 2007; Ota T et al, 2002)
¥ ID3 (Inhibitor of differentiation-3, Inhibitor of DNA binding-3, IDB3) (Pammer et al, 2002; Loboda A et al, 2006; Barbier et al, 2011; Kim JH et al, 2012)
¥ IEX1 (immediate-early response gene, PRG1, PACAP-responsive gene-1, GLY96, IER3, immediate-early response-3, DIF-2, differentiation-dependent gene-2) (Zhang W et al, 2006)
¥ IFI16 (interferon-induced protein 16, interferon-gamma-inducible protein-16, IFNGIP1, interferon-gamma-inducible protein-1, PYHIN2) (Baggetta et al, 2010; Caposio et al, 2007; Gugliesi et al, 2010, 2005; Kerur et al, 2011; Mondini et al, 2007; Raffaella et al, 2004; Sponza et al, 2009)
¥ IFN-alpha (interferon-alpha, Alpha-Interferon, aIFN, B-cell interferon, Leukocyte interferon, LeIFN, Lymphoblast interferon, LyIFN-alpha) (Barbier et al, 2011)
¥¥ IFN-alpha (interferon-alpha, Alpha-Interferon, aIFN, B-cell interferon, Leukocyte interferon, LeIFN, Lymphoblast interferon, LyIFN-alpha) receptors (IFNAR1, IFN-alpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, IFN-alphaR1, IFRC, IFNAR, IFNAR2, IFN-alpha/beta receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-alphaR2, IFNABR) (Tissari et al, 2005; da Silva et al, 2002)
¥ IFN-beta (Beta-Interferon, Interferon-beta, bIFN, Fibroblast interferon, Fi-IFN, F-IFN) (Tissari et al, 2005; Barbier et al, 2011)
¥ IFN-beta (Beta-Interferon, Interferon-beta, bIFN, Fibroblast interferon, Fi-IFN, F-IFN) receptors (da Silva et al, 2002)
¥ IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) (Li et al, 2000, 2004)
¥¥ IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) receptors (IFNGR1, IFN-gamma receptor-1, IFN-gamma-R1, interferon-gamma receptor 1, immune interferon receptor 1, AVP type 2, antiviral protein type 2, CD119, IFNGR2, interferon-gamma receptor 2, IFN-gamma receptor 2, IFN-gamma-R2, IFGR2, IFNGT1, interferon-gamma transducer 1) (Imaizumi et al, 2002; Rothenberg et al, 1995; Maier et al, 1999; Salvucci et al, 2004; Girvin et al, 2002; Zhou et al, 2005; Monnier J et al, 2012)
¥¥ IFN-tau (interferon-tau, IFNT1, interferon-tau-1, Tau-Interferon, TP-1, trophoblast protein-1, Pregnancy recognition hormone, Trophoblastin, Trophoblast interferon) receptors (Tennakoon et al, 2001)
¥ IGF-1 (Insulin-like growth factor-1, Erythropoietic factor, mechano growth factor, MGF, ILGF1, somatomedin C, NSILA, non-suppressible insulin-like activity, Somatomedin A, Somatomedin C, sulfation factor, Mecasermin) (Dahlfors et al, 2000; Eter et al, 2002; Hatch et al, 1998; Glazebrook et al, 1998; Yue et al, 2006; Passerini AG et al, 2003; Barbier et al, 2011)
¥¥ IGF-1 (Insulin-like growth factor-1, Erythropoietic factor, mechano growth factor, MGF, ILGF1, somatomedin C, NSILA, non-suppressible insulin-like activity, Somatomedin A, Somatomedin C, sulfation factor, Mecasermin) receptors (IGF1R, CD221, JTK13) (Castellon et al, 2002; Dahlfors et al, 2000; Miceli et al, 2005; Qiao et al, 2004; Lopez-Lopez et al, 2004; Chisalita and Arnqvist, 2004; Che et al, 2002; Shigematsu et al, 1999; Giannini et al, 2001; Zindy et al, 1992)
¥ IGF-2 (Insulin-like growth factor-2, Growth-promoting activity for vascular endothelial cells, T3M-11-derived growth factor, ILGF2, MSA, multiplication stimulating activity, NSILA, non-suppressible insulin-like activity, Somatomedin A, sulfation factor, SGF, skeletal growth factor, HP1-SMP, HP3-SMP, Somatomedin/insulin-like growth factor-like polypeptides, C11orf43, chromosome 11 open reading frame 43) (Zhong et al, 2004; Zindy et al, 1992)
¥¥ IGF-2 (Insulin-like growth factor-2, Growth-promoting activity for vascular endothelial cells, T3M-11-derived growth factor, ILGF2, MSA, multiplication stimulating activity, NSILA, non-suppressible insulin-like activity, Somatomedin A, sulfation factor, SGF, skeletal growth factor, HP1-SMP, HP3-SMP, Somatomedin/insulin-like growth factor-like polypeptides, C11orf43, chromosome 11 open reading frame 43) receptors (IGF2R, CD222, mannose-6-phosphate receptor; MPR, CIM6PR, cation-independent mannose 6-phosphate receptor, MPRI, MPR300) (Hagiwara et al, 1995; Miceli et al, 2005; Lin et al, 2001; Zindy et al, 1992)
¥ IGFBP1 (Insulin-like growth factor binding protein-1, IGF binding protein-1, 34 k IGFBP, AFBP, amniotic fluid binding protein, Alpha-pregnancy-associated endometrial globulin, Binding protein-25, Binding protein-26, Binding protein-28, BP-34, BP-3A, endometrial protein 14, Growth hormone independent binding protein, IGF-BP25, PP12, placental protein 12, pregnancy-associated endometrial alpha-1-globulin) (Zhang W et al, 2006)
¥ IGFBP2 (Insulin-like growth factor binding protein-2, IGF binding protein-2) (Dahlfors et al, 2000; Giannini et al, 2001; Sommer et al, 2009; Enis et al, 2008; Nelson et al, 2007; Tunica et al, 2009)
¥ IGFBP3 (Insulin-like growth factor binding protein-3, IGF binding protein-3, BP-53, Growth hormone dependent binding protein, Binding protein-29) (Dahlfors et al, 2000; Schmid et al, 2003; Giannini et al, 2001; Grillari et al, 2001; Tucci et al, 1998; Lindenbergh-Kortleve et al, 1997; Le Jan et al, 2006; Sommer et al, 2009; Takeda N et al, 2007; Nelson et al, 2007; Barbier et al, 2011)
¥¥ IGFBP3 (Insulin-like growth factor binding protein-3, IGF binding protein-3, BP-53, Growth hormone dependent binding protein, Binding protein-29) receptors (Granata et al, 2004; Hampel et al, 2008)
¥ IGFBP4 (Insulin-like growth factor binding protein-4, IGF binding protein-4, Colon cancer cell growth inhibitor, HT29-IGFBP, HT29 insulin-like growth factor binding protein) (Dahlfors et al, 2000; Giannini et al, 2001; Tucci et al, 1998; Tunica et al, 2009)
¥ IGFBP5 (Insulin-like growth factor binding protein-5, IGF binding protein-5) (Dahlfors et al, 2000; Giannini et al, 2001; Tucci et al, 1998; Hampel et al, 2008; Nelson et al, 2007)
¥ IGFBP6 (Insulin-like growth factor binding protein-6, IGF binding protein-6) (Tucci et al, 1998; Nelson et al, 2007; Barbier et al, 2011; Zhang C et al, 2012)
¥ IGFBP7 (Insulin-like growth factor binding protein-7, IGF binding protein-7, mac25, meningioma-associated cDNA-25, T1A12, IGFBPrP1, Insulin-like growth factor binding protein related protein-1, TAF, tumor-derived adhesion factor, PSF, Prostacyclin stimulating factor, Angiomodulin) (Izawa et al, 1999; Usui et al, 2002; Tunica et al, 2009)
¥ IGFBP10 (Insulin-like growth factor binding protein-10, IGF binding protein-10, cyr-61, Cysteine-rich angiogenic inducer 61, cysteine-rich 61, CCN1) (Abe and Sato, 2001; Garcia-Conesa et al, 2009; Morikawa et al, 2004; Tunica et al, 2009)
¥¥ IGFBP10 (Insulin-like growth factor binding protein-10, IGF binding protein-10, cyr-61, Cysteine-rich angiogenic inducer 61, cysteine-rich 61, CCN1) receptors (Schutze et al, 2005; Kolesnikova and Lau, 1998; Leu et al, 2002)
¥ IGSF8 (immunoglobulin superfamily member 8, CD81P3, CD81 partner 3, EWI-2, EWI motif-containing protein 2, KASP, KAI1/CD82-associated surface protein, KCT-4, Keratinocytes associated transmembrane protein 4, PGRL, prostaglandin regulatory like, CD316) (Barbier et al, 2011)
¥ IL1 (interleukin-1) (Li et al, 2004; Zhou et al, 2005)
¥ IL1-alpha (IL1A, interleukin-1-alpha, IL1F1, Interleukin-1 family member 1, BAF, B-cell activating factor, BCAF, B-cell activating factor, EP, endogenous pyrogens, LAF, lymphocyte activating factor, LEM, leukocyte endogenous mediator, MCF, mononuclear cell factor, MNCF, mononuclear cell factor, MP, mitogenic protein, TRF-3, T-cell replacing factor-3, Tumor inhibitory factor-2) (Dardik et al, 2005; Watanabe et al, 1995; Steen et al, 1999; Nilsen et al, 1998; Sommer et al, 2009; Barbier et al, 2011)
¥¥ IL1-alpha (IL1A, interleukin-1-alpha, IL1F1, Interleukin-1 family member 1, BAF, B-cell activating factor, BCAF, B-cell activating factor, EP, endogenous pyrogens, LAF, lymphocyte activating factor, LEM, leukocyte endogenous mediator, MCF, mononuclear cell factor, MNCF, mononuclear cell factor, MP, mitogenic protein, TRF-3, T-cell replacing factor-3, Tumor inhibitory factor-2) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Maier et al, 1999)
¥ IL1-beta (IL1B, interleukin-1-beta, IL1F2, Interleukin-1 family member 2, Catabolin, H1, Hematopoietin-1, IFN-beta inducing factor, Interleukin-beta, OAF, osteoclast activating factor) (Sundstrom et al, 2001; Cha et al, 2000; Wondergem et al, 2004; Lee et al, 2004; Wilson et al, 2007; Hamid et al, 2007)
¥¥ IL1-beta (IL1B, interleukin-1-beta, IL1F2, Interleukin-1 family member 2, Catabolin, H1, Hematopoietin-1, IFN-beta inducing factor, Interleukin-beta, OAF, osteoclast activating factor) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Fan et al, 2004; Willam et al, 2000; Saijonmaa et al, 2001; Sato et al, 1995; Kimura et al, 2003; Morisako et al, 2001; Wagnerova et al, 2002; Xu et al, 2006; Duchene et al, 2007; Mountain DJ et al, 2008; RistimŠki A et al, 1998; Kawsar HI et al, 2010)
¥ IL1F6 (Interleukin-1 family member 6, FIL1-epsilon, FIL1E, Family of IL1-epsilon, IL1H1, IL1-epsilon; IL36-alpha, interleukin-36-alpha) (Barbier et al, 2011)
¥ IL1ra (IL1 receptor antagonist, IL1RN, IL1 inhibitor, IRAP, IL1 receptor antagonist protein, IL1 inhibitory activity, ILS, IL1F3, IL1 family member 3, DIRA, deficiency of the IL1 receptor antagonist) (Dewberry et al, 2000; Wilson et al, 2007; Sommer et al, 2009; Morikawa et al, 2004)
¥¥ IL1 (interleukin-1) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Zoellner et al, 1992; Minter et al, 1996; Carley et al, 1996; Alessandri et al, 1999; Banks, 1999; Mohle et al, 1997)
¥ IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) (Starnes et al, 2001; Azizova et al, 2004; Sommer et al, 2009; Barbier et al, 2011)
¥¥ IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) receptors (IL2RA, interleukin-2 receptor-alpha; IL2R-alpha; IL2 receptor-alpha, IL2R, interleukin-2 receptor, TAC antigen, TCGFR, T-cell growth factor receptor, IDDM10, insulin-dependent diabetes mellitus 10, CD25; Ly43, lymphocyte antigen 43, OX39, IL2RB, interleukin-2 receptor-beta; IL2R-beta; IL2 receptor-beta, CD122; IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, IL2R-gamma, common gamma, gammac, gamma common, common cytokine receptor-gamma; cytokine receptor common subunit gamma, CD132, SCIDX1, X-linked severe combined immunodeficiency-1) (Mohle et al, 1997; Sommer et al, 2009; Takeda N et al, 2007)
¥ IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) (Zhong et al, 2004; Weiss et al, 1995; Nilsen et al, 1998)
¥¥ IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) receptors (IL3RA, interleukin-3 receptor-alpha, IL3R-alpha, common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL3 receptor subunit beta; interleukin-3 receptor-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Groger et al, 2004; Korpelainen et al, 1995; DiFalco et al, 2002; Khew-Goodall et al, 1996; Brizzi et al, 1993)
¥¥ IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) receptors (IL4RA, IL4R-alpha, interleukin-4 receptor-alpha, IL4R, interleukin-4 receptor, CD124) (Cuvelier and Patel, 2001; Shinkai et al, 1999; Yao et al, 1996; Goebeler et al, 1997; Parks et al, 1998; Kotowicz et al, 2004; Kim et al, 2003; Iademarco et al, 1995; Lee et al, 2004; Inomata et al, 2009)
¥ IL5 (Interleukin-5, B151-TRF, B151 T-cell replacing factor, BCDF, B-cell differentiation factors, BCDF-alpha, B-cell differentiation factor-alpha, BCDF-mu, B-cell differentiation factor-mu, BCGF-2, B-cell growth factor-2, DL-BCGF, Dennert line B-cell growth factor, BGDF, B-cell growth and differentiation factor, CFU-Eo GSF, colony-forming unit eosinophil growth stimulating factor, EDF, eosinophil differentiation factor, Eo-CSF, Eosinophil colony stimulating factor, Eo-DF, eosinophil differentiation factor, ESP, eosinophil stimulation promoter, IgA-EF, IgA enhancing factor, KHF, killer helper factor, TRF-1, T-cell replacing factor-1) (Mohle et al, 1997; Sommer et al, 2009)
¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) (Albrecht et al, 2004; Dahl et al, 2008; Dechanet et al, 1997; Galdiero et al, 1997; Gaugler et al, 2005; Gerritsen et al, 2003; Gnant et al, 2000; Hamid et al, 2007; Innocenti et al, 2002; Jurczyluk et al, 2003; Kim JY et al, 2009; Lee et al, 2004; Lee WJ et al, 2009; Li et al, 2000; Li et al, 2004; Liu et al, 2009; Munoz et al, 1996; Nelson et al, 2007; Nilsen et al, 1998; Norata et al, 2007; Reyes et al, 2002; Sundstrom et al, 2001; Zhou et al, 2005)
¥¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) receptors (IL6RA, IL6R-alpha, IL6R, interleukin-6 receptor, interleukin-6 receptor-alpha, CD126, IL6ST, IL6 signal transducer, interleukin-6 signal transducer, IL6R-beta, interleukin-6 receptor-beta, IL6RB, CDw130, CD130) (Nakazato et al, 1997; Fee et al, 2000)
¥ IL7 (Interleukin-7, B-cell precursor growth-promoting activity, Lpo-1, lymphopoietin-1, LP-1, PBGF, Pre-B-cell growth factor, serum factor from patients with ulcerative colitis, Thymocyte growth factor) (Roye et al, 1998; Nilsen et al, 1998; Sommer et al, 2009)
¥¥ IL7 (Interleukin-7, B-cell precursor growth-promoting activity, Lpo-1, lymphopoietin-1, LP-1, PBGF, Pre-B-cell growth factor, serum factor from patients with ulcerative colitis, Thymocyte growth factor) receptors (IL7R, IL7RA, IL7R-alpha, interleukin-7 receptor, interleukin-7 receptor-alpha; CD127, CDw127) (Al-Rawi et al, 2005; Takeda N et al, 2007; Hoeth M et al, 2012)
¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) (Abdel-Malak et al, 2007; Alessandri et al, 1999; Beck et al, 1999; Biernacki et al, 2004; Campbell et al, 2004; Chang YH et al, 2005; Cheng et al, 2002; Claise et al, 1996; Damas et al, 2004; Ebnet et al, 1997; Forestal et al, 2003; Gaugler et al, 2005; Gerritsen et al, 2003; Gnant et al, 2000; Goebeler et al, 1997; Guo et al, 2004; Hampel et al, 2008; Innocenti et al, 2002; Inomata et al, 2009; Introna et al, 1993; Jiang et al, 2004; Jonsson and Palmblad, 2001; Jurczyluk et al, 2003; Kahn et al, 2000; Kapper et al, 2002; Lee et al, 2002; Lee WJ et al, 2009; Loboda A et al, 2006; Mao et al, 2002; Middleton et al, 1997; Munoz et al, 1996; Nelson et al, 2007; Nilsen et al, 1998; Pellegrino et al, 2005; Poole et al, 2002; Reyes et al, 2002; Sano et al, 1998; Satta et al, 2008; Schneider et al, 2003; Scholzen et al, 1999; Somasundaram et al, 2005; Sommer et al, 2009; Strasly et al, 2004; Sun et al, 2005; Sundstrom et al, 2001; Takeichi et al, 2008; Wang et al, 2005; Warner et al, 2008; Wolff et al, 1998; Wondergem et al, 2004; Yang et al, 2004; Chen T et al, 2010; Barbier et al, 2011; Fujie et al, 2010; Dolan JM et al, 2012
¥¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) receptors (IL8RA, IL8R-alpha, interleukin-8 receptor-alpha; interleukin-8 receptor type A, IL8R1, IL8 receptor-1, interleukin-8 receptor type 1, CMKAR1, chemokine-alpha receptor 1, CXCR1, CD181, IL8RB, IL8R-beta, interleukin-8 receptor-beta; interleukin-8 receptor type B, IL8R2, IL8 receptor-2, interleukin-8 receptor type 2, CMKAR2, chemokine-alpha receptor 2, CXCR2, CD182) (Gerritsen et al, 2003; Hillyer et al, 2003; Lingen et al, 1996; Salcedo et al, 2000, 2001; Galvez et al, 2005; Heidemann et al, 2003; Schraufstatter et al, 2003; Murdoch et al, 1999; Otto et al, 2000; Martin et al, 2009)
¥ IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) (Sommer et al, 2009)
¥¥ IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) receptors (IL10R, IL10R1, IL10RA, IL10 receptor-alpha, IL10R-alpha, interleukin-10 receptor-alpha; interleukin-10 receptor, CD210, CD210a, CDw210a; IL10R2, IL10RB, IL10R-beta, IL10 receptor-beta, interleukin-10 receptor-beta, CRF2-4, cytokine receptor family 2 member 4, CRFB4; CDw210b) (Gimeno et al, 2003; Scholzen et al, 1998; Parks et al, 1998; Vora et al, 1996)
¥ IL11 (Interleukin-11, AGIF, adipogenesis inhibitory factor, HPAEC survival factor, human pulmonary artery endothelial cell-derived survival factor, Megakaryocyte colony stimulating factor, Plasmacytoma stimulatory activity, Oprelvekin, Neumega) (Dimitriadis et al, 2000; Gerritsen et al, 2003; Li et al, 2004; Li et al, 2000; Zhang et al, 1998; Nilsen et al, 1998; Giuliani et al, 2004; Zhou et al, 2005; Takeda N et al, 2007; Barbier et al, 2011)
¥¥ IL11 (Interleukin-11, AGIF, adipogenesis inhibitory factor, HPAEC survival factor, human pulmonary artery endothelial cell-derived survival factor, Megakaryocyte colony stimulating factor, Plasmacytoma stimulatory activity, Oprelvekin, Neumega) receptors (IL11RA, interleukin-11 receptor-alpha, IL11R-alpha, IL11RA1, interleukin-11 receptor-alpha-1, Etl2, enhancer trap locus 2, Nr1; IL6ST, IL6 signal transducer, interleukin-6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Mahboubi et al, 2001)
¥ IL12 (IL12A, IL12-alpha IL12B, IL12-beta, IL12-p35, IL12-p40, IL12-p70, Interleukin-12, Interleukin-12A, Interleukin-12B, CLMF, cytotoxic lymphocyte maturation factor, NKSF, natural killer cell stimulatory factor, NKSF1, natural killer cell stimulatory factor-1, NKSF2, natural killer cell stimulatory factor-2, TcMF, CTL maturation factor, TSF, T-cell stimulating factor) (Lienenluke et al 2000; Heidemann et al, 2007; Barbier et al, 2011)
¥ IL12-p40 (IL12B, IL12-beta, interleukin-12B, IL23-p40, Interleukin-23 p40) (Lienenluke et al 2000; Sommer et al, 2009)
¥ IL13 (Interleukin-13, NC30, P600) (Li et al, 2000, 2004; Zhou et al, 2005; Barbier et al, 2011)
¥¥ IL13 (Interleukin-13, NC30, P600) receptors (IL13RA1, interleukin-13 receptor-alpha-1, IL13R-alpha-1, IL13RA, NR4, CD213a1) (Goebeler et al, 1997; Shinkai et al, 1999; Bochner et al, 1995; Evans et al, 2000; Gauchat et al, 1997)
¥ IL14 (HMW-BCGF) (Nilsen et al, 1998)
¥ IL15 (Interleukin-15, IL-T, Interleukin T) (Oppenheimer-Marks et al, 1998; Mohamadzadeh et al, 1996; Nilsen et al, 1998; Sommer et al, 2009; Liu X et al, 2009)
¥¥ IL15 (Interleukin-15, IL-T, Interleukin T) receptors (IL15RA, IL15R-alpha, CD215) (Yang et al, 2002; Liu X et al, 2009)
¥ IL16 (Interleukin-16, Lymphocyte chemoattractant factor, LCF) (Gu et al, 2008; Sommer et al, 2009)
¥ IL17 (Interleukin-17, IL17A, interleukin-17A) (Sommer et al, 2009; Di Stefano A et al, 2009; Barbier et al, 2011)
¥¥ IL17 (Interleukin-17, IL17A, interleukin-17A) receptors (IL17RA, interleukin-17 receptor A, IL17 receptor A, CD217, CDw217) (Gerritsen et al, 2003; Numasaki et al, 2004; Honorati et al, 2001; Kebir et al, 2007; Fujie et al, 2010; Wang W et al, 2012)
¥ IL17D (interleukin-17D) (Nelson et al, 2007)
¥¥ IL17D (interleukin-17D) receptors (Starnes et al, 2002)
¥¥ IL17F (interleukin-17F, ML-1) receptors (IL17RA, interleukin-17 receptor A, IL17 receptor A, CD217, CDw217; IL17RC, interleukin-17 receptor C; IL17 receptor C) (Numasaki et al, 2004; Starnes et al, 2001; Fujie et al, 2010)
¥¥ IL17RC (interleukin-17 receptor C; IL17 receptor C, IL17RL, interleukin-17 receptor-like protein) (Ge D and You Z, 2008; Fujie et al, 2010; Gerritsen et al, 2003; Roussel et al, 2010)
¥¥ IL17RD (interleukin-17 receptor D; IL17 receptor D] SEF, similar expression to FGF, hSef, IL17RLM) (Yang RB et al, 2003)
¥ IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) (Gerdes et al, 2002; Yamaoka-Tojo et al, 2003)
¥ IL18BP (IL18 binding protein, interleukin-18 binding protein, IL18BPa, IL18BPb, IL18BPc, IL18BPd, IGIFBP, IGIF binding protein, IFN-gamma inducing factor binding protein, Tadekinig-alpha) (Zhang W et al, 2006; Corbaz et al, 2002; Barbier et al, 2011)
¥¥ IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) receptors (IL18R1, interleukin-18 receptor-1, IL18R-alpha, IL18RA, interleukin-18 receptor-alpha, IL1Rrp, IL1 receptor-related protein, IL1R5, Interleukin-1 receptor 5, IL1 receptor R5, CD218a, CDw218a) (Gerdes et al, 2002; Albrecht et al, 2004; Marino and Cardier, 2003; Hamid et al, 2007)
¥ IL19 (interleukin-19, IL10C, MDA1, ZMDA1, melanoma differentiation antigen-1, melanoma differentiation associated protein-like protein) (Jain S et al, 2011)
¥¥ IL19 (interleukin-19, IL10C, MDA1, ZMDA1, melanoma differentiation antigen-1, melanoma differentiation associated protein-like protein) receptors (Jain S et al, 2011)
¥ IL20 (interleukin-20, Zcyto10; IL10D, interleukin-10D) (Chen et al, 2006; Hsing et al, 2006)
¥¥ IL20 (interleukin-20, Zcyto10; IL10D, interleukin-10D) receptors (IL20RA, interleukin-20 receptor-alpha, IL20R-alpha, IL20R1, IL20 receptor-1, CRF2-8, cytokine receptor family 2 member 8, ZcytoR7; IL20RB, interleukin-20 receptor-beta, IL20R-beta, IL20R2, IL20 receptor-2, DIRS1) (Hammer et al, 2009; HeuzŽ-Vourc'h N et al, 2005; Tritsaris et al, 2007; Chen et al, 2006)
¥¥ IL22 (Interleukin-22, IL-TIF, IL10-related T-cell derived inducible factor) receptors (IL22RA1, interleukin-22 receptor-alpha-1, IL22R-alpha-1, IL22R, IL22R1, CRF2-9, cytokine receptor family 2 member 9) (Ramesh et al, 2004; Kebir et al, 2007; Di Stefano A et al, 2009)
¥ IL22BP (IL22 binding protein, IL22RA2, interleukin-22 receptor-alpha-2, IL22R-alpha-2, CRF2-10, Cytokine receptor family 2 member 10, CRF2-s1, CRF2 soluble 1, cytokine receptor family type 2 soluble-1, CRF2X) (Barbier et al, 2011)
¥ IL23 (interleukin-23, IL12B, IL12-p40, IL23-p40, p19, IL23-p19, IL23A, SGRF, IL6 G-CSF related factor) (Heidemann et al, 2007)
¥ IL24 (interleukin-24, ST16, suppression of tumorigenicity-16, MDA-7, melanoma differentiation-associated gene 7, mob-5, C49a, FISP, IL4 induced secreted protein) (Kragstrup et al, 2008)
¥¥ IL24 (interleukin-24, ST16, suppression of tumorigenicity-16, MDA-7, melanoma differentiation-associated gene 7, mob-5, C49a, FISP, IL4 induced secreted protein) receptors (Ramesh et al, 2004)
¥ IL25 (interleukin-25, IL17E, interleukin-17E) (Sonobe et al, 2009; de Boer et al, 2010)
¥ IL25 (interleukin-25, IL17E, interleukin-17E) receptors (Wang W et al, 2012)
¥ IL27 (interleukin-27, EBI-3, EBV induced gene-3, IL27A, IL27-alpha, interleukin-27-alpha, IL27B; IL27-beta, interleukin-27-beta, p28, IL27p28, IL30, interleukin-30) (Larousserie et al, 2004)
¥¥ IL27 (interleukin-27, EBI-3, EBV induced gene-3, IL27A, IL27-alpha, interleukin-27-alpha, IL27B; IL27-beta, interleukin-27-beta, p28, IL27p28, IL30, interleukin-30) receptors (IL27RA, IL27 receptor-alpha, interleukin-27 receptor-alpha, IL27R, IL27R-alpha, CRL1, Cytokine receptor-like 1, WSX-1, TCCR, T-cell cytokine receptor, ZCytoR1) (Feng XM et al, 2007)
¥ IL28A (IL28, IL28A, IL28-alpha, interleukin-28-alpha, IFN-lambda-2, interferon-lambda-2, IFNL2) (Tissari et al, 2005)
¥ IL28B (IL28, IL28-beta, interleukin-28-beta, IFN-lambda-3, interferon-lambda-3, IFNL3) (Tissari et al, 2005)
¥ IL29 (IFN-lambda-1, interferon-lambda-1, IFNL1) (Tissari et al, 2005)
¥ IL32 (interleukin-32, IL32-alpha, IL32-beta, IL32-delta, IL32-epsilon, IL32-gamma, IL32-zeta, NK4, natural killer cell transcript 4, TAIF, tumor necrosis factor alpha-inducing factor, TAIFa, TAIF-alpha, TAIFb, TAIFc, TAIF-beta, TAIFd, TAIF-delta) (Zhang W et al, 2006; Nelson et al, 2007; Nold-Petry CA et al, 2009; Kobayashi H et al, 2009; Kobayashi H and Lin PC, 2009; Barbier et al, 2011)
¥ IL33 (interleukin-33, NFHEV, nuclear factor from high endothelial venules, C9orf26, chromosome 9 open reading frame 26, DVS27) (Onda et al, 1999; Zhong et al, 2004; Carriere V et al, 2007; Cayrol C and Girard, 2009; KŸchler AM et al, 2008; Manetti M et al, 2010; Marvie P et al, 2010; Matsuda A et al, 2009; Miller AM et al, 2008; Moussion C et al, 2008; Schmitz et al, 2005; Le Goffic et al, 2011; Yasuoka et al, 2011; Zeyda M et al, 2012)
¥¥ IL33 (interleukin-33, NFHEV, nuclear factor from high endothelial venules, C9orf26, chromosome 9 open reading frame 26, DVS27) receptors (IL33R, IL1RL1, IL1 receptor-like-1, IL1R4, interleukin-1 receptor 4, IL1 receptor R4, T1, T1/ST2, ST2, ST2L, Fit-1, fos-induced transcript-1, Ly84, lymphocyte antigen 84, DER4, delayed early response gene 4) (Aoki S et al, 2010; Bartunek et al, 2008; Manetti M et al, 2010; Yagami et al, 2010; Sommer et al, 2009; Aoki et al, 2009, Tunica et al, 2009; Ota T et al, 2002; Demyanets S et al, 2011; Zeyda M et al, 2012; Zeyda M et al, 2012)
¥¥ IL34 (interleukin-34, C16orf77, chromosome 16 open reading frame 77) receptors (CSF1R, fms, FIM2, CD115) (presence inferred from observation that IL34 binds to the M-CSF receptor, fms)
¥ InhBP (inhibin binding protein, InhBP/p120, IGSF1, immunoglobulin superfamily gene 1, IGDC1, immunoglobulin-like domain-containing 1, PGSF2, Pituitary gland-specific factor 2, KIAA0364) (Barbier et al, 2011)
¥ inhibin-alpha (INHA) (Zhou et al, 2005)
¥ Inhibin-beta-B (INHBB) (Barbier et al, 2011)
¥ inhibins (Li et al, 2004)
¥¥ insulin receptors (CD220, INSR) (Artwohl et al, 2007; Bottaro et al, 1989; Chisalita et al, 2006; Chisalita and Arnqvist, 2005; Frank et al, 1986; Gogg et al, 2009; Gosmanov et al, 2006; Kolaczynski JW et al, 1993; Li et al, 2009; Miller et al, 1994; Milton and Knutson, 1993; Nitert et al, 2005; Oliver, et al, 1991; Roberts and Sandra, 1992; Soda and Tavassoli, 1983; Stentz and Kitabchi, 2006; Wang et al, 2006; Zeng and Quon, 1996; Zindy et al, 1992)
¥ insulysin (insulin-degrading enzyme, IDE, insulin protease, insulin proteinase, insulinase, EC3.4.24.56, AURA99, augmented in rheumatoid arthritis 99) (Lynch et al, 2006; Gao et al, 2004)
¥ Intelectin (ITLN, Intelectin-1, ITLN1, HL-1, Endothelial lectin HL-1, XL-35, Omentin, lactoferrin receptor, LFR) (Lee et al, 2001)
¥¥ Intelectin (ITLN, Intelectin-1, ITLN1, HL-1, Endothelial lectin HL-1, XL-35, Omentin, lactoferrin receptor, LFR) receptors (Zhong X et al, 2012)
¥ IRAK1 (IL1 receptor-associated kinase-1, IRAK, IL1 receptor-associated kinase; mPLK, Pelle-like protein kinase, Plpk) (Satta et al, 2008)
¥ IRAK2 (IL1 receptor-associated kinase-2) (Guo et al, 1999)
¥ ISG15 (interferon-stimulated gene-15, UCRP, ubiquitin cross-reactive protein, IP17) (Nelson et al, 2007)
¥¥ Isthmin (ISM, ISM1, isthmin-1) receptors (Xiang et al, 2011)
¥ ITF (intestinal trefoil factor, trefoil factor-3, TFF-3, hP1.B) (Nelson et al, 2007)

¥ jagged-1 (JAG1, JAGL1, jagged, Serrate-1) (Dixelius et al, 2004; Takeda N et al, 2007; Strasser et al, 2010)
¥ Jagged-2 (JAG2, serrate-2) (Favre et al, 2003; Tsai et al, 2000)
¥ JAM1 (Junctional adhesion molecule 1, JAM-A, Junctional adhesion molecule A, JCAM, Platelet F11 receptor, F11R, F11 receptor, platelet adhesion molecule 1, PAM-1, Ly106, lymphocyte antigen 106, CD321) (Gupta et al, 2001; Babinska et al, 2002)
¥ JAM3 (Junctional adhesion molecule 3, JAM-C, Junctional adhesion molecule C, Gi11 antigen) (Arrate et al, 2001)

¥ KGF (keratinocyte growth factor, HBGF-7, heparin binding growth factor-7, FGF-7, fibroblast growth factor-7, palifermin) (Khodarev et al, 2003; Sommer et al, 2009; Antoine et al, 2005)
¥¥ KGF (keratinocyte growth factor, HBGF-7, heparin binding growth factor-7, FGF-7, fibroblast growth factor-7, palifermin) receptors (KGF receptor, KGFR, CD332, fibroblast growth factor receptor-2, TK-14, bek, bacterially expressed kinase, Cek3, chicken embryonic kinase 3, K-sam, KATO-III cell-derived stomach cancer amplified gene) (Nelson et al, 2007)
¥ Kininostatin receptors (Guo et al, 2000)
¥ KISS-1 (kisspeptin-1, kisspeptin-54, KP-54, kisspeptins, Kp-10; Kisspeptin-10, Kp-13; Kisspeptin-13, Kp-14; Kisspeptin-14, metastin) (Mead et al, 2007)
¥¥ KISS-1 (kisspeptin-1, kisspeptin-54, KP-54, kisspeptins, Kp-10; Kisspeptin-10, Kp-13; Kisspeptin-13, Kp-14; Kisspeptin-14, metastin) receptors (KISS1R, KISS-1 receptor, AXOR12, GPR54, G-protein-coupled receptor-54, OT7T175) (Ramaesh et al, 2010; Mead et al, 2007)
¥ KLK1 (kallikrein-1) (Dedio et al, 2001)
¥ Klotho (KL, Alpha-Klotho, alpha-KL, a-KL) (Hamdi and Castellon, 2004; Carracedo et al, 2012)
¥¥ Klotho (KL, Alpha-Klotho, alpha-KL, a-KL) receptors (Ikushima et al, 2006; Rakugi et al, 2007; Yang K et al, 2012; Carracedo et al, 2012)
¥ Ku70 (XRCC6, X-ray repair complementing defective repair in Chinese Hamster cells 6, X-ray repair cross-complementing protein 6, Ku antigen, Ku autoantigen, Lupus autoantigen p70, TLAA, Thyroid-Lupus autoantigen, ATP-dependent DNA helicase 2, DNA helicase 2, CTCBF, CTC box-binding factor 75 kDa subunit, CTC75, G22p1) (Cherepanova et al, 2012)

¥¥ lactoferrin (LF, Lactotransferrin, LTF, CIF, colony inhibitory factor, Talactoferrin, TLF, AURA19, augmented in rheumatoid arthritis 19) receptors (Elass et al, 2002; Shimamura et al, 2004; Kim et al, 2006; Kim CW et al, 2012)
¥ Langerin (CD207, CLEC4K, C-type lectin domain family 4 member K, DCGM4) (Nelson et al, 2007)
¥ LBP (LPS binding protein, lipopolysaccharide-binding protein, BPIFD2, BPI fold containing family D member 2) (Sun R et al, 2012)
¥¥ leptin (ob, ob/ob, obese protein, obesity factor, Metreleptin) receptors (LEPR, OBR, CD295, db, db/db, fatty, fa, fa/fa) (Misztal-Dethloff et al, 2004; Wolf et al, 1999; Artwohl et al, 2002; Suganami et al, 2004; Bouloumie et al, 1999; Yamagishi et al, 2001; Quehenberger et al, 2001; Park et al, 2001; Singh et al, 2007; Takeda N et al, 2007; Clasper S et al, 2008; Singh et al, 2010)
¥ LIF (leukemia inhibitory factor; myeloid leukemia inhibitory factor, ABAE cell growth-inhibitory activity; CDF, cholinergic differentiation factor, CNDF, cholinergic neuronal differentiation factor, D-Factor, differentiation stimulating factor, DIA, differentiation inhibiting activity, DIF, differentiation inducing factor, DRF, Differentiation-retarding factor, ES cell growth factor, ESCGF, embryonic stem cell growth factor, GATS, growth stimulatory activity for TS1 cells, HILDA, human interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2, HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase inhibitor, M1 differentiation inducing activity, MCGEF, mast cell growth-enhancing factor, MLPLI, melanoma-derived lipoprotein lipase inhibitor, OAF, osteoclast activating factor) (Dechanet et al, 1997; Zhong et al, 2004; Grosset et al, 1995; Kubota et al, 2008; Dowsing et al, 2001; Grosset et al, 1999; LŸbbert et al, 1991; Mi et al, 2001)
¥¥ LIF (leukemia inhibitory factor; myeloid leukemia inhibitory factor, ABAE cell growth-inhibitory activity; CDF, cholinergic differentiation factor, CNDF, cholinergic neuronal differentiation factor, D-Factor, differentiation stimulating factor, DIA, differentiation inhibiting activity, DIF, differentiation inducing factor, DRF, Differentiation-retarding factor, ES cell growth factor, ESCGF, embryonic stem cell growth factor, GATS, growth stimulatory activity for TS1 cells, HILDA, human interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2, HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase inhibitor, M1 differentiation inducing activity, MCGEF, mast cell growth-enhancing factor, MLPLI, melanoma-derived lipoprotein lipase inhibitor, OAF, osteoclast activating factor) receptors (LIFR, leukemia inhibitory factor receptor, LIF receptor, LIFR-alpha, leukemia inhibitory factor receptor-alpha, LIF receptor-alpha, LIFR-beta, LIF receptor-beta; leukemia inhibitory factor receptor-beta, CD118, IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Hooper et al, 1997; Nakazato et al, 1997; Ruprecht et al, 2001; Collo and Pepper, 1999; Yu et al, 2007; Pepper et al, 1995)
¥ lipocalin-2 (LCN2, 24p3, 25 kDa alpha-2-microglobulin-related subunit of MMP-9, Alpha-2-microglobulin related protein, Ex-FABP, extracellular fatty acid-binding protein, HNL, human neutrophil lipocalin, lipocalin 24p3, MSFI, migration stimulating factor inhibitor, NGAL, neutrophil gelatinase-associated lipocalin, NRL, neu-related lipocalin, Scn, siderocalin, SIP24, superinducible protein 24 kDa, SV40-induced 24P3 protein, Uterocalin) (Liu and Nilsen-Hamilton, 1995; Hamzic N et al, 2013)
¥ LRRFIP1 (leucine rich repeat (in FLII) interacting protein 1; Leucine-rich repeat flightless-interacting protein 1; LRR FLII-interacting protein 1, FLAP-1, FLIIAP1, FLI LRR associated protein-1, GCF2, GC-binding factor 2, TRIP, TAR RNA-interacting protein, Transcription factor 9-like, HUFI-1) (Khachigian et al, 1999)
¥ L-SIGN (Liver/lymph node-specific ICAM-3-grabbing nonintegrin, CD299, CD209L, CD209-like, CD209L1, CD209-like-1, CLEC4M, C-type lectin domain family 4 member M, DC-SIGN-2, Dendritic cell-specific ICAM-3-grabbing nonintegrin-2, DC-SIGNR, DC-SIGN-related, DC-SIGNR1, DC-SIGN-related-1) (Li et al, 2007; Mukhtar et al, 2002; Martens et al, 2006)
¥ LTBP1 (Latent TGF-beta binding protein-1) (Ota T et al, 2002)
¥ LTBP4 (Latent TGF-beta binding protein-4, LTBP4S, LTBP4L) (Nelson et al, 2007)
¥ Lubricin (Lubricating glycoprotein-1, LGP-1, Proteoglycan-4, PRG-4, MSF, megakaryocyte stimulating factor, hemangiopoietin, HAPO, PSLF, purified synovial lubricating factor, superficial zone proteoglycan, SZP, superficial zone protein, camptodactyly-arthropathy-coxa vara-pericarditis, CACP, DOL54, downstream of the liposarcoma-associated fusion oncoprotein 54) (Zhang W et al, 2006)
¥ Lumican (LUM, LCN, LDC, corneal keratan sulfate proteoglycan 37B core protein, SLRR2D) (Albig et al, 2007; Baba et al, 2001)
¥ Ly6C (lymphocyte antigen 6C, Ly6C1, lymphocyte antigen 6C1) (Jutila et al, 1988)
¥ lymphotoxin-beta (LT-beta, LTB, TNFSF3, TNF ligand superfamily member 3, TNF C, tumor necrosis factor C) (Murakami et al, 2000; Takeda N et al, 2007)
¥¥ lymphotoxin-beta (LT-beta, LTB, TNFSF3, TNF ligand superfamily member 3, TNF C, tumor necrosis factor C) receptors (Chang YH et al, 2005; Xu Y et al, 2011)
¥ LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1, CRSBP-1, Cell surface retention sequence binding protein-1) Al-Rawi et al, 2005; Fiedler et al, 2006; Gordon et al, 2008; Gu et al, 2006; Kriehuber et al, 2001; Lin et al, 2008; Martens et al, 2006; Mouta Carreira et al, 2001; Nonaka et al, 2007; Pfeiffer et al, 2008; Prevo et al, 2001; Whitehurst et al, 2006; Wr—bel et al, 2005; Salven et al, 2003; Norgall et al, 2007; Martens et al, 2006)

¥ MARCO (macrophage receptor with collagenous structure, SCARA2, scavenger receptor class A member 2; Ly112, lymphocyte antigen 112) (HIN-2 receptor) (Martens et al, 2006)
¥ matriptase (MT-SP1) (Aimes et al, 2003)
¥ Maspin (mammary serpin, mammary serine protease inhibitor, Serpin B5, protease inhibitor-5, proteinase inhibitor-5, PI5) (Qin and Zhang, 2010; Buchwalter et al, 2008)
¥¥ Maspin (mammary serpin, mammary serine protease inhibitor, Serpin B5, protease inhibitor-5, proteinase inhibitor-5, PI5) receptors (Zhang M et al, 2000)
¥ MAVS (mitochondrial antiviral signaling protein, KIAA1271, IPS1, Interferon-beta promoter stimulator protein 1, VISA, Virus-induced-signaling adapter, CARDIF, CARD adapter inducing interferon-beta) (Buss et al, 2011)
¥ M-CSF (macrophage colony stimulating factor, CSF-1, colony stimulating factor-1, CSF-HU, Urinary colony stimulating factor, MGF, macrophage growth factor, MGI-1M, macrophage-granulocyte inducer, op, osteopetrotic, toothless, tl, Lanimostim) (Lehmann et al, 2000; Reyes et al, 2002; Peng et al, 1995; Green and Harrington, 2000; Jonsson and Palmblad, 2001)
¥¥ M-CSF (macrophage colony stimulating factor, CSF-1, colony stimulating factor-1, CSF-HU, Urinary colony stimulating factor, MGF, macrophage growth factor, MGI-1M, macrophage-granulocyte inducer, op, osteopetrotic, toothless, tl, Lanimostim) receptors (fms, CSF1R, CSF-1 receptor, FIM2, CD115) (Takeda N et al, 2007)
¥ MCPIP (MCP-1-induced protein; Monocyte chemotactic protein-induced protein, MCPIP1, MCP-1-induced protein 1; Monocyte chemotactic protein-1-induced protein-1, ZC3H12A, zinc finger CCCH domain-containing protein 12A) (Nalla et al, 2011; Niu et al, 2008; Qi Y et al, 2010; Roy and Kolattukudy, 2012)
¥ MDA-5 (melanoma differentiation-associated gene 5, IFIH1, interferon-induced helicase 1, Interferon-induced helicase C domain-containing protein 1, Helicard, Helicase with 2 CARD domains, RH116, RNA helicase-DEAD box protein 116, IDMM19) (Pluvinet et al, 2008; BerghŠll et al, 2006)
¥ MDGI (mammary-derived growth inhibitor, FABP3, Fatty acid-binding protein 3, H-FABP, Heart-type fatty acid-binding protein, M-FABP, Muscle fatty acid-binding protein) (Antohe et al, 1998; Breter and Erdmann, 1994; Sakai et al, 1995; Van Nieuwenhoven et al, 1994; Vogel et al, 1990; Watanabe et al, 1993)
¥¥ melanotransferrin (CD228, MAP97, melanoma-associated antigen p97, p97 melanoma antigen, Mfi2) receptors (Michaud-Levesque et al, 2005)
¥ mer (MERTK, eyk, East Lansing Tyrosine Kinase, nyk, NCAM-related tyrosine kinase, RP38, retinitis pigmentosa type 38, tyro12, tyrosine-protein kinase 12) (Shao WH et al, 2010; Chan MC et al, 2000)
¥ metallothioneins (Takeda N et al, 2007)
¥ Met-Enkephalin (Met5-Enkephalin, MENK, OGF, opioid growth factor) (Zagon et al, 1996; Wu et al, 1998)
¥¥ Met-Enkephalin (Met5-Enkephalin, MENK, OGF, opioid growth factor) receptors (Zagon et al, 1996; Wu et al, 1998)
¥ MIC1 (macrophage inhibitory cytokine-1, GDF15, growth/differentiation factor-15, PL74, PTGF-beta, Placental Transforming Growth Factor-beta, PDF, prostate-derived factor, PLAB, Placental bone morphogenetic protein, NAG-1, NSAID activated gene-1) (Jurczyluk et al, 2003)
¥ Midkine (MK, Mdk, MK1, midgestation and kidney protein, NEGF-2, neurite growth-promoting factor-2, ARAP, Amphiregulin-associated protein, RIHB, retinoic acid-inducible heparin binding protein) (Kojima et al, 1995)
¥¥ Midkine (MK, Mdk, MK1, midgestation and kidney protein, NEGF-2, neurite growth-promoting factor-2, ARAP, Amphiregulin-associated protein, RIHB, retinoic acid-inducible heparin binding protein) receptors (Tran et al, 2000; Kojima et al, 1995)
¥ MIF (MMIF, macrophage migration inhibitory factor, GIF, GLIF, glycosylation inhibiting factor, DER6, Delayed early response protein 6, phenylpyruvate tautomerase, PPT, EC5.3.2.1, phenylpyruvate keto-enol isomerase; phenylpyruvate tautomerase; phenylpyruvate keto-enol isomerase; EC5.3.2.1) (Schmeisser et al, 2005; Shimizu et al, 2004; Nishihira et al, 1998; Sommer et al, 2009; Simons D et al, 2011)
¥ MINOR (mitogen inducible nuclear orphan receptor, NR4A3, nuclear receptor subfamily 4 group A member 3, NOR1, neuron-derived orphan receptor-1, CHN, CSMF) (Martorell L et al, 2007; Martorell L et al, 2008; Martorell L et al, 2009; Rius J et al, 2006; Zhao Y et al, 2010)
¥ Mitofusin-2 (MFN2, KIAA0214, MARF, Mitochondrial assembly regulatory factor, dmfn, HSG, Hyperplasia suppressor gene, HRG-1, hypertension-related gene-1) (Lugus et al, 2011)
¥ MMP-1 (matrix metalloproteinase-1, collagenase, collagenase-1, CL-1, CLG1, fibroblast collagenase, fibroblast-type collagenase, interstitial collagenase, tissue collagenase, EC3.4.23.7) (Hanemaaijer et al, 1993; Cornelius et al, 1995; Vorotnikova et al, 2004; Zucker et al, 1998; Jackson and Nguyen, 1997; Morata et al, 2003; Nelimarkka et al, 1998; Nikkari et al, 1995; Reed et al, 2000; Ikeda et al, 2000; Huang et al, 2001; Krikun et al, 2005; Schonherr et al, 2001; Plaisier et al, 2004; Wang et al, 2004; Nordskog et al, 2004; Game et al, 2003; Saunders et al, 2005; Duhamel-Clerin et al, 1997; Jorg et al, 2005; Klein-Soyer et al, 1997; Masckauchan et al, 2006; Montero et al, 2006; Struewing et al, 2009; Philp D et al, 2006; Tunica et al, 2009; Heo SH et al, 2010)
¥ MMP-2 (matrix metalloproteinase-2, EC3.4.24.24, 70 kDa gelatinase, 72 kDa gelatinase, 72 kDa metalloproteinase, collagenase type 4, collagenase type 4A, 72 kDa type IV collagenase, Gelatinase 72 kDa, Gelatinase A, Type IV collagenase, Type IVA collagenase, neutrophil gelatinase) (Hanemaaijer et al, 1993; Ito et al, 1995; Gebbia et al, 2001; Vorotnikova et al, 2004; Deo et al, 2004; Jackson et al, 1998; Lamoreaux et al, 1998; Zucker et al, 1998; Jackson and Nguyen, 1997; Hanemaaijer et al, 1998; Nelimarkka et al, 1998; De Lorenzo et al, 2000; Puyraimond et al, 2001; Schonherr et al, 2001; Plaisier et al, 2004; Ottino et al, 2004; Arenas et al, 2004; Zhang et al, 2001; Poole et al, 2002; von Offenberg Sweeney et al, 2004; Wang S and Hirschberg R, 2009; Hummel et al, 2001; Wang and Keiser, 2000; Krikun et al, 2005; Morata et al, 2003; Kawano et al, 1997; Duhamel-Clerin et al, 1997; Adya et al, 2008; Guegan et al, 2008; Ho et al, 2007; Son et al, 2006; Park et al, 2001; Yanez-Mo et al, 2008; Philp D et al, 2006; Tunica et al, 2009; Heo SH et al, 2010)
¥ MMP-3 (matrix metalloproteinase-3, stromelysin-1, STMY1, STR1, SL-1, transin, transin-1, collagenase activating protein, procollagenase activator, proteoglycanase) (Hanemaaijer et al, 1993; Cornelius et al, 1995; Nelimarkka et al, 1998; Pintucci et al, 2003; Hummel et al, 2001; Duhamel-Clerin et al, 1997; Klein-Soyer et al, 1997; Heo SH et al, 2010)
¥ MMP-7 (matrix metalloproteinase-7, matrilysin, Matrilysin-1, PUMP, punctuated metalloproteinase, pump-1, putative metalloproteinase-1, matrin, EC3.4.24.23) (Nagashima et al, 1997; Heo SH et al, 2010; Hoeth M et al, 2012)
¥ MMP-8 (matrix metalloproteinase-8, neutrophil collagenase, PMNL collagenase, polymorphonuclear leukocyte collagenase, collagenase-2, CLG2, CL-2) (Hanemaaijer et al, 1998; Hanemaaijer et al, 1997; Heo SH et al, 2010)
¥ MMP-9 (matrix metalloproteinase-9, EC3.4.24.35, gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase, or PMNL gelatinase, polymorphonuclear leukocyte gelatinase, gelatinase type IV-B, collagenase type 5, collagenase-5, CL-5) (Cornelius et al, 1995; Hanemaaijer et al, 1998; Nelimarkka et al, 1998; Schonherr et al, 2001; Gerdes et al, 2002; Jadhav et al, 2004; Von Offenberg Sweeney et al, 2005; Arkell and Jackson, 2003; Shastry and Tyagi, 2004; Hummel et al, 2001; Gebbia et al, 2001; Adya et al, 2008; Annabi et al, 2008; Yue et al, 2006; Ho et al, 2007; Park et al, 2001; Philp D et al, 2006; Kahn et al, 2000; Heo SH et al, 2010)
¥ MMP-10 (matrix metalloproteinase-10, stromelysin-2, STMY2, SL-2, ST-2, transin-2, EC3.4.24.22) (Saunders et al, 2005; Krikun et al, 2005; Morata et al, 2003; Rodriguez et al, 2008; Zhao et al, 2008; Montero et al, 2006; Abid et al, 2008; Heo SH et al, 2010)
¥ MMP-11 (matrix metalloproteinase-11, stromelysin-3, STMY3, SL-3, ST-3) (Heo SH et al, 2010)
¥ MMP-12 (matrix metalloproteinase-12, macrophage elastase, macrophage metalloelastase, EC3.4.24.65, MME, HME) (D'Alessio et al, 2004; Hummel et al, 2001)
¥ MMP-13 (matrix metalloproteinase-13, Collagenase-3, CLG3, CL-3) (Gerdes et al, 2002; Lopez-Rivera et al, 2005; Schmidt-Hansen et al, 2004; Zaragoza et al, 2002; Morata et al, 2003; Sosnoski and Gay, 2007; Heo SH et al, 2010)
¥ MMP-14 (matrix metalloproteinase-14, MT1-MMP, Membrane-type matrix metalloproteinase-1, MT-MMP-1, MMP-X1) (Deo et al, 2004; Nelimarkka et al, 1998; Schonherr et al, 2001; Plaisier et al, 2004; Ottino et al, 2004; Galvez et al, 2005; Wang and Keiser, 2000; Morata et al, 2003; Yana et al, 2007; Guegan et al, 2008; Krubasik et al, 2008; Koike et al, 2002; Langlois S et al, 2004; Yanez-Mo et al, 2008; Enis et al, 2008; Tunica et al, 2009; Heo SH et al, 2010; Hawinkels LJ et al, 2010)
¥ MMP-15 (matrix metalloproteinase-15, MT2-MMP, Membrane-type matrix metalloproteinase-2, MT-MMP-2) (Heo SH et al, 2010)
¥ MMP-16 (matrix metalloproteinase-16, MT3-MMP, Membrane-type matrix metalloproteinase-3, MT-MMP-3, C8orf57, chromosome 8 open reading frame 57) (Plaisier et al, 2004; Heo SH et al, 2010)
¥ MMP-17 (matrix metalloproteinase-17, MT4-MMP, Membrane-type matrix metalloproteinase-4, MT-MMP-4) (Plaisier et al, 2004)
¥ MMP-18 [matrix metalloproteinase-18] (collagenase-4) (Poland et al, 1995)
¥ MMP-19 (matrix metalloproteinase-19, RASI-1, rheumatoid arthritis synovium inflamed-1) (Kolb et al, 1999; Hieta et al, 2004; Heo SH et al, 2010)
¥ MMP-25 (matrix metalloproteinase-25, Membrane-type matrix metalloproteinase-6, MT6-MMP, MT-MMP-6, leukolysin, MMPL1, matrix metalloproteinase-like 1, matrix metallopeptidase-like 1) (Barbier et al, 2011)
¥ MMP-26 (matrix metalloproteinase-26, matrilysin-2, endometase, endometrial tumor-derived metalloproteinase) (Chegini et al, 2003)
¥ MMP-28 (matrix metalloproteinase-28, epilysin) (Nelson et al, 2007)
¥ Mortalin (mortalin-1, mot-1, mortalin-2, mot-2, p66-mot-1, PBP74, peptide binding protein 74, grp75, glucose regulated protein 75, HSPA9B, heat shock 70 kDa protein 9B, HSPA9, heat shock 70 kDa protein 9 mthsp75, CRP40, catecholamine regulated 40 kDa protein) (Hamdi and Castellon, 2003; Yi P et al, 2010)
¥ Mx (myxovirus resistance 1, Mx1, MxA, IFI-78k, interferon-inducible 78 kDa protein; IFI-78) (Nelson et al, 2007)
¥ myeloblastin (MBN, Proteinase-3, PR3, PRTN3, AGP7, Azurophil granule protein-7, p29 autoantigen, Wegener Autoantigen p29, c-ANCA, antineutrophil cytoplasmic autoantibody, AURA21, augmented in rheumatoid arthritis 21) (Mayet et al, 1997; de Bandt et al, 1997)

¥ Naofen (WDR35, WD repeat domain 35, IFT121, intraflagellar transport protein 121, IFTA-1, intraflagellar transport protein A1, KIAA1336) (An et al, 2008, Feng GG et al, 2008)
¥ N-cadherin (Neural cadherin, Cadherin-2, CDH2, A-CAM, adherens junction cell adhesion molecule, CDHN, neural calcium-dependent adhesion protein, CD325) (Zhu et al, 2008)
¥ Nectin-1 (Nectin, Nectin-1-alpha, Nectin-1-delta, CLPED1, ED4, ectodermal dysplasia 4, HevC, HIgR, Herpesvirus Ig-like receptor, HVEC, Herpesvirus entry mediator C, Herpes simplex virus entry protein C, PRR, poliovirus receptor-related, PRR1, poliovirus receptor-related-1, PVRL1, poliovirus receptor-like-1, PVRR, poliovirus receptor-related, PVRR1, poliovirus receptor-related-1, SK-12, CD111) (Hung et al, 2002)
¥ neogenin (NGN, NEO1, neogenin-1, IGDCC2, Immunoglobulin superfamily DCC subclass member 2) (Larrieu-Lahargue F et al, 2010)
¥ nucleobindin-2 (NUCB2, NEFA, ZG4, gastric cancer antigen ZG4, Wa antigen, nesfatin, nesfatin-1) (Islam et al, 2006)
¥¥ netrin-1 (NTN1, NTN1L, netrin-1 like) receptors (DCC, Deleted in Colorectal Cancer, CRC18, colorectal cancer related chromosome sequence 18) (Lu et al, 2004)
¥ Neuregulin-1 (NRG-1, GGF, Glial growth factor, GGF-1, glial growth factor-1, NDF, neu differentiation factor, Acetylcholine receptor inducing activity, ARIA, Heregulin, heregulin-alpha, HGL, HRGA) (Iivanainen et al, 2003; Cote et al, 2005; Nelson et al, 2007)
¥ Neuritin (NRN, Neuritin 1, NRN1, CPG15, Candidate Plasticity Gene 15) (Le Jan et al, 2006)
¥¥ Neuritin (NRN, Neuritin 1, NRN1, CPG15, Candidate Plasticity Gene 15) receptors (Han D et al, 2011)
¥ neurokinin A receptors (Brylla et al, 2005)
¥ neurokinin B receptors (Brylla et al, 2005)
¥ neurolysin (NLN, KIAA1226, EC3.4.24.16, AGTBP, Angiotensin-binding protein; angiotensin-2 binding protein, endopeptidase 24.16, endopeptidase 3.4.24.16; EP24.16, microsomal endopeptidase, MOP, Mitochondrial oligopeptidase M, neurolysin(24-16), NT endopeptidase, Neurotensin endopeptidase, Oligopeptidase M) (Norman et al, 2003; Cotter et al, 2004)
¥ neuromedin U (NmU, Neuromedin U-8, NmU-8, Neuromedin U-25, NmU-25, Neuromedin U-23, NmU-23) (Nelson et al, 2007)
¥ neuron-specific enolase (NSE, Gamma-enolase, EC4.2.1.11, Enolase-2, ENO2, phosphopyruvate hydratase) (Barbier et al, 2011)
¥ neuropeptide Y (NPY, Y Neuropeptide) (Alvaro et al, 2007)
¥¥ neuropeptide Y (NPY, Y Neuropeptide) receptors (Kitlinska et al, 2005; Ghersi et al, 2001; Zukowska-Grojec et al, 1998; Sanabria and Silva, 1994; Nan et al, 2004; Hoeth M et al, 2012)
¥¥ Neurotensin (NTS, NT, NT/NN, NT/N, Neuromedin N, NN, NMN) receptors (Schaeffer P et al, 1995)
¥ neuropilin-1 (Neuropilin, NPN-1, NP-1, NRP1, A5-antigen, BDCA4, Blood dendritic cell antigen 4, VEGF-165R, CD304) (Becker et al, 2005; Chung et al, 2004; Favre et al, 2003; Gerritsen et al, 2003; Giraudo et al, 1998; Guttmann-Raviv et al, 2007; Holmes and Zachary, 2008; Kessler et al, 2004; Kinney et al, 2008; Kokolakis et al, 2006; Lee S et al, 2009; Lim JI et al, 2005; MelŽndez-Herrera et al, 2008; Narazaki et al, 2008; Nguyen et al, 2007; Ottino et al, 2004; Pan et al, 2007; Shintani et al, 2006; Soker et al, 1998; Tao et al, 2003; Valdembri et al, 2009; Yang et al, 2004; Yang et al, 2005; You et al, 2005; Zhong et al, 2004)
¥ neuropilin-2 (NPN-2, NP-2, NRP2) (Bielenberg et al, 2004, 2008; Chung et al, 2004; Guttmann- Raviv et al, 2007; Kessler et al, 2004; Kim et al, 2009; Kinney et al, 2008; Narazaki et al, 2008; Yang et al, 2004; Yang H et al, 2005; Zhong et al, 2004; Barbier et al, 2011; Zhang W et al, 2006)
¥ neurturin (NTN, NRTN) (Barbier et al, 2011)
¥¥ neurturin (NTN, NRTN) receptors (Igarashi et al, 2001)
¥ Nexin-1 (PN-1-alpha, Glial-derived neurite promoting factor, GdNPF, Glia-derived nexin, GDN, NPF, neurite-promoting factor, Serpin E2) (Takeda N et al, 2007)
¥ NG2 (neuronal/glial 2, AN2, MCSP, melanoma chondroitin sulfate proteoglycan, mel-CSPG, MCSPG, melanoma chondroitin sulfate proteoglycan, HMW-MAA, high molecular weight-melanoma-associated antigen, CSPG4, chondroitin sulfate proteoglycan 4) (Takeda N et al, 2007)
¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) (Biernacki et al, 2005; Cantarella et al, 2002; Moser et al, 2004; Tanaka et al, 2004; Lecht et al, 2010)
¥¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) receptors (NGFR, p75NTR, p75 neurotrophin receptor, p75LNGFR, p75NGFR, LNGFR, p75 low affinity NGF receptor, TNFRSF16, TNF receptor superfamily member 16, CD271) (Kim et al, 2004; Cantarella et al, 2002; Milner et al, 2004; Steinle and Granger, 2003; Moser et al, 2004; Tanaka et al, 2004; Foster et al, 2003; Raychaudhuri et al, 2001)
¥ NGF-beta (nerve growth factor-beta, NGFB) (Sommer et al, 2009)
¥ Ninein (Nin, KIAA1565, ninein-lm, ninein like mouse, GSK3B interacting protein, Glycogen synthase kinase 3 beta-interacting protein) (Matsumoto et al, 2008)
¥¥ nociceptin (PNOC, PPNOC, Orphanin FQ, Nociceptin/Orphanin FQ, N/OFQ, Orphanin FQ/Nociceptin, OFQ/N) receptors (LC132, NOCIR, OPRL1, ORL1, opioid receptor-like 1, opiate receptor-like 1, OP4, opioid receptor 4, NOP, non-classical opioid receptor) (Granata et al, 2003)
¥ NOD1 (Nucleotide-binding oligomerization domain protein 1, CARD4, caspase recruitment domain-containing protein-4, NLRC1, NLR family, CARD domain containing 1) (Opitz et al, 2005)
¥ NOD2 (Nucleotide-binding oligomerization domain protein 2, CARD15, caspase recruitment domain-containing protein-15, NLRC2, NLR family, CARD domain containing 2, IBD1, inflammatory bowel disease 1, BLAU, CLR16.3) (Davey et al, 2006; Oh et al, 2005; Gutierrez et al, 2002; Lin ZM et al, 2009)
¥ Nogo (neurite outgrowth inhibitor, NI-220, neurite growth inhibitor 220, KIAA0886, vp20, reticulon-4, RTN4, IN-1 antigen) (Qiu et al, 2008)
¥¥ noggin (NOG) receptors (Reese et al, 2004)
¥¥ Norrin (NDP, Norrie disease protein, Ndph, Norrie disease protein homolog, FEVR, familial exudative vitreoretinopathy, EVR2, exudative vitreoretinopathy 2 protein) receptors (Ohlmann et al, 2010)
¥ Notch-1 (Notch, Motch, Motch A, TAN-1, translocation-associated notch homolog-1) (You et al, 2005; Noseda et al, 2004; Favre et al, 2003; Liu et al, 2003; Shawber CJ et al, 2007; Funahashi Y et al, 2010)
¥¥ Notch-1 (Notch, Motch, Motch A, TAN-1, translocation-associated notch homolog-1) receptors (Itoh et al, 2004)
¥ Notch-2 (Motch B) (Nelson et al, 2007; Quillard T et al, 2010)
¥ Notch-3 (CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) (Nelson et al, 2007; Barbier et al, 2011)
¥¥ Notch-3 (CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) receptors (Uyttendaele et al, 2000; Shirayoshi et al, 1997)
¥ Notch-4 (int-3) (Favre et al, 2003; Hainaud et al, 2006; Claxton and Fruttiger, 2004)
¥¥ Notch-4 (int-3) receptors (MacKenzie et al, 2004)
¥ nov (nephroblastoma overexpressed gene, novH, CCN3, IGFBPrP3, Insulin-like growth factor binding protein related protein-3, IGFBP9, Insulin-like growth factor binding protein-9) (Gellhaus et al, 2006)
¥¥ nov (nephroblastoma overexpressed gene, novH, CCN3, IGFBPrP3, Insulin-like growth factor binding protein related protein-3, IGFBP9, Insulin-like growth factor binding protein-9) receptors (Lafont et al, 2005)
¥¥ NPR3 (natriuretic peptide receptor 3, NPR-C, natriuretic peptide receptor-C, ANPRC, atrial natriuretic peptide clearance receptor C, C5ORF23, chromosome 5 open reading frame 23, osteocrin receptor, musclin receptor, longjohn, Lgj, longjohn-2J, lgj(2J), strigosus, stri) (Khambata et al, 2011; Liu Y et al, 2011; Pedram et al, 2001; Wilcox et al, 1991; Xing J et al, 2012)
¥ NT-3 (neurotrophin-3, neuronotrophin-3, neurotrophic factor-3, NTF-3, HDNF, hippocampus-derived neurotrophic factor, NGF-2, Nerve growth factor-2) (Sommer et al, 2009)
¥¥ NT-4 (neurotrophin-4, neuronotrophin-4, neurotrophic factor-4) receptors (Kermani et al, 2005)
¥ nucleobindin-2 (NUCB2, NEFA, ZG4, gastric cancer antigen ZG4, Wa antigen, nesfatin, nesfatin-1) (Islam et al, 2006)
¥ nur-77 (nuclear receptor-77, NAK1, NGFI-B, nerve growth factor-inducible B, RNR-1, regenerating liver nuclear receptor, NR4A1, nuclear receptor subfamily 4 group A member 1, TIS1, TPA-inducible sequence-1, tetradecanoyl phorbol acetate-inducible sequence-1) (You et al, 2009; Liu et al, 2001)
¥ Nurr-1 (nuclear receptor-related factor 1, NR4A2, nuclear receptor subfamily 4 group A member 2, NOT, nuclear receptor of T-cells, TINUR, transcriptionally inducible nuclear receptor) (Liu et al, 2001)

¥¥ Oncostatin M (OSM, OM, Onco M, OnM) receptors (OSMR, oncostatin M receptor, OSMRB, Oncostatin-M receptor-beta OSMR-beta, Oncostatin-M-specific receptor subunit beta, IL31R-beta, IL31RB, Interleukin-31 receptor-beta; IL6ST, IL6 signal transducer, interleukin-6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Wijelath et al, 1997; Ruprecht et al, 2001; Saijonmaa et al, 1998; Pourtau et al, 1998; Yao et al, 1996; Kallmann et al, 2002; Hooper et al, 1997; Nakazato et al, 1997; Saijonmaa et al, 2000; Pourtau et al, 1998; Mahboubi et al 2003; Rychli et al, 2010)
¥ osteopontin (OPN, OP, Osp, 2ar, 44 kDa bone phosphoprotein, 66 kDa bone phosphoprotein, bone sialoprotein, bone sialoprotein-1, BSP, BSP1, BSPI, Calcium oxalate crystal growth inhibitor protein, Eta-1, early T-lymphocyte activation protein 1, Nephropontin, Spp-1, Secreted Phosphoprotein-1, transformation-related phosphoprotein, tumor-secreted phosphoprotein, urinary stone protein, Uropontin) (Xie et al, 2001; Bishop E et al, 2012)
¥¥ osteopontin (OPN, OP, Osp, 2ar, 44 kDa bone phosphoprotein, 66 kDa bone phosphoprotein, bone sialoprotein, bone sialoprotein-1, BSP, BSP1, BSPI, Calcium oxalate crystal growth inhibitor protein, Eta-1, early T-lymphocyte activation protein 1, Nephropontin, Spp-1, Secreted Phosphoprotein-1, transformation-related phosphoprotein, tumor-secreted phosphoprotein, urinary stone protein, Uropontin) receptors (Khan et al, 2002; Malyankar et al, 2000; Cui et al, 2009)
¥ osteoprotegerin (OPG, FDCR-1, FDC-derived receptor-1, OCIF, osteoclastogenesis inhibitory factor, OCIF/OPG, OPG/OCIF, TNFRSF11B, TNF receptor superfamily member 11B, TR1, TNF receptor-like-1) (Kobayashi-Sakamoto et al, 2004; Collin-Osdoby et al, 2001; Malyankar et al, 2000; Bock et al, 2005; Zannettino et al, 2005; Corallini et al, 2009; Reidet al, 2009)
¥¥ osteoprotegerin (OPG, FDCR-1, FDC-derived receptor-1, OCIF, osteoclastogenesis inhibitory factor, OCIF/OPG, OPG/OCIF, TNFRSF11B, TNF receptor superfamily member 11B, TR1, TNF receptor-like-1) receptors (Kobayashi-Sakamoto M et al, 2010)
¥¥ Oxytocin (OT, OXT) receptors (Weston et al, 2002; Nakamura et al, 2000; Thibonnier et al, 1999; Szeto et al, 2008)

¥ PAI-1 (Plasminogen activator inhibitor-1, PAI, plasminogen activator inhibitor, endothelial plasminogen activator inhibitor, Serpin E1, MSF, monocyte suppressor factor, EIP-1, EGF-inducible protein 1, mesosecrin) (Arnman et al, 1992; Bednarek et al, 2008; Boncela et al, 2006; Chen et al, 2008; Cicila et al, 1989; Dietzmann et al, 2000; Feener et al, 1995; Helenius et al, 2008; Ito et al, 1995; Jerczynska and Pawlowska, 2009; Kimura et al, 2002; Kunieda et al, 2003; Mehta et al, 2002; Milkiewicz et al, 2008; Muth et al, 2004; Nachman et al, 1986; Nishimura et al, 1997; Norata et al, 2004; Norata et al, 2007; Olofsson B et al, 1998; Ota H et al, 2008; Patel N et al, 2010; Pepper et al, 1995; Poole et al, 2002; Sahni et al, 2004; Sato et al, 1998; Singh et al, 2010; Sugano et al, 2001; Takeda N et al, 2007; Tunica et al, 2009; Ulrich et al, 2006; Vaughan et al, 1995; Wang et al, 2005; Yamamoto et al, 2004; Yoshizumi et al, 1998, 1999; Zhang et al, 2001; Zoellner et al, 1992; Marchand A et al, 2012)
¥ PAI-2 (Plasminogen activator inhibitor-2, placental plasminogen activator inhibitor, epidermal plasminogen activator inhibitor, monocyte-derived plasminogen activator inhibitor, Monocyte Arg-serpin, PLANH2, urokinase inhibitor, PP10, placental protein 10, Serpin B2) (Feener et al, 1995; Webb et al, 1987; Muth et al, 2004; Dietzmann et al, 2000; Zoellner et al, 1992; Arnman et al, 1995; Zoellner et al, 1998; Ulrich et al, 2006; Kimura et al, 2002; Nelson et al, 2007; Barbier et al, 2011)
¥ PAP-3 (pancreatitis-associated protein-3) (Yoshioka et al, 2002)
¥ par-4 (prostate apoptosis response protein 4, WT1-interacting protein, PAWR, PRKC apoptosis WT1 regulator protein) (Roussigne et al, 2003)
¥ PDCD6 (programmed cell death-6, ALG2, Apoptosis-linked gene-2) (Qiu et al, 2008)
¥ PD-ECGF (platelet-derived endothelial cell growth factor, ECGF-1, endothelial cell growth factor-1, GLS, GLS/TP, Gliostatin, platelet-derived endothelial cell mitogen, EC2.4.2.4, thymidine phosphorylase, dThdPase, TYMP, Pyrimidine phosphorylase) (Salvucci et al, 2004)
¥ PDGF (platelet-derived growth factor, PDGF-1, PDGF-2, PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast-derived growth factor, GDGF, glioma-derived growth factor-1, GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid-suppressible mitogenic activity, MDF, mesangial cell proliferating factor, MDGF, monocyte-derived growth factor, OBIF, osteoblastogenesis inhibitory factor, ODGF, osteosarcoma-derived growth factor, T47D factor) (Dardik et al, 2005; Nilsson et al, 2004; Heydarkhan-Hagvall et al, 2003; Gerritsen et al, 2003; Li et al, 2004; Coombes et al, 2001; Zhong et al, 2004; Krettek et al, 1997; Sapienza et al, 1998; Kobayashi et al, 1998; Grandaliano et al, 1998; Sumpio et al, 1998; Arkonac et al, 1998; Axel et al, 1997; Bao et al, 1999; Li et al, 1997; Zhao and Xu, 2000; Zhang et al, 2002; Morimoto et al, 2001; Wondergem et al, 2004; Shi et al, 2004; Sasahara et al, 1995; Mizutani et al, 1995; Yang H et al, 2005; Kawano et al, 1995; Delbridge and Khachigian, 1997; Aromatario et al, 1997; Yoon et al, 2000; Yue et al, 2006; Zhou et al, 2005; Yang et al, 2005; Takeda N et al, 2007; Passerini AG et al, 2003; Barbier et al, 2011; Strasser et al, 2010)
¥¥ PDGF (platelet-derived growth factor, PDGF-1, PDGF-2, PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast-derived growth factor, GDGF, glioma-derived growth factor-1, GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid-suppressible mitogenic activity, MDF, mesangial cell proliferating factor, MDGF, monocyte-derived growth factor, OBIF, osteoblastogenesis inhibitory factor, ODGF, osteosarcoma-derived growth factor, T47D factor) receptors (PDGFR, PDGFR1, PDGFR2, PDGFRA, PDGFR-alpha, PDGFRB, PDGFR-beta, PDGF receptor, PDGF receptor-1, PDGF receptor-2, PDGF receptor-alpha, PDGF receptor-beta; patch; CD140a, CD140b, JTK12) (Grandaliano et al, 1998; Wang et al, 1999; Usui et al, 2000; Sano et al, 2002; Castellon et al, 2002; Langley et al, 2004; Iguchi et al, 1995; Kimura et al, 1997; Lingen et al, 1996; Ross et al, 2001; Yoon et al, 2000; Zhang D et al, 2010)
¥ PDGF-C (Platelet-derived growth factor-C, PDGF-CC, SCDGF, Spinal cord-derived growth factor, fallotein) (Martinez et al, 2004; Uutela et al, 2001)
¥¥ PDGF-C (Platelet-derived growth factor-C, PDGF-CC, SCDGF, Spinal cord-derived growth factor, fallotein) receptors (Li et al, 2005)
¥ PDGF-D (PDGF-DD, platelet-derived growth factor-D, Iris-expressed growth factor, IEGF, SCDGF-B, Spinal cord-derived growth factor-B) (Uutela et al, 2001; Nelson et al, 2007)
¥ PDL2 (programmed death-1 ligand 2, PDCD1L2, PDCD1LG2, PDCD1 Ligand 2, B7-DC, Butyrophilin B7-DC, CD273) (Brown et al, 2003; Nelson et al, 2007)
¥ PEA-15 (phosphoprotein enriched in astrocytes 15, PED, phosphoprotein enriched in diabetes, MAT1, mammary transforming gene 1) (Glienke et al, 2000)
¥ PEAR1 (platelet endothelial aggregation receptor 1, Jedi, Jedi-1, MEGF12, multiple epidermal growth factor-like domains 12) (Nanda et al, 2005)
¥ PEDF (pigment epithelium-derived factor, EPC-1, early population doubling level cDNA, Caspin, SDF-3, Stromal cell-derived factor-3, Serpin F1) (Aparicio et al, 2005; Tombran-Tink et al, 2004; Yamagishi et al, 2005)
¥¥ PEDF (pigment epithelium-derived factor, EPC-1, early population doubling level cDNA, Caspin, SDF-3, Stromal cell-derived factor-3, Serpin F1) receptors (Aparicio et al, 2005; Yamagishi et al, 2004; Apte et al, 2004; Hutchings et al, 2002; Zhang et al, 2006)
¥ Pentraxin-3 (Pentaxin-3, PTX3, TNFAIP5, tumor necrosis factor-alpha-induced protein 5, pentraxin-related gene rapidly induced by IL1-beta, TSG-14, tumor necrosis factor-stimulated gene sequence-14) (Breviario et al, 1992; Lee et al, 1993; Napoleone et al, 2002; Alles et al, 1994; Introna et al, 1993; Norata et al, 2008; Gustin et al, 2008; Kawanami et al, 2004; Introna et al, 1996; Morikawa et al, 2004; Tunica et al, 2009; Maina et al, 2009)
¥¥ Pentraxin-3 (Pentaxin-3, PTX3, TNFAIP5, tumor necrosis factor-alpha-induced protein 5, pentraxin-related gene rapidly induced by IL1-beta, TSG-14, tumor necrosis factor-stimulated gene sequence-14) receptors (Presta et al, 2007)
¥ PI9 (proteinase inhibitor-9, Serpin B9, CAP3, cytoplasmic antiproteinase 3, serine protease inhibitor-6, SPI-6) (Buzza et al, 2001; Vermijlen et al, 2002 )
¥¥ pleiotrophin (PTN, HARP, heparin affin regulatory peptide, HBBM, heparin binding brain mitogen, HB-GAF, heparin binding growth-associated factor, HB-GAM, heparin binding growth-associated molecule, HBGF-8, heparin binding growth factor-8, HBNF, heparin binding neurotrophic factor, NEGF-1, neurite growth-promoting factor-1, OSF-1, osteoblast-specific factor-1) receptors (Fang et al, 1992; Li et al, 2005; Kojima et al, 1995; Kokolakis et al, 2006)
¥ plexin-A1 (PLXNA1, Plexin-1, NOV) (Kessler et al, 2004)
¥ plexin-A2 (PLXNA2, Plexin-2, OCT, KIAA0463) (Kessler et al, 2004)
¥ Plexin-B1 (PLXNB1, Plexin-5, SEP, Semaphorin 4D receptor, CD100 receptor, KIAA0407) (Conrotto et al, 2005; Basile et al, 2004, 2007)
¥ plexin-B3 (PLXNB3, Plexin-6, semaphorin 5A receptor) (Artigiani et al, 2004)
¥ plexin-D1 (PLXND1, KIAA0620) (Toyofuko et al, 2007; Gitler et al, 2004; Gu et al, 2005; Nelson et al, 2007; Smith EP et al, 2011)
¥ PlGF (placenta growth factor, Placental growth factor, PGF, PlGF-1, placenta growth factor-1, PlGF-2, placenta growth factor-2) (Yao YG et al, 2005; Yonekura H et al, 1999; Yang W et al, 2003; Zhou et al, 2005; Kahn et al, 2000; Harrington LS et al, 2008; Helmestam M et al, 2010; Loboda A et al, 2006; Ota T et al, 2002; Pan P et al, 2010)
¥¥ PlGF (placenta growth factor, Placental growth factor, PGF, PlGF-1, placenta growth factor-1, PlGF-2, placenta growth factor-2) receptors (Dhar-Mascareno et al, 2009; Fu et al, 2009; Clauss M et al, 1996; Desai J et al, 1999; Funahashi Y et al, 2010; Harrington LS et al, 2008; Holmes DI and Zachary I, 2004; Hauser S and Weich HA, 1993; Arroyo J et al, 2004; Patel N and Kalra VK, 2010; Patel N et al, 2010)
¥ PlGF-3 (placenta growth factor-3) (Yang et al, 2003)
¥ PlGF-4 (placenta growth factor-4) (Yang et al, 2003)
¥¥ PlGF (placenta growth factor, Placental growth factor, PGF, PlGF-1, placenta growth factor-1, PlGF-2, placenta growth factor-2) receptors (Castellon et al, 2002; Yao et al, 2005; Arroyo et al, 2004; Adini et al, 2002)
¥ PLXDC1 (plexin domain containing 1, Plexin domain-containing protein 1, TEM7, Tumor endothelial marker 7, TEM3, plexin domain containing 1, Plexin domain-containing protein 1) (Nanda et al, 2004; Carson-Walter et al, 2001; Conejo-Garcia et al, 2005; Wang XQ et al, 2005; Yamaji et al, 2008)
¥ PLXDC2 (plexin domain containing 2, Plexin domain-containing protein 2, TEM7R, Tumor endothelial marker 7-related protein) (Carson-Walter et al, 2001; Nanda et al, 2004)
¥ podoplanin (PDPN, T1A, T1A2, T1-alpha, gp36, gp40, RTI40, gp38, OTS8, E11 antigen, AGGRUS, RANDAM-2, PA2.26) (Breiteneder-Geleff et al, 1999; Groger et al, 2004; Kriehuber et al, 2001; Lin et al, 2008; Wick et al, 2008; Al-Rawi et al, 2005; Salven et al, 2003; Norgall et al, 2007; Nelson et al, 2007; Kulkarni et al, 2009; Kilic N et al, 2007; Spinella F et al, 2009)
¥ polo-like kinase-1 (Plk-1, Plk, polo-like kinase) (Kahn et al, 2000; Nelson et al, 2007)
¥ PR-39 receptors (Wu et al, 2004)
¥ prokineticin-2 (PROK2, PK2, Bv8 homolog) (prokineticin-2 Battersby )
¥¥ prokineticin-2 (PROK2, PK2, Bv8 homolog) receptors (PROKR1, ZAQ, PK-R1, GPR73, GPR73a, GPR73b, G-protein-coupled receptor-73, G-protein-coupled receptor-73a, G-protein-coupled receptor-73b, PROKR2, I5E, PK-R2, GPR73L1, G-protein-coupled receptor-73-like 1) (LeCouter J et al, 2003; Masuda et al, 2002; Guilini C et al, 2010; Battersby S et al, 2004; Jiang X et al, 2009; Urayama K et al, 2007; Kisliouk T et al, 2003, Podlovni H et al, 2006)
¥ Prolactin (PRL, lactogenic hormone, lactotropin, lactotropic hormone, mammotropin, mammotropic hormone, luteotropic hormone, LTH, luteotropin) (Ochoa et al, 2001; Clapp et al, 1998)
¥¥ prolactin (PRL, lactogenic hormone, lactotropin, lactotropic hormone, mammotropin, mammotropic hormone, luteotropic hormone, LTH, luteotropin) receptors (PRLR) (Merkle et al, 2000; Martini et al, 2000; Clapp et al, 1998; D'Angelo et al, 1995)
¥ Prolactin releasing hormone receptors (Nelson et al, 2007)
¥ proopiomelanocortin (POMC, ACTH, ACTH[1-13], ACTH[18-39], ACTH[22-39], adrenocorticotropin, Alpha-Endorphin, alpha-melanocortin, alpha-melanotropin, Alpha-MSH, Beta-cell trophin, Beta-Endorphin, Beta-Lipotropin, Beta-LPH, beta-melanotropin, Beta-MSH, CLIP, corticotrophin, corticotropin, corticotropin-like intermediate peptide, Gamma-Endorphin, Gamma-Lipotropin, Gamma-LPH, Gamma-MSH, Lipotropin, melanocyte stimulating hormone-alpha, melanocyte stimulating hormone-beta, melanocyte stimulating hormone-gamma, melanotropin, POC, pro-ACTH-Endorphin, proopiocortin) (Scholzen et al, 1999, 2000)
¥ prosaposin (Saposin A, Saposin B, Saposin C, Saposin D, sphingolipid activator protein, SAP, cerebroside sulfate activators, N-9F-proliferation factor, SGP-1, Sulfated glycoprotein-1) (Tunica et al, 2009)
¥ protein C (Aimes et al, 2003)
¥ Protein S (PROS1, PSA, PS-alpha, protein S-alpha, PSB, PS-beta, protein S-beta, Vitamin K-dependent protein S) (Dougherty et al, 1998; Hooper et al, 1997)
¥¥ PSG23 (Pregnancy-specific glycoprotein 23, CEA11, carcinoembryonic antigen 11) receptors (Wu et al, 2008)
¥ Psoriasin (PSOR1, S100A7, RIS-1, retinoic acid inducible skin-specific 1) (Tunica et al, 2009)
¥ PTHrP (parathyroid hormone-like related protein, PTH-related protein, parathyroid hormone-related protein, PTHR, PTH-related peptide, Parathyroid hormone-related peptide, parathyroid hormone-like hormone, PTHLH) (Schorr et al, 2003; Degenhardt et al, 2002; Eto et al, 1998; Wenzel et al, 2001; Jiang et al, 1998)
¥ PUMA (p53 upregulated modulator of apoptosis, BBC3, Bcl-2 binding component 3, JFY1) (Yan JH et al, 2008; Yan J et al, 2011)
¥ PYPAF1 (Pyrin-containing APAF-1-like protein 1, NLRP3, NLR family, pyrin-domain containing 3, NALP3, NACHT-LRR-PYD-containing protein-3, CIS1, CIAS1, cold-induced auto-inflammatory syndrome, Cryopyrin, CLR1.1) (Kolly et al, 2010; Reimer et al, 2010)

¥ RAGE (receptor for advanced glycosylation end products, AGER, advanced glycosylation end product-specific receptor) (Hsieh et al, 2004; Yamagishi and Takeuchi, 2004; Yonekura et al, 2003; Zhong et al, 2006; Yan et al, 2009; Lv et al, 2009; Ishibashi Y et al, 2010; Gong F et al, 2012)
¥ RAMP-2 (receptor activity-modifying protein-2) (Fernandez-Sauze, 2004; Fukai et al, 2003)
¥ RAMP-3 (receptor activity-modifying protein-3) (Fernandez-Sauze, 2004; Fukai et al, 2003)
¥ RANKL (RANK ligand, receptor activator of NF-kappa-B ligand, ODF, Osteoclast differentiation factor, OPGL, Osteoprotegerin ligand, SOFA, Stromal osteoclast-forming activity, TRANCE, tumor necrosis factor-related activation induced cytokine, TNFSF11, TNF ligand superfamily member 11) (Okada et al, 2003; Collin-Osdoby et al, 2001; Ishida et al, 2002; Barbier et al, 2011)
¥¥ RBP4 (retinol binding protein 4, plasma retinol-binding protein, sRBP, serum retinol binding protein) receptors (Takebayashi et al, 2011)
¥ Reelin (RELN, RL, reeler, CR-50 antigen) (Samama and Boehm, 2005; Pulido et al, 2007; Norgall et al, 2007)
¥¥ Reelin (RELN, RL, reeler, CR-50 antigen) receptors (VLDLR, very low density lipoprotein receptor, APOER2, Apolipoprotein E receptor 2, LRP8, low density lipoprotein receptor-related protein 8) (Wyne et al, 1996; Hiltunen et al, 1998; Wittmaack et al, 1995; Hu et al, 2008; Korschineck et al, 2001; Takeda N et al, 2007)
¥ Relaxin (RLN, RLX, RLN1, relaxin 1, relaxin H1, H1 relaxin, RLXH1, RXN1, RLN2, relaxin 2, relaxin H2, H2 relaxin, RLXH2, RXN2, relaxin 1/2) (Dschietzig et al, 2001)
¥¥ Relaxin (RLN, RLX, RLN1, relaxin 1, relaxin H1, H1 relaxin, RLXH1, RXN1, RLN2, relaxin 2, relaxin H2, H2 relaxin, RLXH2, RXN2, relaxin 1/2) receptors (Dschietzig et al, 2003, 2009; Fu et al, 2008; Failli et al, 2002; Kohsaka et al, 1998; Quattrone et al, 2004; Min et al, 1998)
¥¥ resistin (RSTN, RETN, RETN1, ADSF, adipose tissue-specific secretory factor, FIZZ-3, found in inflammatory zone-3, XCP4, ten-cysteine protein 4) receptors (Kawanami et al, 2004; Kougias et al, 2005; Verma et al, 2003; Di Simone et al, 2006; Chen C et al, 2010; Manduteanu I et al, 2010; Cho Y et al, 2011; Pirvulescu M et al, 2012)
¥ RGMa (Repulsive guidance molecule A; RGM domain family member A) (Schnichels et al, 2011, 2012; Schwab et al, 2005)
¥ RGS5 (regulator of G-protein signaling 5) (Chen et al, 2004; Furuya et al, 2004)
¥ RIG-I (Retinoic acid inducible gene-I, DDX58, DEAD box polypeptide 58, DEAD/H BOX 58) (Imaizumi et al, 2005; Pluvinet et al, 2008; BerghŠll et al, 2006)
¥ Robo-1 roundabout-1, sax3, DUTT1, deleted in U Twenty Twenty cells, DYX5) (Wang et al, 2003; Zhang B et al, 2009)
¥ Robo-4 (roundabout-4, magic roundabout, MRB) (Huminiecki et al, 2002; Okada et al, 2007, 2008; Park KW et al, 2003; Huang L et al, 2009; Zhang B et al, 2009)
¥ RXFP1 (LGR7, leucine-rich repeat-containing G-protein-coupled receptor 7, RLNR, relaxin receptor) (Dschietzig et al, 2009)
¥ ryk (ryk1) (Favre et al, 2003; Klein et al, 2008)

¥¥ S1PR1 (sphingosine-1-phosphate receptor 1, S1P receptor 1, S1P1, Endothelial differentiation G-protein coupled receptor 1, EDG1, endothelial differentiation gene 1, CD363) (Akiyama T et al, 2008; Favre CJ et al, 2003; Igarashi J et al, 2003, 2007; Imasawa T et al, 2010; Kimura T et al, 2003; Langlois S et al, 2004; Lee H et al, 2000; Lee JF et al, 2006; Lin CI et al, 2007; Mazurais D et al, 2002; Wang L et al, 2008; Yoon CM et al, 2008)
¥ S100A8 (S100 calcium binding protein A8, MRP-8, migration inhibition factor-related protein-8, myeloid-related protein-8, CP-10, chemotactic protein 10, CAGA, Calgranulin A, CGLA, CFAG, cystic fibrosis antigen, CF antigen) (Xu et al, 2001; Yen et al, 1998; Tunica et al, 2009)
¥¥ S100A8 (S100 calcium binding protein A8, MRP-8, migration inhibition factor-related protein-8, myeloid-related protein-8, CP-10, chemotactic protein 10, CAGA, Calgranulin A, CGLA, CFAG, cystic fibrosis antigen, CF antigen) receptors (Eue et al, 2002; Viemann et al, 2005)
¥ S100A9 (S100 calcium binding protein A9, MRP-14, migration inhibition factor-related protein-14, myeloid-related protein-14, Calgranulin B, CAGB, CGLB, Calprotectin, CFAG, cystic fibrosis antigen, CF antigen) (Tunica et al, 2009; Beckhove P et al, 2010)
¥¥ S100A9 (S100 calcium binding protein A9, MRP-14, migration inhibition factor-related protein-14, myeloid-related protein-14, Calgranulin B, CAGB, CGLB, Calprotectin, CFAG, cystic fibrosis antigen, CF antigen) receptors (Eue et al, 2002; Viemann et al, 2005)
¥ S100A13 (S100 calcium binding protein A13) (Qiu et al, 2007; Cao R et al, 2010; Hsieh et al, 2002; Ridinger et al, 2000)
¥ S100A13 (S100 calcium binding protein A13) receptors (Hsieh et al, 2004)
¥ S100A14 (S100 calcium binding protein A14, BCMP84,breast cancer membrane protein 84) (Nelson et al, 2007)
¥¥ S100b (S100-beta, S100, Astrocyte-derived growth factor, NEF, neurite extension factor) receptors (Tskitishvili E et al, 2010)
¥ Salusin-alpha (TOR2A, torsin family 2 member A, torsin 2A, TORP1, torsin-related protein-1) (Shichiri et al, 2003)
¥ Salusin-beta (TOR2A, torsin family 2 member A, torsin 2A, TORP1, torsin-related protein-1) (Shichiri et al, 2003)
¥¥ Salusin-beta (TOR2A, torsin family 2 member A, torsin 2A, TORP1, torsin-related protein-1) receptors (Shichiri et al, 2003)
¥ Sca-1 (stem cell antigen-1, Ly6A/E, Ly6D, TAP, T-cell activating protein, Ly6.2, lymphocyte antigen 6.2) (Luna et al, 2004; Matsuda K et al, 2010)
¥ SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) (Gerritsen et al, 2003; Li et al, 2004; Ko et al, 1999; Ochiai et al, 1999; Jonsson and Palmblad, 2001; Zhong et al, 2004; Meininger et al, 1995; Kallmann et al, 2002; Yamaguchi et al, 1996; Zhou et al, 2005)
¥¥ SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) receptors (kit, SCFR, CD117) (Matsui et al, 2004; Miettinen et al, 2000; Konig et al, 1997; Yamaguchi et al, 1996; Gerritsen et al, 2003)
¥ SCUBE1 (Signal peptide-CUB-EGF-like domain containing protein 1, is EGF-like domain containing protein-1) (Yang et al, 2000; Favre et al, 2003)
¥ SCUBE2 (Signal peptide-CUB-EGF-like domain containing protein 2, CEGB1, CEGF1, CEGP1, YOU) (Yang et al, 2000)
¥ SCUBE3 (Signal peptide-CUB-EGF-like domain containing protein 3) (Wu et al, 2004)
¥ secretagogin (SCGN, SEGN, SECRET) (Pipp et al, 2007)
¥ Secretoneurin (SN, Chromogranin C, CHGC, SCG2, SgII, Secretogranin-2, gonadotrope polypeptide, GP-87, TSP86/84, tyrosine-sulfated protein 86/84 kDa) (Shyu et al, 2008)
¥¥ Secretoneurin (SN, Chromogranin C, CHGC, SCG2, SgII, Secretogranin-2, gonadotrope polypeptide, GP-87, TSP86/84, tyrosine-sulfated protein 86/84 kDa) receptors (Kahler et al, 2002; Yan et al, 2006)
¥ SEF [similar expression to FGF] (Yang et al, 2003)
¥ Semaphorin 3A (SEMA3A, SEMA1, Semaphorin 3, sema III, collapsin-1, coll-1, Hsema-I, Semaphorin D, Sem D, SEMAD) (Damon, 2006; MelŽndez-Herrera et al, 2008)
¥¥ Semaphorin 3A (SEMA3A, SEMA1, Semaphorin 3, sema III, collapsin-1, coll-1, Hsema-I, Semaphorin D, Sem D, SEMAD) receptors (Guttmann-Raviv et al, 2007)
¥ Semaphorin 3B (SEMA3B, Semaphorin 5, SEMA5, Semaphorin A, Sem A, semaV, SEMAA, LUCA-1) (Damon, 2006)
¥ Semaphorin 3C (SEMA3C, SEMAE, Sem E, Semaphorin E, collapsin-3, coll-3) (Favre et al, 2003; Banu et al, 2006)
¥¥ Semaphorin 3C (SEMA3C, SEMAE, Sem E, Semaphorin E, collapsin-3, coll-3) receptors (Banu et al, 2006)
¥ Semaphorin 3E (SEMA3E, Semaphorin H, SEMAH), M-semaH, M-SemaK, collapsin-5, coll-5) (Damon, 2006)
¥ Semaphorin 3F (SEMA3F, Semaphorin 4, SEMA4, sema IV, Semaphorin K, SEMAK) (Damon, 2006)
¥¥ Semaphorin 3F (SEMA3F, Semaphorin 4, SEMA4, sema IV, Semaphorin K, SEMAK) receptors (Bielenberg et al, 2008; Guttmann-Raviv et al, 2007; Kessler et al, 2004)
¥ Semaphorin 3G (SEMA-3G) (Kutschera S et al, 2011; Hoeth M et al, 2012)
¥¥ Semaphorin 3G (SEMA-3G) receptors (Kutschera S et al, 2011)
¥ Semaphorin 4A (SEMA4A, Semaphorin B, SEMAB, Sem B) (Toyofuko et al, 2007)
¥¥ Semaphorin 4D (SEMA4D, Semaphorin J, SEMAJ, CD100, M-sema G, collapsin-4, coll-4, BB18, A8, GR3, C9orf164, chromosome 9 open reading frame 164) receptors (Basile et al, 2005, 2007)
¥¥ Semaphorin 5A (SEMA5A, Semaphorin F, sem F, SEMAF) receptors (Artigiani et al, 2004; Sadanandam et al, 2010)
¥ Semaphorin 7A (SEMA7A, Semaphorin L, SEMAL, H-Sema-L, H-Sema K1, Semaphorin K1, CD108, CDw108, JMH human blood group antigen) (Nelson et al, 2007)
¥ serglycin (SRGN, PRG1, PRG, PPG, platelet proteoglycan protein core) (Yasuo et al, 2008; Schick et al, 2001; Kulseth et al, 1999; Barbier et al, 2011)
¥ Serpin B1 (LEI, Leukocyte elastase inhibitor, MNEI, monocyte neutrophil elastase inhibitor, ELANH2, Monocyte/neutrophil elastase inhibitor-2, EI, elastase inhibitor, L-DNase II, LEI-derived DNase II) (Valamanesh et al, 2009)
¥ sFRP1 (secreted frizzled-related protein 1, FrzA, frizzled A, SARP-2, secreted apoptosis-related protein-2, FRP, frizzled-related protein) (Takeda N et al, 2007; Nelson et al, 2007)
¥ sFRP2 (secreted frizzled-related protein 2, FRP2, frizzled-related protein 2, SARP-1, secreted apoptosis-related protein-1, SDF-5, stromal cell derived factor-5, FKSG12) (Yeom HJ et al, 2009; Sun ZC et al, 2010)
¥¥ sFRP2 (secreted frizzled-related protein 2, FRP2, frizzled-related protein 2, SARP-1, secreted apoptosis-related protein-1, SDF-5, stromal cell derived factor-5, FKSG12) receptors (Courtwright et al, 2009)
¥ sirtuin-1 (SIRT1, SIR2L1, Sir2-like 1, SIR2-alpha) (Arunachalam G et al, 2010; Chen Z et al, 2010, Gracia-Sancho J et al, 2010, Homma K et al, 2010; Mattagajasingh et al, 2007; Potente M et al, 2007; Scalera F et al, 2009; Menghini R et al, 2009; Orimo M et al, 2009; Ota H et al, 2008; Yang L et al, 2012)
¥ Slit-2 (slit homolog-2, RGC growth cone collapsing factor, retinal ganglion cell growth cone collapsing factor) (Urbich et al, 2009)
¥¥ Slit-2 (slit homolog-2, RGC growth cone collapsing factor, retinal ganglion cell growth cone collapsing factor) receptors (Robo-1) (Wang et al, 2003)
¥ Slit-3 (slit homolog-3, MEGF5, multiple epidermal growth factor-like domains 5) (Zhang B et al, 2009)
¥¥ Slit-3 (slit homolog-3, MEGF5, multiple epidermal growth factor-like domains 5) receptors (Robo-1, Robo-4) (Zhang B et al, 2009)
¥ SMAD1 (Sma and Mad related protein-1, Mad, Mothers against decapentaplegic, MADH1, Mothers against decapentaplegic homolog 1, Mothers against DPP homolog 1, MADR1, Mad-related protein 1, BSP1, TGF-beta signaling protein-1, JV41) (Upton et al, 2008; Ray BN et al, 2010; Tian F et al, 2010; Wang S and Hirschberg R, 2009; Ota T et al, 2002; Van Geest et al, 2010)
¥ SMAD2 (Sma and Mad related protein-2, JV18-1, MADR2, Mad-related protein 2, MADH2, Mothers against DPP homolog 2, Mothers against DPP homolog 2) (Wang S and Hirschberg R, 2009; Van Geest et al, 2010)
¥ SMAD3 (Sma and Mad related protein-3, MADH3, Mothers against decapentaplegic homolog 3, Mothers against DPP homolog 3, JV15-2) (Wang S and Hirschberg R, 2009)
¥ SMAD5 (Sma and Mad related protein-5, JV5-1, MADH5, Mothers against DPP homolog 5, Mothers against DPP homolog 5) (Upton et al, 2008; Tian F et al, 2010; Wang S and Hirschberg R, 2009; Ray BN et al, 2010)
¥ SMAD6 (Sma and Mad related protein-6, MADH6, Mothers against DPP homolog 6, Mothers against DPP homolog 6) (Topper et al, 1997; Ota T et al, 2002)
¥ SMAD7 (Sma and Mad related protein-7, MADH7, Mothers against DPP homolog 7, Mothers against DPP homolog 7, CRCS3, colorectal cancer susceptibility 3) (Ota T et al, 2002)
¥ SMAD8 (Sma and Mad related protein-8) (Ray BN et al, 2010; Van Geest et al, 2010)
¥ SMOC-2 (secreted modular calcium-binding protein 2, SMAP-2, Smooth muscle-associated protein 2, SPARC related modular calcium binding 2) (Sosnoski and Gay, 2007; Albig et al, 2007)
¥ SOCS1 (Suppressor of cytokine signaling-1, SSI1, STAT induced STAT inhibitor-1, JAB, JAK binding protein, TIP3, TEC-interacting protein 3, CISH1, Cytokine inducible SH2-containing protein-1) (Inomata et al, 2009)
¥
SOCS3 (Suppressor of cytokine signaling-3, CIS3, Cytokine inducible SH2-containing protein-3, SSI3, STAT induced STAT inhibitor-3) (Mahboubi et al 2003; Pirvulescu M et al, 2012)
¥ somatostatin (SST, Somatotropin release inhibiting hormone, SIH, Somatotropin release inhibiting factor, SRIF, growth hormone-inhibiting hormone, GIH, growth hormone release inhibitory hormone, GH-RIH) (Yan et al, 2005)
¥¥ somatostatin (SST, Somatotropin release inhibiting hormone, SIH, Somatotropin release inhibiting factor, SRIF, growth hormone-inhibiting hormone, GIH, growth hormone release inhibitory hormone, GH-RIH) receptors (Adams et al, 2005; Badway et al, 2004; Leszczynski et al, 1995; Watson et al, 2001; Nelson et al, 2007; Yan et al, 2005)
¥¥ Sonic hedgehog (Shh) receptors (Kanda et al, 2003; Fujita et al, 2009)
¥ SPARC (secreted protein acidic and rich in cysteine, osteonectin, BM-40, basement-membrane protein 40, 43K glycoprotein ) (Lane et al, 1994; Sage et al, 1986; Puolakkainen et al, 1999; Kato et al, 2001; Shanker et al, 2001; Tunica et al, 2009)
¥¥ SPARC (secreted protein acidic and rich in cysteine, osteonectin, BM-40, basement-membrane protein 40, 43K glycoprotein ) receptors (Motamed et al, 2003; Murphy-Ullrich et al, 1995)
¥ sprouty-1 (Spry-1) (Impagnatiello et al, 2001; Sabatel et al, 2010)
¥ sprouty-2 (Spry-2) (Impagnatiello et al, 2001; Paik et al, 2007; Antoine et al, 2005)
¥ sprouty-3 (Spry-3) (Antoine et al, 2005)
¥ sprouty-4 (Spry-4) (Antoine et al, 2005)
¥ stanniocalcin 1 (STC1, STC, STC50, stanniocalcin, hypocalcin, teleocalcin) (Klein et al, 2009; Li et al, 2008; Enis et al, 2008; Holmes and Zachary, 2008; Abdel-Malak et al, 2007; Liu et al, 2003; Zlot et al, 2003; Sato et al, 1998; Kahn et al, 2000; Sheikh-Hamad, 2010; Mattaliano et al, 2009; Takeda N et al, 2007)
¥¥ stanniocalcin 1 (STC1, STC, STC50, stanniocalcin, hypocalcin, teleocalcin) receptors (Chen et al, 2008; Chakraborty et al, 2007; Zlot et al, 2003; Kahn et al, 2000)
¥ stanniocalcin 2 (STC2, STCRP, stanniocalcin-related protein) (Takeda N et al, 2007)
¥ STAT1 (signal transducer and activator of transcription-1, STAT1-alpha, STAT1-beta, p91, Stat91, p84) (Ota T et al, 2002)
¥ STAT2 (signal transducer and activator of transcription-2, p113) (Zhang W et al, 2006)
¥ STAT3 (signal transducer and activator of transcription-3, APRF, acute phase response factor, STAT3-alpha, STAT3-beta, STAT3-gamma, STAT3-delta) (Yang et al, 2005; Kim JY et al, 2009; Pirvulescu M et al, 2012; Zhang W et al, 2006)
¥ STAT5 (signal transducer and activator of transcription-5, STAT5a, STAT5b) (Barbier et al, 2011)
¥ STAT6 (signal transducer and activator of transcription-6, IL4-STAT, IL4 induced nuclear-activating factor, IL4-NAF) (Nelson et al, 2007; Inomata et al, 2009; Zhang W et al, 2006)
¥ STRO-1 (Ning et al, 2011)
¥ substance P (Neurokinin-1, NK1, NKA, Neurokinin A, Tac1, tachykinin-1) (Milner et al, 2004; Chiwakata et al, 1996; Bodin et al, 1995)
¥¥ substance P (Neurokinin-1, NK1, NKA, Neurokinin A, Tac1, tachykinin-1) receptors (Brylla et al, 2005; Bailey and Cunningham, 2001; Jones et al, 2001; Quinlan et al, 1999; Bowden et al, 1996; Nakagawa et al, 1995; Sharma and Davis, 1995; Manabe et al, 1995)
¥ Survivin (SVV, Apoptosis inhibitor 4, API4, TIAP, Thiol inhibitor of apoptosis, BIRC5, baculoviral IAP repeat-containing protein-5) (Ohashi et al, 2004; Singh et al, 2005; Iurlaro et al, 2004; Tran et al, 2002; Mahboubi et al, 2001; Abdou and Hanout, 2008; Zhang et al, 2007; O'Connor et al, 2000; Papapetropoulos et al, 2000; Conway et al, 2003; Kirkiles-Smith et al, 2004; Daly et al, 2004; Nelson et al, 2007; Quillard T et al, 2010)
¥ SVEP1 (Polydom, SEL-OB) (Schwanzer-Pfeiffer et al, 2010)
¥ SVBP (small vasohibin-binding protein, CCDC23, Coiled-coil domain-containing protein 23) (Suzuki et al, 2010)
¥ Syndecan-1 (syndecan, syndecan proteoglycan 1, SDC1, Synd1, SD-1, 104-9 antigen, 1D4 antigen, B-B2 antigen, B-B4 antigen, Mi15, CD138) (Kainulainen et al, 1996; Nelimarkka et al, 1998; Bobardt et al, 2003; Yuan et al, 2004; Kovalszky et al, 1994; Zhang W et al, 2006; Bjšrnson A et al, 2005; Schmidt et al, 2005; Li J et al, 1997)
¥ syndecan-2 (syndecan proteoglycan 2, SDC2, SYND2, HSPG, Heparan sulfate proteoglycan core protein, HSPG1, Heparan sulfate proteoglycan core protein-1, fibroglycan, CD362) (Mertens G et al, 1992; Fears CY et al, 2006; Halden Y et al, 2004; Noguer O et al, 2009; Patterson et al, 2008; Schmidt et al, 2005; )
¥ syndecan-3 (SDC3, Synd3, N-Syndecan, neural syndecan, neural-type syndecan, SDCN) (Zhang W et al, 2006; Cizmeci-Smith et al, 1997; Patterson et al, 2005, 2008; Schmidt et al, 2005; )
¥ Syndecan-4 (SDC4, SYND4, amphiglycan, ryudocan) (Lopes et al, 2006; Lacal et al, 2009; Kojima et al, 1992; Shworak et al, 1993, 1994; Tkachenko et al, 2004, 2006; Elfenbein et al, 2012; Trindade et al, 2008)
¥ tbdn-1 (tubedown-1, tbdn, tubedown, NATH, Nat1 homolog, Ga19, Gastric cancer antigen Ga19, NARG1, NMDA receptor regulated 1) (Gendron et al, 2000, 2001; Paradis et al., 2002, 2008)
¥ TCTP (translationally controlled tumor protein, TPT1, tumor protein translationally-controlled-1, fortilin, p23, IgE-HRF, IgE-dependent histamine releasing factor) (Qiu et al, 2007
¥ TEM5 (Tumor endothelial marker 5, GPR124, G-protein-coupled receptor-124, KIAA1531) (Carson-Walter et al, 2001; Vallon and Essler, 2006; Vallon et al, 2010; Yamamoto et al, 2004; St. Croix et al, 2000)
¥ tenascin-C (TN-C, Tenascin, TN, TNC220, TNS, TNC320, TNL, Cytotactin, hexabrachion, HXB, myotendinous antigen, M1 antigen, GMEM, Glioma-associated-extracellular matrix antigen, neuronectin, J1 Glycoprotein, J1/tenascin, tenascin-J1) (Aziz SM et al, 1997; Ballard VL et al, 2006; Castellon R et al, 2002; Hahn AW et al, 1995; Hamid C et al, 2007; Kondo S et al, 2007; Lenz O et al, 1998; Ljubimov AV et al, 1998; Schenk S et al, 1999; Soini Y et al, 1997; Yoshida H et al, 1996; Yoshida H et al, 2002; Zagzag D et al, 1996; Zagzag D et al, 2002; Zhao Y and Young SL, 1995)
¥¥ tenascin-C (TN-C, Tenascin, TN, TNC220, TNS, TNC320, TNL, Cytotactin, hexabrachion, HXB, myotendinous antigen, M1 antigen, GMEM, Glioma-associated-extracellular matrix antigen, neuronectin, J1 Glycoprotein, J1/tenascin, tenascin-J1) receptors (Castellon R et al, 2002; Zagzag D et al, 2002)
¥ TFPI (tissue factor pathway inhibitor, TFPI-1, tissue factor pathway inhibitor-1, EPI, extrinsic pathway inhibitor, LACI, lipoprotein-associated coagulation inhibitor) (Ameri et al, 1992; Nishimura et al, 1997; Bajaj et al, 1999; Chen et al, 2008; Tunica et al, 2009; Jin H et al, 2010)
¥ TFPI-2 (tissue factor pathway inhibitor-2, MSPI, matrix-associated serine protease inhibitor, REF-1, RPE cell factor, retinal pigment epithelial cell factor-1, PP5, placental protein 5) (Xu et al, 2006; Kahn et al, 2000)
¥¥ TFPI-2 (tissue factor pathway inhibitor-2, MSPI, matrix-associated serine protease inhibitor, REF-1, RPE cell factor, retinal pigment epithelial cell factor-1, PP5, placental protein 5) receptors (Xu et al, 2006)
¥ TGF-alpha (transforming growth factor-alpha, TGFA, TGF-A, MDGF-2, milk-derived growth factor-2, TCGF, transformed cell growth factor, wa-1, waved-1) (Nelson et al, 2007)
¥ TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) (Heydarkhan-Hagvall et al, 2003; Komatsu et al, 1996; Wolf et al, 1999; Cheng et al, 2003; Li et al, 2000; Kallmann et al, 2002; Hannan et al, 1988; Nilsen et al, 1998; Zhou et al, 2005; Kahn et al, 2000; Starnes et al, 2001; Wang S and Hirschberg R, 2009; Passerini AG et al, 2003)
¥ TGF-beta-1 (TGFB1, transforming growth factor-beta-1, CIF-A, cartilage inducing factor A, ISF, immunosuppressive factor, MGF-b, milk growth factor, PDGI, platelet-derived endothelial cell growth inhibitor) (Axel et al, 1997; Briones et al, 2001; Wondergem et al, 2004; Zhong et al, 2004; Yoon et al, 2000; Sommer et al, 2009)
¥¥ TGF-beta-1 (TGFB1, transforming growth factor-beta-1, CIF-A, cartilage inducing factor A, ISF, immunosuppressive factor, MGF-b, milk growth factor, PDGI, platelet-derived endothelial cell growth inhibitor) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Ohji et al, 1995; Kawsar HI et a, 2010; Clavin NW et al, 2008; Barbier et al, 2011)
¥ TGF-beta-2 (transforming growth factor-beta-2, TGFB2, G-TsF, Glioblastoma-derived T-cell suppressor factor, CIF-B, cartilage inducing factor B, Corneal epithelial inhibitor of stromal cell collagenase synthesis, DSF, decidual suppressor factor, MGF-a, milk growth factor) (Briones et al, 2001; Yoon et al, 2000)
¥¥ TGF-beta-2 (transforming growth factor-beta-2, TGFB2, G-TsF, Glioblastoma-derived T-cell suppressor factor, CIF-B, cartilage inducing factor B, Corneal epithelial inhibitor of stromal cell collagenase synthesis, DSF, decidual suppressor factor, MGF-a, milk growth factor) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Ohji et al, 1995; Yoon et al, 2000)
¥ TGF-beta-3 (transforming growth factor-beta-3, TGFB3, ARVD1, Arrhythmogenic right ventricular cardiomyopathy type 1) (Poole et al, 2002; Yoon et al, 2000; Khodarev et al, 2003)
¥¥ TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Yamamoto T et al, 1998; Lomnytska et al, 2004; Weiss et al, 1999; Wunderlich et al, 2000; Zhong et al, 2004; Fee et al, 2004; Goumans et al, 2003; Lingen et al, 1996; Dahlfors et al, 2000; Tang et al, 2005; Wong et al, 2000; Sankar et al, 1995; Ohji et al, 1995; Gamble et al, 1993; Khodarev et al, 2003; Loboda A et al, 2006; Rudini N et al, 2008)
¥ Thimet oligopeptidase (THOP1, Thimet oligopeptidase 1, EC3.4.24.15, Endopeptidase 24.15, EP24.15, MP24.15, metalloendopeptidase 24.15, TOP, thiol-activated metallo-oligopeptidase, BIE, bradykinin inactivating endopeptidase, MP78, Pz-peptidase, endo-oligopeptidase A)
(Lew et al, 1994; Norman et al, 2003; Cotter et al, 2004)
¥ thioredoxin (TRX, TRX1, thioredoxin-1, TRX80, BSF-MP6, B-cell stimulating factor MP6, ADF, adult T-cell leukemia-derived factor) (Takeda N et al, 2007; Chen B et al, 2009)
¥¥ Thrombin (coagulation factor-2, factor IIa) receptors (Belloni et al, 1992; Zucker et al, 1998; Lafleur et al, 2001; Huang et al, 2002; Failli et al, 2000; Draijer et al, 1995; Zlock et al, 1997; Peracchia et al, 1994; Wang et al, 1997; Kaplanski et al, 1998; Ludeman et al, 2004; Shreeve et al, 1996; Grandaliano et al, 1998; Minami et al, 2004; Tang et al, 2005; Shimizu et al, 2004; Duhamel-Clerin et al, 1997; Zania et al, 2008; Blackburn and Brinckerhoff, 2008; Popovic et al, 2008; Gu et al, 2000; Seguin et al, 2008; Kawanami et al, 2011; Martorell L et al, 2007; Martorell L et al, 2008)
¥¥ Thrombin receptor (TR, CF2R, coagulation factor 2 receptor, F2R, PAR-1, Proteinase-activated receptor 1) (Auld GC et al, 2001; Bae JS et al, 2008; Banfi C et al, 2007; Banfi C et al, 2009; Banfi C et al, 2011; Blackburn JS and Brinckerhoff CE, 2008; Brueckmann M et al, 2005; Day JR et al, 2006; Fu J et al, 2005; Fujiwara M et al, 2004; Gšdecke S et al, 2012; Kataoka H et al, 2003; Kim YV et al, 2004; Lidington EA et al, 2000; Lin Z et al, 2006; Ludeman MJ et al, 2004; McLaughlin JN et al, 2007; Nguyen KT et al, 2001; Paria BC et al, 2006; Popovic M et al, 2008; Popović M et al, 2010; Riewald M et al, 2002; Riewald M et al, 2003; Rullier A et al, 2004 Shimizu T et al, 2004; Soh UJ and Trejo J, 2011; Tull SP et al, 2012; Uzonyi B et al, 2006; Vu et al, 1991)
¥ thrombopoietin (TPO, THPO, c-MPL ligand, MPL ligand, ML, MGDF, megakaryocyte growth and development factor, Mk-CSF, megakaryocyte colony stimulating factor) (Zhong et al, 2004; El Andaloussi et al, 2001; Cardier and Dempsey, 1998; Zhang J et al, 2010)
¥¥ thrombopoietin (TPO, THPO, c-MPL ligand, MPL ligand, ML, MGDF, megakaryocyte growth and development factor, Mk-CSF, megakaryocyte colony stimulating factor) receptors (MPL, TPOR, CD110) (Cardier and Dempsey, 1998; Geddis et al, 2006; Zhang J et al, 2010)
¥ Thrombospondin-1 (Thrombospondin, TSP1, TSP, THBS1) (Aparicio et al, 2005; Fischer et al, 2001; Chua et al, 1997; Niu et al, 2004; Garcia-Conesa MT et al, 2009; Tunica et al, 2009; Kondo S et al, 2007; Webersinke G et al, 1992; Dolan JM et al, 2012)
¥¥ Thrombospondin-1 (Thrombospondin, TSP1, TSP, THBS1) receptors (Tolsma et al, 1997)
¥ thrombospondin-2 (TSP2, THBS2) (Park et al, 2004)
¥ thymopoietin (Tpo, TP, TMPO, TP-5, thymopentin, thymopoietin 32-36, Lamina-associated polypeptide 2, LAP2) (Park et al, 2008; Nelson et al, 2007)
¥ THSD7A (thrombospondin type-1 domain-containing protein 7A, KIAA0960) (Wang CH et al, 2010)
¥¥ thymosin-alpha-1 (Prothymosin-alpha, PTMA, Thymalfasin, Zadaxin) receptors (Malinda et al, 1998)
¥ thymosin-beta-4 (TMSB4, TMSB4X, Tb4, Tbeta-4, 6-26, Fx, PTMB4, THYB4) (Huang and Wang, 2001; Li et al, 2004; Oh et al, 2002; Grant et al, 1995; Bednarek et al, 2008; Larsson and Holck, 2007; Xu et al, 2005)
¥¥ thymosin-beta-4 (TMSB4, TMSB4X, Tb4, Tbeta-4, 6-26, Fx, PTMB4, THYB4) receptors (Al-Nedawi et al, 2004; Malinda et al, 1997; Boncela et al, 2006; Mu et al, 2006; Cierniewski et al, 2007; Philp D et al, 2006; Al-Nedawi KN et al, 2004; Bock-Marquette et al, 2009)
¥ Thymosin-beta-10 (TMSB10, Tbeta-10, Tb10, PTMB10, THYB10) (Li et al, 2000; Vasile et al, 2001; Zhou et al, 2005)
¥¥ Thymosin-beta-10 (TMSB10, Tbeta-10, Tb10, PTMB10, THYB10) receptors (Mu et al, 2006)
¥¥ Thyrotropin (TSH, thyroid stimulating hormone, Thyrotropic hormone) receptors (Donnini et al, 2003)
¥ Tim-3 (T-cell immunoglobulin and mucin domain-containing protein 3; T-cell membrane protein 3, T-cell immunoglobulin mucin 3, T-cell Ig mucin 3, Timd3, HAVCR2, hepatitis A virus cellular receptor 2) (Wu FH et al, 2010; Huang X et al, 2010)
¥ TIMP-1 (tissue inhibitor of metalloproteinases-1, TIMP metallopeptidase inhibitor 1, TIMP, tissue inhibitor of metalloproteinases, HCI, human collagenase inhibitor, CLGI, 3/10, 16C8, Fibroblast elongation factor, fibroblast collagenase inhibitor, B1 anticollagenase, Beta-1 anticollagenase, EPA, erythroid promoting activity, embryogenin-1, TPA-S1, TPA-induced protein S1) (Hanemaaijer et al, 1993; Boulday et al, 2001; Chua et al, 1996; Cornelius et al, 1995; Ito et al, 1995; Jackson et al, 1998; Klein-Soyer et al, 1997; Lamoreaux et al, 1998; Zucker et al, 1998; Jackson and Nguyen, 1997; Bugno et al, 1999; Hanemaaijer et al, 1998; Krikun et al, 2005; Nelimarkka et al, 1998; De Lorenzo et al, 2000; Reed et al, 2000; Ikeda et al, 2000; Huang et al, 2001; Salvucci et al, 2004; Shastry and Tyagi, 2004; Morata et al, 2003; Ho et al, 2007; Game et al, 2003; Koike et al, 2002; Park et al, 2001; Klein-Soyer et al, 1997; Milkiewicz et al, 2008; Sommer et al, 2009; Barbier et al, 2011; Zhang W et al, 2006)
¥ TIMP-2 (tissue inhibitor of metalloproteinases-2, TIMP metallopeptidase inhibitor 2, CSC-21K, MI, CHIAMP, Chondrocyte-derived inhibitor of angiogenesis and metalloproteinase activity) (Hanemaaijer et al, 1993; De Clerck et al, 1989; Arenas et al, 2004; Cornelius et al, 1995; Ito et al, 1995; Deo et al, 2004; Klein-Soyer et al, 1997; Lamoreaux et al, 1998; Hanemaaijer et al, 1998; Nelimarkka et al, 1998; Puyraimond et al, 2001; Ottino et al, 2004; Krikun et al, 2005; Morata et al, 2003l Kawano et al, 1997; Yue et al, 2006; Ho et al, 2007; Game et al, 2003; Koike et al, 2002; Park et al, 2001; Klein-Soyer et al, 1997; Zhang W et al, 2006)
¥ TIMP-3 (tissue inhibitor of metalloproteinases-3, TIMP metallopeptidase inhibitor 3, mitogen-inducible gene 5, mig-5; SFD, Sorsby fundus dystrophy) (Hanemaaijer et al, 1993; Bugno et al, 1999; Chegini et al, 2003; Morata et al, 2003; Milkiewicz et al, 2008; Dolan JM et al, 2012; Zhang W et al, 2006)
¥ TIMP-4 (tissue inhibitor of metalloproteinases-4, TIMP metallopeptidase inhibitor 4) (Shastry and Tyagi, 2004; Chegini et al, 2003)
¥ Tissue factor (TF, TFA, thromboplastin, tissue thromboplastin, CD142, factor III, factor 3, F3, FIII, coagulation factor III) (Pendurthi et al, 1997; Herbert et al, 1996; Wondergem et al, 2004; Zucker et al, 1998; Kimura et al, 2002; Sugano et al, 2001; Kim et al, 2002; Ovanesov et al, 2005; Mackman et al, 1990; Colucci et al, 1983; Maynard et al, 1977; Pendurthi et al, 1997; Nishimura et al, 1997; Napoleone et al, 2002; Yoshizumi et al, 1999; Yoshizumi et al, 1998; Kunieda et al, 2003; Gnant et al, 2000; Terry et al, 2004; Slupsky et al, 1998; Cirillo et al, 2008; Helenius et al, 2008; Chen et al, 2008; Lv et al, 2009; Murugesan G et al, 2000; Clauss M et al, 1996; Nachman et al, 1986; Jiang R et al, 2010; Wang HJ et al, 2012; Cirillo P et al, 2012)
¥ tissue plasminogen activator (Mehta et al, 2002; Zhang et al, 2001; Nishimura et al, 1997; Ito et al, 1995; Witmer et al, 2004; Sato et al, 1998; Liu et al, 2001; Singh P et al, 2010)
¥ TLR-1 (Toll-like receptor-1, rsc786, randomly sequenced cDNA 786, TIL, Toll-interleukin-1 receptor-like, CD281) (Spitzer et al, 2002; Hijiya et al, 2002; Garrafa E et al, 2011)
¥ TLR-2 (Toll-like receptor-2, TIL-4, Toll-interleukin-1 receptor-like-4, Ly105, lymphocyte antigen 105, CD282) (Talreja et al, 2004; Fan et al, 2003; Zhang et al, 1999; Faure et al, 2001; Lentschat et al, 2005; Dunzendorfer et al, 2004; Constantin et al, 2004; Satta et al, 2008; Lv et al, 2009; Garrafa E et al, 2011; Su X et al, 2011; Diesel B et al, 2012)
¥ TLR-3 (Toll-like receptor-3, CD283) (Kaiser et al, 2004; Tissari et al, 2005; Imaizumi et al, 2007; Pluvinet et al, 2008; BerghŠll et al, 2006; Heidemann et al, 2007; Garrafa E et al, 2011)
¥ TLR-4 (Toll-like receptor-4, human Toll, TOLL, Ly87, Rasl2-8, CD284) (Gioannini et al, 2003; Dunzendorfer et al, 2004; Talreja et al, 2004; Brito et al, 2004; Fan et al, 2003; Zhang et al, 1999; Faure et al, 2001; Spitzer et al, 2002; Zeuke et al, 2002; Hijiya et al, 2002; Ishida et al, 2002; Lentschat et al, 2005; Constantin et al, 2004; Lv et al, 2009; Norata et al, 2007; Garrafa E et al, 2011; Su X et al, 2011; Barbier et al, 2011)
¥ TLR-5 [Toll-like receptor-5, TIL-3, Toll-interleukin-1 receptor-like-3) (Maaser et al, 2004; Garrafa E et al, 2011)
¥ TLR-6 (toll-like receptor-6, CD286) (Garrafa E et al, 2011)
¥ TLR-9 (Toll-like receptor-9, A6RP, A6-related protein, CD289) (Li et al, 2004; Constantin et al, 2004; Garrafa E et al, 2011)
¥ TLR-13 (Toll-like receptor-13) (Mishra BB et al, 2008)
¥ TMPRSS2 (serine protease 10) (Aimes et al, 2003)
¥ TNFAIP1 (tumor necrosis factor-alpha-induced protein 1, TNF-alpha-induced protein 1, TNFAIP, tumor necrosis factor-alpha-induced protein, TNF-alpha-induced protein, B12, EDP1, endothelial TNF-alpha-induced protein 1) (Wolf et al, 1992)
¥ TNFAIP8 (tumor necrosis factor-alpha-induced protein 8, TNF-alpha-induced protein 8, NDED, NF-kappa-B-inducible DED-containing protein, GG2-1, SCC-S2, Oxi-alpha or Oxi-a, Oxidative stress regulated gene-alpha) (Barbier et al, 2011)
¥ TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) (Arenas et al, 2004; Sundstrom et al, 2001; Galdiero et al, 1997; Hoffmann et al, 2004; Stoelcker et al, 2000; Nilsen et al, 1998; Di Francesco et al, 2009; Sommer et al, 2009)
¥¥ TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) receptors (CD120a, TNFRSF1A, TNF receptor superfamily member 1A, FPF, TNFAR, TNFR, TNFR1, TNFR55, TNFR60, TNFR-alpha, TNF receptor 1; CD120b, TNFRSF1B, TNF receptor superfamily member 1B, p75TNFR, TNFR2, TNFR75, TNFR80, TNFR-beta) (Zoellner et al, 1992; Hawari et al, 2004; Kimura et al, 2003; Maier et al, 1999; Nelimarkka et al, 1998; Kim et al, 2000; Willam et al, 2000; Saijonmaa et al, 2001; Lehmann et al, 2000; Feil and Augustin, 1998; Ahn et al, 2004; Salvucci et al, 2004; Iademarco et al, 1995; Hoffmann et al, 2004; Stoelcker et al, 2000; Murakami et al, 2000; Leeuwenberg et al, 1995; Wagnerova et al, 2002; Girvin et al, 2002; Xu et al, 2006; Ahmed et al, 2009; Moon et al, 2006; Giraudo et al, 1998; Lin et al, 2009; Chen T et al, 2010)
¥ TNF-beta (tumor necrosis factor-beta, TNFB, Coley's toxin, LT, lymphotoxin, lymphotoxin-alpha, LT-alpha, LTA, Necrosin, NKCF, natural killer cytotoxic factor, NK-CIA, Natural killer colony-inhibiting activity, TNFSF1, TNF ligand superfamily member 1) (Sommer et al, 2009)
¥ TNFRSF25 (TNF receptor superfamily member 25, TNFRSF12, DR3, death receptor-3, TR3, TNF receptor-like-3, LARD, lymphocyte-associated receptor of death, APO-3, apoptosis antigen-3, TRAMP, TNF receptor apoptosis-mediating protein, wsl-1) (Nelson et al, 2007)
¥ Tob1 (transducer of erbB2 1, Tob, transducer of erbB2) (Barbier et al, 2011)
¥ tPA (tissue plasminogen activator, tissue-type plasminogen activator, PLAT, plasminogen activator, tissue) (Dolan JM et al, 2012)¥ TRADD (TNFR1-associated death domain protein) (Barbier et al, 2011)
¥ TRAF1 (TNF receptor associated factor-1, Tumor necrosis factor receptor-associated factor-1, EBI-6, EBV induced gene-6) (Murakami et al, 2000)
¥ TRAF2 (TNF receptor associated factor-2, Tumor necrosis factor receptor-associated factor-2, TNF receptor-associated protein, TRAP) (Barbier et al, 2011)
¥ TRAF4 (TNF receptor associated factor-4, Tumor necrosis factor receptor-associated factor-4, RNF83, RING finger protein 83, CART-1, Cysteine rich domain associated to RING and TRAF protein) (Barbier et al, 2011)
¥ TRAF6 (TNF receptor associated factor-6, Tumor necrosis factor receptor-associated factor-6, RNF85, RING finger protein 85) (Barbier et al, 2011)
¥ TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) (Pritzker et al, 2004; Daly et al, 2004; Barbier et al, 2011)
¥ TRANCE receptors (Kim et al, 2002)
¥ TRANK (thioredoxin peroxidase-related activator of NF-kappa-B and c-Jun N-terminal kinase, PRDX4, peroxiredoxin-4, PRX4, AOE372, antioxidant enzyme AOE372) (Park et al, 2008)
¥ transferrin (TRF, serotransferrin, siderophilin, DF-77, GPBP, granulocyte/pollen-binding protein, Lung-derived growth factor) (Mallgard et al, 1988)
¥¥ transferrin (TRF, DF-77, GPBP, granulocyte/pollen-binding protein, Lung-derived growth factor) receptors (CD71, TFR, TFR1, TRFR, TFRC, OKT9, T9, OX26) (Visser et al, 2004; van Gelder et al, 1995)
¥ transthyretin (TTR, Thyroxine-binding prealbumin, TBPA, prealbumin, PALB) (Beckhove P et al, 2010)
¥¥ transthyretin (TTR, Thyroxine-binding prealbumin, TBPA, prealbumin, PALB) receptors (Borish et al, 1992)
¥ TREM1 (triggering receptor expressed on myeloid cells 1, CD354) (Chen et al, 2008; Barbier et al, 2011)
¥ TREM2 (triggering receptor expressed on myeloid cells 2, TREM2a, TREM2b) (Chen et al, 2008)
¥ TREM3 (triggering receptor expressed on myeloid cells 3) (Chen et al, 2008)